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ABSTRACT
Seven new multidrug resistant variants of six established cell 
lines were developed with the drug adriamycin, HEP-2A, HEP-2B, 
DLKP-A, OAW42-A, SKMES1-A, SKLU1-A and DLRP-A. All the cell lines, 
except for DLRP-A were found to cross resistant to a range of 
drugs. There is a consistent rank order correlation between 
resistance to the selecting drug and cross resistance to other 
drugs. The detailed cross resistant profile varies markedly among 
cell lines selected with the same drug. Heterogenity in the level 
of drug resistance was a feature of all the MDR variants tested. 
The MDR variants were generally found to have altered biophysical 
properties, with sensitivity to standard freezing and standard 
subculture procedures noted. Additionally, the MDR variants were 
found to be more resistant to sonication, indicating possible 
altered lipid composition of the cell membranes. The P-170 
mechanism of resistance was investigated by Western Blotting, 
Immunofluorescence and antisense transfection, and was found to be 
involved in resistance in CHrC5, DLKP-A, HEP-2A, HEP-2B, SKMES1-A 
and OAW42-A. There are however indications of other mechanisms of 
resistance, (e.g. cross resistance to 5-Flurouracil and 
cis-platin). Additionally incomplete reversal of resistance by
Antisense oligomer transfection is suggestive of alternative
mechanisms of resistance to P-170 present in a number of the cell 
lines. SKLU1-A was negative in all the P-170 studies so 
alternative mechanisms of resistance must be causative reason of 
MDR in this cell line. Cytogenetic manifestation of MDR in the 
form of DMs was evident in DLKP-A, HEP-2A and HEP-2B, Drug
resistant cell lines were generated by transfection with a complete
murine cDNA for mdrl. The drug resistance pattern observed were
significantly different from those of the variants obtained by 
adaptation from the corresponding parental cell line. It was 
possible to circumvent adriamycin resistance with clinically
relevant doses of a number of compounds, verapamil, quinine, 
quinidine, nifedipine, chloroquinine, caffeine, generic and 
standard aspirin.
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CHAPTER 1
INTRODUCTION
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1.1 INTRODUCTION.
Multidrug resistance (MDR) is a phenomenon whereby cells exhibit 
resistance to a broad range of structurally unrelated cytotoxic 
drugs. This is found to be an inherent property of certain cancers 
which never respond to chemotherapy eg. colon carcinoma. Other 
cancers are intially responsive to a given chemotherapeutic regime 
but eventually acquire resistance not only to the drugs that have 
been administered but a broad range of other compounds. The 
chemicals involved are the Anthracyclines (Adriamycin, 
Daunorubicin), Vinca alkaloids (Vinblastine, Vincristine), 
epipodophyllotoxins (VP-16, VM-26), Actinomycin D, and Taxol (all
these compounds being hydrophobic natural compounds). There are 
many systems involved in drug resistance but the best understood is 
the decreased accumulation of drug in resistant cells when compared 
to their sensitive counterparts. The resistant cells express a 
gene for multidrug resistance which encodes a 170 KDa membrane 
glycoprotein termed P-glycoprotein, or P-170. The procedures used 
to clone the mdrl gene, which codes for P-glycoprotein have been 
described by Croop et al, (1989); Endicott and Ling,(1989); 
Gottesman and Pastan (1988), and Bradley et al.(1988). It has been 
found (using transfection experiments) that overexpression of mouse 
and human mdrl cDNA is sufficent to confer the MDR phenotype (Gros 
et al.,1986b; Ueda et al.,,1987a). Although P-170 is believed to be 
a pump that actively effluxes drugs from resistant cells (Dano et 
al.,1973; Safa et al.,1987) the actual mechanism for this activity 
is not understood. It has also been proven that the P-170 can 
transport a wide range of organic chemicals as well as anticancer 
drugs ( Ichikawa et al.,1991). This could suggest that one of the 
physiological functions of P-170 is the secretion of organic
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substances. It has been suggested that the M.W. of the drugs is a 
important determinant in the MDR phenotype. Selassi et al.(1990) 
have suggested that current chemotherapy regimes may be improved by 
treating resistant cells with antineoplastic agents displaying 
physiochemical characteristics opposite to that of the original 
inducing agent.
It is now thought that P-170 acts as a flippase (C.Higgins, 
personal communication) which actively shunts drugs out of the 
cell. This would explain the lack of substrate specificity that is 
the hallmark of MDR. The involvement of the P-170 in MDR of tissue 
cultured cells is now quite clear, however the direct role of this 
protein in cancer chemotherapy has been more difficult to 
determine. Since there is differential expression of P-170 in 
normal tissue (Section 1.5) it seems that P-170 acts as a pump in 
normal cells as well.
1.2 Protein Organisation and Function.
The ATP binding cassette (ABC) superfamily of transport systems now 
includes over 30 proteins that share extensive sequence similarity 
and domain organisation (Hyde et al.,1990). The MDR protein 
designated P-170 glycoprotein is included in this super family. 
P-170 is approximately 1280 amino acids in length and consists of 
12 transmembrane domains and two nucleotide binding sites (figure 
1.1); There are two homologous halves plus a variable linker 
region. According to the current model of P-170 orientiation in the 
membrane, the highly charged amino acid termini are both 
intracellular, the nucleotide binding sites are cytoplasmic, and 
there are three potential glycosylation sites in the first
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extracellular loop. This model is supported by the fact that 
antibodies to specific regions of P-170 recognise extracellular or 
intracellular determinants as predicted (Bradley et al.,1990). Also 
ATP binding sites in the cytoplasm would be expected if the protein 
functions to pump drugs out of cells. Finally at least one of the 
putative extracellular glycosylation sites contain carbohydrate 
residues since treatment with endopeptidase F allows an antipeptide 
antibody specific for the sequence at this site, to bind there. 
There are striking similarities in sequence and apparent structure 
between P-170 and a number of procaryotic transport proteins (Chen 
et al.,1986, Higgins et al.,1989) and a number of the bacterial 
transport proteins. The strongest homology is with HLYB. the 
ATP-binding hemolysin export protein in E.Coli (Felmlee et 
al.,1985; Blight et al.,1990); NDV-A a protein possibly involved 
in JJ-(1-2)glycan transport in Rhizobium Meliloti (Stanfield et 
al.,1988);Ikt ,a leukotoxin secretion determinant in Pasteurella 
Haemolvtica. analogous to HLYB (Strathdee and Lo,1989). Also the 
extracellular secretion of the antibacterial toxin colicin V is 
mediated by a signal sequence independent process which requires 
the product of two linked genes: cvaA and cvaB. The nucleotide
sequence of the cvaB reveals that its product is a member of ABC 
subfamily of proteins, (Gilson et al.,1990). Also the amplified H 
circle of Leishmania tarentolae contains a novel P-glycoprotein 
gene (Ouellette et al.,1990). Although these proteins are most 
similar to P-170 in their ATP binding domains, homology does extend 
to other regions. P-170 is also very structurally similar to a 
number of eukaryotic proteins thought to be also involved in 
cellular transport processes. There is at least one homologue of 
the MDR gene in Malaria parasites pfMDR. Plasmodium falciparum 
Multidrug resistance gene (Foote et al.,1989). Structure and
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sequence homologies have also been found in the brown and white 
protein pigments in Drosophila. (Dressen et al.,1988) and in a 
yeast protein which is thought to be involved in the secretion of 
mating factor-a. The product of the STE6 gene shows almost 57% 
amino acid sequence homology with human P-170 (Kuhler et al.,1989, 
Me Grath,J.P.,1989) Also , the product of the cystic fibrosis gene 
(CFTR) has also been classified into the ABC group of transporters, 
(Hyde et al.,1990, Riordan et al.,1989). In addition to the 4 
domains present in all the other proteins mentioned above, CFTR 
has another domain designated as the regulatory domain R. Because 
the best homologies have been found for pumps involved in protein 
efflux (HYLB and STE6), it has been suggested that one function of 
the MDR system may involve efflux of proteins or peptides (Me Grath 
et al.,1989). However, none of the substrate binding sites for 
these transporters have been identified, and until such information 
is available it is not possible to predict substrate specifity from 
sequence data.
Figure 1.1: Model of the MDR Transporter.
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1.3 Gene Structure and Organisation.
MDR is the result of overexpression and amplification of multidrug 
resistant genes, designated mdrl and mdr2 (or mdr3) in human, and 
mdr, pop or pqy in non human species, (Croop et al., 1989; 
Endicott and Ling., 1989, Raymond et al., 1990a). (There are 
discrepancies in the terminology used for the human and mouse MDR 
genes, see table 1.1 for details). In human, mouse and hamster 
these make up a small multi-gene family, with two human (Roninson 
et al., 1986, Van der Bliek et al., 1986) and three rodent genes, 
(mdrla. mdrlb. mdr2) (Ng et al., 1989), see table 1.2 for 
interspecies and intergene homology at the amino acid level. 
Transfection experiments with full cDNA from the mdrl gene have 
unambigously shown that increases in P-170 expression are sufficent 
to cause the MDR phenotype. Monoclonal antibodies have proved to 
date to be the most exact method for determining the expression of 
different P-glycoprotein genes in normal and human tissue. 
P-glycoprotein specific monoclonal antibodies have been used to 
isolate P -glycoprotein cDNA clones from libraries prepared in the 
expression vector Lambda gtll (Riordan et al., 1989). A 
P-glycoprotein cDNA sequence pCHP-1 was first isolated from the 
CHrB30, a resistant clone of CHrC5. The clone pCHP-1 was proven 
to code P-170 by its detection with three monoclonal antibodies 
(C219, C494 and C32), its hybridisation to an mRNA of 4.7kb and its 
hybridisation to amplified genomic DNA sequences in different MDR 
cell lines. It was found on hybridisation of the pCHP-1 probe to 
hamster resistant DNA cut with ECOR1, that 12 differentially 
stained bands resulted. This was the first indication that P-170 
may be encoded by a multigene family. P-glycoprotein sequences are
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amplified in MDR cella. This has allowed P-glycoprotein expression 
to be analysed by the technique of differential hybridisation or by 
gel renaturation (Roninson et al., 1989). These methods were 
advantageous to use because other genes coamplified with 
P-glycoprotein have also been isolated. The presence and the
analysis of these genes may contribute to our understanding of the 
MDR phenotype.
Using the technique of differential hybridisation to labelled 
single stranded cDNA from CHOCHrC5 (the Chinese hamster ovary MDR 
cell line) and to cDNA from the parental drug sensitive cell line 
AuxBl, five different classes of transcript (Classes 1-5) 
distinguished on the basis of their hybridisation to mRNAs of 
different lengths on northern blot analysis, were initially 
isolated (Roninson et al., 1983 ; Van der Bliek et al., 1986). 
Since then, a sixth sequence (Class six) has been isolated (Borst 
et al., 1988). The class 2 cDNA clones were found to hybridise to 
pCHP-1 and to an mRNA transcript of 4.7kb. This transcript was the 
only one found to be consistantly overexpressed in MDR cells (De 
Bruijn et al., 1986). Mapping experiments using the technique of 
pulse field electrophoresis have shown that there are three class 2 
genes in mouse; these correspond to the three pgp genes found in 
hamster. The two human class 2 genes mdrl and mdr3 are linked 
within 330kb of each other on chromosome 7, band q21.1 (Chin et 
al., 1989). These two genes encode proteins that are 80% homologous 
at an amino acid level, (Van Der Bliek et al., 1986), suggesting 
that the genes arose from a duplication event. See figure 1.2 for 
comparison of deduced amino sequences of the three MDR proteins and 
the human mdrl protein and figure 1.3 for comparison of the 
putative start site of transcription. A function for the mdr3 has
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not yet been determined, however it has been found that it 
undergoes differential splicing (Hsu et al., 1989). The transcript 
for the mdr3 gene is found to be consistently shorter (4.1Kb Vs 
4.5Kb), partly as a result of differences in the lengths of the 
31-untranslated region. Three different transcripts for mdr3 were 
isolated from cDNA libraries from human liver. The predominant 
transcript isolated aligned with the mdrl sequence. The other two 
variant sequences have either an in frame 21-base pair insertion 
between the region encoding the highly conserved 'A' and 'B' 
nucleotide-binding consenus sequences in the C-terminal cytoplasmic 
domain of P-glycoprotein, or alternatively a deletion that removes 
sequences encoding the fifth potential transmembrane region from 
the C-terminal domain. Differences in 3'-untranslated region 
processing have also been reported for both hamster pqpl and pqp2 
transcripts (Endicott et al.,1989). The biological significance of 
these observations is not known.
The fact that the P-170, and therefore MDR genes, are composed of 
two homologous halves has suggested that the gene itself was 
generated by a duplication event before mdrl and mdr3 divergence. 
On the analysis of the mouse, hamster and human MDR sequences 
there appears to be a greater relationship between entire MDR class 
molecules of different species (i.e. mdrl Vs mdrla or mdrlb) than 
between the two halves of any single gene, (Hsu et al., 1989). 
Futhermore, a very surprising finding has come from the intron 
/exon structural analysis of human mdrl and mouse mdrlb genes (Chen 
et al., 1990; Raymond et al., 1989). It has been found for both 
these genes, that even though each half contains about the same 
number of introns and exons most of the introns occur at different 
places in the two halves of the gene. It is possible that this
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gene structure is the result of a primodrial gene containing few 
introns, with subsequent insertion of introns, giving the resultant 
gene (Raymond et al., 1989). However, it has been suggested that 
the gene for P-170 arose by fusion of two structurally similar
genes which had evolved separately and not by gene duplication
(Chen et al., 1990).
On cloning and transfection of the mouse mdrl. mdr2 and mdr3 
(Devault et al., 1990) it was found that mdrl and mdr3 conferred 
the MDR phenotype with overlapping but distinct substrate 
specificities. Cells transfected with and expressing the mdrl 
showed a 2-3 fold preferential resistance to colchicine and 
adriamycin compared with cells expressing an equivalent amount of 
mdr3. Conversely cells transfected and expressing mdr3 showed a 
preferential resistance to actinomycin D. Transfection of full 
cDNA of the mdr2 into sensitive cells did not confer the MDR 
phenotype. This situation is probably unique to rodent , unlike 
human in which only full cDNA from the mdrl can confer the MDR 
phenotype.
Roninson et al. (1988), Devine et al. (1991) and Croop et al.
(1991) have provided direct evidence in the human mdrl gene
(Glycine-185) that alterations probably occuring during the course 
of drug selection, can modify the profile of drug resistance in 
human cells. Gekeler et al., (1990) undertook a study to determine 
if alterations in the nucleotide sequence would result in 
alterations in the cross resistance profile. Using PCR technology, 
the sequences around codon 185 which codes for an amino acid 
residue possibly influencing the drug binding function of the P-170 
were cloned and sequenced. Altogether, only 2 single nucleotide
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differences in an intron were found in 2 out of 40 recombinants 
each harbouring a 209 bp genomic or a 269bp cDNA fragment of the 
mdrl / P-glycoprotein gene. Results conclude that clustered 
mutations around this region are not a causative reason for 
different multidrug resistant profiles.
Additionally in a murine system with J774.2 (Lothstein et 
al., 1989), the mdrla and the mdrlb encode the 120-125kda 
P-glycoprotein precursors, a switch of gene product was noted from
mdrlb to mdrla which was associated with an approximate 4-fold
increase in resistance to vinblastine, taxol and doxorubicin, 
with no dectectable changes in immunoreactive P-glycoprotein. It
was suggested that the mdrla may encode a more efficient
P-glycoprotein. Although the mechanism governing the gene switching 
event is not understood, it is likely to occur within a single 
cell. These findings suggest that differential expression of 
distinct MDR genes which encode unique P-glycoprotein isoforms is a 
possible mechanism for generating divergence in the phenotype.
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Table 1.1. Mammalian P-glycoprotein genes.
P-glycoprotein
Class
Human Mouse Hamster Involved in MDR
1 mdrl mdr3 
(mdrla1
pqpl Yes
11 mdrl
(mdrlbl
ESE2 Yes
111 mdr3 
(mdr2)
mdr2 pqp3 Unknown
Alternative designations are given in parenthesis.
Table 1.2. Relationship between the mouse genes and their hamster 
and human homologues based on sequence comparison of 
their linker regions.
Mu-mdrla Mu-mdrlb Hu-mdrl Ha-mdrlb Hu-mdr2
Mu-mdrla — 47% 68% 45% 20%
Mu-mdrlb 47% — 48% 67% 13%
Mu-mdr2 25% 20% 23% 23% 60%
The percentages indicate the degree of optimised amino acid 
homology. Mu= Mouse, Ha= Hamster, Hu=Human.
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Figure 1.2. Comparison of deduced amino acid sequences of the mouse 
mdr proteins and the human mdrl protein. For the mouse mdr 
proteins, only the residues which differ from the human mdrl 
sequence are shown; identical amino acids are marked with a dash, 
asterisks mark positions where at least two distinct mouse mdr 
proteins differ from the human mdrl. predicted transmembrane 
domains (tm) and nucleotide binding sites (nbs) are as determined 
for the human mdrl sequence.
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mdrl - Human TTGGTGGCCGTTCCAAGGAGCGCGAGGTCGGGATGGATCTTGAAGGGGACCGC
mdr2 - Mouse AAGGAAACCCGGAGGTGGCACGTGAGGTGGTGATGGAGTTTGAAGAGAACCTT 
mdr3 - Human CCTGCCAGACAGACACGCGCGAGGTTCGAGGCTGAGAGATGGATCTTGAGGGG
A
Consensus sequence GccGcc ccATGG
G
Figure 1.3. Alignment of nucleotide sequences flanking the putative 
start site of translation for human mdrl, mdc3 and mouse mdr2. The 
consenus sequence is given below with the most common nucleotide in 
capital letters, the ATG start codon is underlined.
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1.4 Cytogenetic Alterations in MDR Cells.
The P-Glycoprotein amplicon maps to chromosome 7q21-31 (Jongsma et 
al.,1990). Five gene classes that are co-amplified with 
P-glycoprotein have been isolated and appear by a number of 
investigations to map with the P-glycoprotein amplicon (Van der 
Bliek, 1986, Borst, 1988). By the use of pulse field gradient 
electrophoresis, it has been shown that llOOkb of DNA can be 
co-amplified with P-glycoprotein sequences, and that this DNA 
encodes for five additional genes (termed gene classes 1 and 3-6). 
Only the gene product of class 4 gene and class 2 has been 
identified to date. The class 4 gene encodes sorcin, a cytosolic 
calcium binding protein, that is homologous to calpain (Van der 
Bliek et al., 1986). This protein has been identified in increased 
amounts in vincristine resistant Chinese hamster and mouse cells 
(Meyers et al., 1981). In one study (Meyers et al., 1985), 
increases in sorcin expression paralled changes in DNA 
amplification, suggesting that increased sorcin expression resulted 
from increased gene expression. Four other RNA transcripts are 
also overexpressed by being part of the six gene amplicon. It is 
not known what role, if any, these additional proteins may play in 
the modulating the MDR phenotype, but it is interesting to note 
that the overall organisation of the genes identified within the 
P-glycoprotein amplicon are conserved among human, mouse and 
hamster cells. The mdrl and mdr3 genes (The two class 2 genes) 
have been localised to 7q 21.1 approximately 300 bases apart.
Double Minute (DM) chromosomes and Homogenously Staining Regions 
(HSRs) are the most common manifestation of amplification present 
in MDR cells (Bell et al., 1987). In metaphase chromosome spreads
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DMs appear as small paired usually spherical chromosome-like 
structures. Characteristically, DMs vary in number and size from 
cell to cell and can accumulate in certain cell populations. Their 
features include varying ability in the uptake of stain, and the 
lack of a functional centromere (Barker et al., 1982). The
resistance of DMs to loss by classic mechanisms might result from 
the abnormal replication or segregation. An unexplored additional 
possibility that might explain the retention of DMs is extramitotic 
transfer of DMs between cells. Ruiz et al.(1989) have offered 
another explanation, it has been shown that DMs can be formed from 
submicroscopic circular precursors referred to as episomes. A
variety of methods including electrophoresis of undigested DNAs in 
high voltage gradients, Notl digestion, and the production of
double stranded breaks by gamma irradiation; were used to
distinguish between mdrl sequences amplified on submicroscopic 
circular molecules and those amplified within DMs or chromosomal 
DNA. The gamma irradiation procedure provides a new method for 
detecting and determining the size of circular molecules from 50kb 
to greater than lOOOkb. These procedures revealed that some of the 
amplified mdrl genes in vinblastine-resistant KB-V1 cells are 
contained in supercoiled circular molecules of between 600 and 
750kb. It was found from Meselson-Stahl density shift experiments 
that these molecules replicate approximately once per cell cycle. 
Ruiz et al.(1989) has added further support to a model for gene 
amplification in which DMs are generally formed from smaller, 
autonomously replicating episomes. Chromosome banding applied to
tumor cells led to the discovery of HSRs which are distinctive 
regions representing amplification of uniformly stained regions on 
a chromosome. HSRs have been identified in a variety of tumor
cells from man and experimental animals (Barker et al., 1982;
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Barker et al., 1980) and frequently as with DMs , in neuroblastomas 
(Brodeur et al., 1980). The presence of HSRs is not restricted to 
cell lines: Kovacs et al. (1979) showed HSRs in chromosome
preparations made from solid tumors. A HSR present in a cell line 
derived from a breast carcinoma patient was also present in a 
subsequently obtained pleural effusion from the same patient (Lau 
et al., 1986). In a number of studies it has been found that the 
number of DMs and the length of the HSRs correlate well with the 
degree of resistance. In a study of the mouse cell line J774.2 it 
was found the DMs were absent in revertant cells (Sandberg et al., 
1983), also in the colchicine resistant variant the number of DMs 
correlated very well to the degree of resistance (Lothstein et al., 
1986). Biedler et al.,(1983) noted in vincristine resistant 
Chinese hamster lung (DC-3F) that the length of the HSR (localised 
to chromosome 7) studied in a range of resistant cells correlated 
proportionally to the degree of resistance. Jongsma et al.(1990), 
also noted that a decrease in the length of the 7q HSR correlated 
with the decreases in relative colchicine resistance. A most 
interesting study involved four neuroblastoma cell lines (Sandberg 
et al., 1983), in which with banding techniques, all the cell 
lines were shown to contain a marker with a long HSR. This 
HSR-containing chromosome differed in each cell line. One line 
contained two classes of cells: one with an HSR marker and the
other with DMs. It was suggested that DMs are derived from the 
HSR, with the location and the size of the HSR differing from one 
cell line to the next. This phenomenon, whereby either HSRs or 
DMs are present, has been observed in a number of cases , (see 
table 1.3 for details). The presence of both HSRs and DMs 
concomitantly has been only noted in three cases (Quinn et al., 
1979; Meyers et al., 1989; Slovak et al., 1987). Table 1.3
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summarises the cytogenetic observations in MDR cell lines. It is 
interesting that HT1080/DX4 is the most resistant population 
studied, with DMs been only noted in the less resistant cells. This 
would suggest that HSRs are predominantly found in the more
resistant cells and DMs are found at earlier stages of resistance 
(Riordan et al., 1985). In addition there have been a number of 
suggestions that DMs are related to the de novo appearance of
unusual chromosomes or markers with long HSRs (Balaban-Malenbaum et
al.,1977). These investigators described a neuroblastoma
population cell line that had two populations. In one cell 
population, DMs were observed. In the other cell population, no 
DMs were evident, but marker chromosomes with HSRs were present. 
Since there were marker chromosomes common to both cell populations 
it is possible that both cell populations were derived from a
common precursor. A similar phenomenon was noted in COLO-320 and 
COLO-321. In both cases DMs were observed from the earliest
cytogenetic anaylsis. A number of subcultures lost DMs and gained
HSR markers after 1 to 1.5 years in culture. It was noted that the
number of DMs were drastically reduced in 99% of the cells with HSR 
markers. The basis for the sudden appearance of a new marker
chromosome with a HSR and concurrent disaappearance of DMs is not 
clear.
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Table 1.3. Cytological Evidence for Gene Amplification
in Cell Lines and Tumors.
Cell Line Cytological Evidence for Gene 
Amplification / Comments
Reference
DC-3F/VCR
MAZ/VCR-U
SH-SY5Y/VCR
HSRS
DMs, absent in revertants. 
DMs, absent in revertants.
Meyers et al., 
1985.
HA-A
Melanoma 
Cell Line
Less than 1% of cells had HSR 
alone; greater than 90% had only 
DMs present
Trent et al., 
1984.
CHOB30 Presence of a number of large 
HSRs
Riordan et 
al.,1985.
SH-SY5Y/VCR 100% of cells has 10-100 very 
small DMs
Meyers et al., 
1989.
CEM/MTXR3 
Leukemia 
CEM/VLB.100
MCF7/ADR
Primary Human 
Neuroblastoma
DMs in 10% of cells analysed
HSR present on chromosome 1
HSR present on chromosome 7 
Translocation on chromosome 11 
HSR present on chromosome 13p
Kavallaris et 
al.,1990.
Hill et al., 
1988.
Fairchild et 
al.,1987. 
Balban et al., 
1982.
WiDR/R
Colon
Carcinoma
1GROV1/VCR
Two versions of a HSR 
predominant on the short arm 
of chromosome 7
Del short arm of chromosome 11 
del (6)(ql6)
Dalton et al.,
1988.
Benard et al.,
1989.
Human
Leukemia
Presence of ABR (Abnormal band 
region) on chromosome 13. Not 
sure if it an amplified gene.
Beck et al., 
1987.
NCI-H249P 
Human NSCLC
DMs present ,unstable lost in 
the absense of selection
Curt et al., 
1983.
KB/ADR
KB/VLB
KB/COLCH
DMs present in all resistant 
lines, found to be very 
unstable in absence of drug
Fojo et al., 
1985.
Colo-320
Colo-321
MC-IXC
HT1080/DX4
At low levels of resistance 
100% DMs; in latter stages of 
resistance the number of HSRs 
increased
DMs and HSRs CHR19p and 22q.
DMs and HSRs present in the 
most resistant, DMs only 
present in less resistant.
Quinn et al., 
1979.
Meyers et al., 
1989.
Slovak et al., 
1987.
18
1.5. P-170 Function in Normal Cells.
Expression of P-170 has been detected in a number of normal 
tissues, both as mRNA and protein. Using immunohistochemical 
staining of normal tissues, P-170 is found in liver, adrenal 
glands, pancreas, kidney, colon and jujenum (Fojo et al.,1987). 
Localisation within these tissues appears to be extremely specific; 
it is on the apical surface only of epithelial cells in liver, 
kidney, colon and jujenum; on the bilary canalicular front of 
hepatocytes; on small bilary and pancreatic ductules; and on the 
adrenal cortex (Thiebaut et al.,1987, Sugawara et al.,1988b). 
P-170 has also been detected in human placenta (Sugawara et al., 
1988a) and is expressed on specialised endothelial cells in the 
brain and testis (Cordon-Cardo, 1989 and 1990). Preliminary 
results suggest that in the brain it is on the luminal surface of 
endothelial cells of some post capillary venules. Gene specific 
RNA analysis indicates that most P-170 in normal tissue results 
from mdrl expression. Expression of human mdr3 gene is at lower 
levels, with highest expression in the liver (Van der Bliek et al., 
1986; Chin et al.,1989; Arias et al.,1990). It has been shown in a 
study by Teeter et al.(1990) that the over expression of mdr3 gene 
in mouse liver tumors does not requir exposure of the animals to a 
carcinogenic agent and suggests that its overexpression is 
associated with a general pathway of hepatic tumor development. The 
overexpression of the mdr3 gene in hepatocellular tumors may be 
responsible for the poor response of the tumors to chemotherapeutic 
agents. From the above data, it is evident that P-170 has a normal 
function. The localisation of P-170 to specialised cells in human 
tissues indicates that it might be involved in transepithelial 
secretion of toxic substances or unknown cellular metabolites into
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the bile or the lumen of the GI tract. The fact that the mdrl gene 
can be co-induced with the P4501A1 gene possibly supports this 
(Burt et al.,1988). The discovery of P-170 in the endometrium of 
mouse gravid uterus (Yang et al., 1989) also suggests it might be
involved in secretion of steroid hormones. In a MDR mouse line
1 3binding of [ H] azidopine or [ H] vinblastine to P-170 is inhibited
by steroid progesterone. Also reports by Kacinski et al.,(1989)
and McGuire et al.,(1990) offer evidence that in cancer specimens,
overexpression of P-170 is inversly correlated with the expression
of the progesterone receptor. Using in situ hybridisation Kalinski
et al.(1989) showed that in 9/16 untreated breast cancer patients,
there was a strong inverse correlation between increased mdrl
expression and expression of progesterone receptors. This study
also raises the possibility that in-situ hybridisation may be a
more sensitive technique for detecting mdrl expression in solid
tumors. From both these studies it can be seen that an endogenous
steroid hormone is at least capable of interacting with P-170 and
might represent one class of natural substances for the pump
activity. Another possible function is that P-170 dependent efflux
represents an alternative pathway for the secretion of proteins and
peptides which have no formal signal sequences (McGrath et al.,
1989). This concept was thought to explain the broad range of
drugs transported by P-170 itself, since they could be bound to
different proteins, which were in turn transported by the pump
(Gerlach et al., 1986). Although it has been suggested that host
substrates interact directly with the transporter itself, hence no
carrier proteins would be necessary, other data suggests that
certain proteins may be substrates for P-170. One necessary
requirement noted for P-170 substrates is hydrophobicity. There
appears to be a direct correlation between hydophobicity and
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ability to serve aa a drug substrate for P-170, such that the 
ability of steroids to inhibit P-170 in mouse cells, increases with 
increasing hydrophobicity (Yang et al., 1990a). Further proof of 
this point is that the yeast mating factor-a, a natural substrate 
for the STE6 gene product, is a dodecapeptide containing a 
lipophilic farnesyl group at its carboxyl terminus. In addition 
multidrug resistant cells are resistant to the hydrophobic 
cytotoxic peptides,gramicidin D and valinomycin. One possible 
substrate for P-170 according to the mechanism of protein secretion 
is interleukin-1 (IL-1) (McGrath et al.,1989), a secreted protein 
that is not handled in the classical manner. Like yeast mating 
factor-a, IL-1 has no signal sequence and the mature peptide is 
modified by the lipid myristic acid (Bürsten et al.,1988). In the 
eventuality of mdrl (P-170) not being responsible for protein 
transport, a more distantly related transporter may be found to 
play the role.
The mode of regulation of the mdr genes has been investigated 
extensively. It has been found in the rat that liver damage caused 
by hepatectomy (Thorgeirsson et al., 1987) or treatment of the 
animal with cytotoxic drugs, results in large increases in MDR 
(Gottesman et al., 1988). The mechanism of regulation is unknown, 
but it could involve RNA stabilisation, since new transcription as 
determined by nuclear run-off assays is not seen (Marino et 
al.,1989). The large number of tissue culture models available has 
proven to be a valuable source of material for the study of the 
regulation of the mdr genes. Current examples include heat shock 
or arsenite induction of the mdrl gene in human renal 
adenocarcinoma (Chin et al.,1990) and increased expression in human 
neuroblastoma cells after retonic acid treatment (Bates et
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al.,1990). Regulation of the mdrl gene also appears to involve 
differential promoter utilisation. In a study on human KB cells 
transcription initation starts at one of the two major promoters 
(Ueda et al.,1987a), whereas in most normal tissues only the 
downstream promoter is used. The significance of the activation of 
the upstream promoter is unclear, but it could possibly be related 
to the increased expression of the mdrl gene after drug selection, 
since human childhood acute Lymphocytic Leukemias can show 
activation of this promoter (Rothenburg et al.,1989). In the mouse 
mdrl gene, Raymond et al,(1990b) have cloned the 5' end of the 
gene in an attempt to define cis acting elements implicated in 
transcriptional regulation. Sequences located between nucleotides 
-93 and +84 were able to confer basal promoter activity and cell 
specificity to the reporter gene. The addition to the basal 
reporter of sequences upstream of position +141 was found to 
up-regulate or down regulate the basal level of expression of the 
reporter gene in a tissue specific manner. This suggests that the 
tissue specific expression of mdrl is controlled by the combination 
of positively and negatively cis-acting 5' regulatory elements. 
This suggests a basis for the identification and characterization 
of the trans-acting factors mediating, this regulation both in 
normal tissues and in MDR cells. Another particularly interesting 
study by Cornwell et al.,(1990) found that deletion of sequence 5' 
and 3' of the transcriptional initiation site modulated the level 
of transcription. Deletion of exon 1 sequence +5 to +127, 
completely inhibited accurate initiation of mdrl transcription. 
Replacement of just the +5 site , used for initation in vitro and 
in vivo did not reverse inhibition. mdrl transcription was 
specifically inhibited by an oligonucleotide corresponding to 
sequences +46 to +58. This again proves that sequences upstream
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and downstream of the transcription initiation site affect the 
efficiency of the mdrl proximal promoter. A similar case is noted 
in the mouse J774.2 cell line (Hsu et al.,1990), who showed that 
transcriptional initation from the putative upstream promoter 
correlated with a 70% to 85% decrease in steady state mdrla protein 
levels relative to transcript levels. In addition, the 
identification of putative AP-1 and AP-2 promoter elements suggest 
a possible role for protein kinase A and protein kinase C in the 
regulation of mdrla. It has been suggested that the mdrla gene may 
be regulated by transcription factors which mediate the signal 
transduction pathways involving both protein kinase A and protein 
kinase C.
It has been noted also, that a decrease in Protein Kinase A 
(Abraham et al.,1990, Staats et al.,1990) leads to an increased 
drug sensitivity. A lower level of expression of the MDR gene and 
protein has been described in cells that carry the dominant
regulatory subunit gene of the cAMP dependent protein kinase (PKA) 
gene (Abraham et al.,1990). This suggests a direct effect of PKA 
on maintaining levels of the P-glycoprotein in these cells, 
probably through control effects on gene expression. However, in a 
study by Schwartz et al.(1991), using MCF7-ADR and resistant MOLT 
cells, it was found that the PKC activity can be increased or 
decreased in MDR cells. Both staurosporine and phorbol ester 
activation failed to produce changes in drug resistance, PKC in
MCF7-ADR and MOLTS seems to be unrelated to mdrl levels. To
further define the role of PKC-catalysed phosphorylation
P-glycoprotein function, it will be necessary to inhibit 
phosphorylation, and studies utilizing PKC inhibitors are in 
progress. An alternative approach, whereby PKC is depleted by
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prolonged exposure of cells to phorbol 12-myristate 13-acetate 
(PMA), was precluded, since KB-V1 PKC was relatively resistant to 
PMA down-regulation (Chambers et al.,1990b). Evidence for the role 
of PKC in numerous secretion and transport processes has been well 
documented. PKC activation is associated with release of 
neurotransmittors, hormones and other agents, and with the 
transport of glucose and ions such as Ca++, H+, Na+, K+ and Cl- 
(Nishizuka et al.,1986). The transporter proteins responsible for 
some of these processes have been identified and in some cases 
phosphorylation in vivo noted eg. glucose transporter (Sardet et 
al.,1990). However, the modulation of transport activity via PKC 
phosphorylation of P-170 glycoprotein appears to be unique,and is 
possibly a important factor in the regulation of P-170 glycoprotein 
function.
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1.6 Structure Function Relationship of P-170.
If the structural homologies between P-170 and other transport 
proteins are significant, it appears that a motif of six 
transmembrane portions and a nucleotide binding site is important 
to function. The proof that P-170 exists as a dimer (Boscoboinik 
et al., 1990) could suggest that for conformational reasons there 
may be a need for such transport proteins to be present in at least 
two subunits. One suggestion is that a large structure may be 
necessary to form a membrane channel or pore big enough to 
transport high M.W. substances. Alternatively each unit of 
transmembrane domain may contribute separately and uniquely to 
substrate binding specificity, such that P-170 must be thought of 
as a whole molecule rather than two halves. This observation is 
substantiated by the finding that neither half can function alone 
(Currier et al., 1989). Independent evidence shows that the 
binding sites in each half of P-170, are extremely important in 
drug resistance. Inactivation of either site alone leaves no 
activity, inactivation of one site only leaves only a small amount 
of residual activity (Azzaria et al., 1989). On mutation of the 
nucleotide binding site, the patterns of residual resistance are 
different. This would suggest that both halves of P-170, and 
possibly the 2 nucleotide binding sites are contributary to the 
specificity of drug recognition or binding. Also, slight changes in 
amino acid sequence have been shown to alter drug sensitivity 
patterns or totally abolish them. It is evident that the 
determinants of substrate specificity, interaction and transport 
function will be complex and probably encompass the entire 
structure of these proteins. Intermolecular and interspecies 
chimeras might be interesting in terms of dissecting the
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relationship between structure and function.
1.7. Clinical Relevance of the MDR Genes and P-170 Protein Levels.
Levels of the P-170 glycoprotein and the mdrl specific mRNA have 
been anaylsed in a large number of tumors. In general, expression 
of the mdrl gene is high in those tumors which derive from tissues 
that naturally express high levels of P-170. Tumors derived from 
the colon, kidney, liver and the pancreas usually have such high 
levels. In poorly differentiated kidney and colon tumors the levels 
are often lower because of the altered differentiation state of 
these tumors. In most differentiated tumors of the kidney, high 
levels of expression of P-170 were noted (Kanamura et al.,1989). 
Human tumors of this type are often intrinsically resistant to 
standard chemotherapy, therefore the response rate is normally 
very low. Expression of the mdrl gene is sometimes high in 
leukemias, lymphomas, and some other tissues that do not normally 
express the mdrl gene. This phenomenon is difficult to explain, it 
is thought that one of the biochemical or genetic events that occur 
in carcinogenesis could possible activate the mdrl gene. For 
example when chronic myeloid leukemia goes into blast crisis, the 
mdrl gene is often activated (Pirker et al.,1991). Several kinds 
of tumors have low levels of the mdrl gene and are known to be drug 
sensitive. These include Wilm's tumor and cancer of the ovary and 
the breast. However a number of tumors exhibit low levels of mdrl 
expression but are resistant to chemotherapy, for example 
adenocarcinoma of the lung and non small cell lung cancer. This 
indicates that mechanisms of resistance other than P-170 are 
prevalent, for example involving Topoisomerase 11 or GST. Such 
alternative mechanisms of resistance could also be partially
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responsible for intrinsic drug resistance in colon carcinomas or 
hepatomas. These tumors are derived from tissues that are involved 
in detoxification of exogenous and endogenous toxic compounds, and 
such alternative detoxifying systems could contribute to the 
intrinsic drug resistance of these cancers. A list of the tumors 
in which mdrl expression is usually high, sometimes high, or 
usually low is shown in Table 1.4.
Table 1.4. MDR1 Expression in Untreated Human Cancer.
Usually High Sometimes High Usually Low
Colon Acute Leukemias SCLC
Kidney Lymphomas NSCLC
Liver NSCLC-NE Gastric
Adrenal CML-blast crisis Eesophageal
Pancreas Neuroblastoma Ovary 
Wilm's
Head and Neck
Myeloma
Breast
(Pastan et al.,1991)
Many groups are now investigating mdrl expression in patients with 
acquired drug resistance. Increased expression has been noted in 
drug resistant leukemias, myelomas, ovarian cancer, breast 
cancer, sarcomas and neuroblastomas (Goldstein et al.,1989; 
Bourhis et al.,1989; Golstein et al.,1990; Dalton et al.,1989a and 
1989b). In most cases an increase in mdrl expression was predictive 
of failure to respond to chemotherapy. Elevated levels of P-170 
(both mRNA and protein) have been noted in some solid tumors 
following chemotherapy, however the relationship between clinical 
resistance and elevated levels of P-170 have been very difficult to 
ascertain, (see Table 1.5 for details).
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Table 1.5. Cancers In Which MDR1 Expression has been 
Found to Increase After Chemotherapy.
Acute Leukemias Ovary
Breast cancer Pheochromocytoma
Lymphomas Rhabdomyosarcoma
Multiple Myeloma Sarcomas
Neuroblastoma
(Pastan et al.,1991)
28
A number of case Btudies from different tumor classifications and 
origins will be now highlighted.
Hematological Maligancies:
Expression of P-170 and mdrl RNA has bee found in untreated 
hematological maligancies in which the intrinsic levels of P-170 
would not be apparent e.g. Myelodysplastic syndromes (Holmes et 
al.,1989; Weide et al.,1990) and in chronic myelogenous leukemia in 
blast crisis, but not in chronic phase (Goldstein et al.,1989). 
In some Lymphomas, high levels of expression of mdrl mRNA have been 
noted with 7 of 12 patients with indolent cancers possesing 
moderate levels, but only one of the more aggressive lymphomas 
having comparable levels of expression (Moscow et al.,1989a). 
However high incidences of recurrences have been reported. 
Overexpression of mdr3 mRNA has been reported in many cases of 
polylymphocytic leukemia Nooter et al.,1990b), mdrl overexpression 
was noted in one patient with this disease. The patient in 
question had prior chemotherapy; this was the factor that 
attributed to the increased levels of mdrl. Ma et al.,(1987) used 
western blotting procedures to show P-170 overexpression (following 
initial chemotherapy) in sequential samples from patients with 
progressive chronic myeloid leukemia during chemotherapy. Similar 
findings of a relationship between P-170 overexpression and 
clinical resistance has been reported by Carulli et al.(1988) in 
hematological maligancies.
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Table 1.6. The clinical relevance of the expression of 
the MDR1 gene in hematological maligancies.
Tumor Type
Number of Patients with mdrl expression
Treated Untreated
Secondary acute
myeloblastic
leukemia
(Holmes et al.,1989) 9/13 2/8
Acute Myeloblastic 
Leukemias
(Notter et al.,1990a) 6/10 1/6
Chronic Lymphoblastic 
leukemia
(Holmes et al.,1990) 11/17 2/15
Acute Lymphoblastic 
leukemia, salvage 
chemotherapy 
(Rothernburg et al., 
1989)
3/15 1/9
Acute myeloblastic 
leukemia 
Acute Leukemia 
(Ito et al.,1989)
0/14
0/5
Acute myeloblastic 
leukemia
(Sato et al.,1990a,b) 45/65 28/36
Acute lymphoblastic 
leukemia 
Acute Myeloid 
Leukemia
(Kumazuru et al.1990)
4/11
9/17
Acute Myeloid 
Leukemia
(Pirker et al.,1991) 50/63
In another study by Herweijer et al.(1990) expression levels of 
mdrl and mdr3 were ascertained using an RNase protection assay on 
peripheral blood from 69 patients with acute and chronic leukemias. 
Increased mdrl levels were noted from patients with acute 
lyphocytic leukemia (13/17), CML chronic phase (10/10), blast 
crisis (3/4), ALL (8/11), B-CLL (17/17) and Hairy Cell Leukemia
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(1/2), but not at all in B-cell prolymphocytic leukemia; 
expression of mdr3 was only not noted in B-cell lymphocytic 
leukemias. This study did not specify whether the samples were 
taken before or after chemotherapy.
70% of patients with multiple myleoma are normally treated with the 
VAD (Vincristine, Doxorubicin, Dexamethasone) regime of therapy, 
however nearly all relapse. It has been established that most 
patients who relapse after this regimen express high level of P-170 
(Dalton et al.,1986). The percentage of cells expressing P-170 in 
these treated patients, quantified by immunohistochemistry, was 
significantly greater than found in untreated patients (Epstein et 
al.,1989) Results from an ¿n vitro study by Carulli et al.,(1990a) 
have also supported the implication of P-170 as a mechanism of 
resistance in multiple myeloma. Partial circumvention of 
resistance to the VAD regimen has been possible with verapamil 
(Dalton et al.,1989a).
Malignant Melanoma :
P-glycoprotein expression was measured, using Northern blotting for 
mRNA analysis and immunohistochemistry with MAB C219, in a number 
of primary and metastatic melanoma, (Fuchs et al.,1991). 
Substantial expression was noted in only 1/37 primary melanoms and 
only 1/27 melanoma metastases. None of the patients with negative 
metastases responded to chemotherapy. However, a complete 
remision of metastatic growth was observed in the patient in whom 
metastasis significantly expressed the P-glycoprotein. Sequential 
studies revealed no significant increases of P-glycoprotein during 
and after chemotherapy. It was concluded that P-glycoprotein is 
not a mechanism of resistance in malignant melanoma metastases.
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Colon Carcinoma :
P-glycoprotein was noted in 65 of 95 primary colon carcinomas
(using RNA and protein analysis) which were stage B1 or greater 
(Weinstein et al.,1991). An interesting observation was that P-170 
positive invasive colon cancer cells appear to have an increased 
potential for dissemination, suggesting that P-170 may influence 
cellular properties other than drug resistance.
Childhood Sarcoma:
In general, the high level of expression of P-170 appears to be an 
adverse prognostic factor for tumor response to chemotherapy.
P-170 was elevated in nine patients with childhood sarcoma, all of 
whom relapsed after an initial response, whereas only one of 20 
initially negative P-170 patients, relapsed after clinical response 
(Chan et al.,1990).
These workers used a markedly improved immunohistochemical 
technique for P-glycoprotein detection that can be applied to 
formalin fixed, paraffin embedded tissue sections. In the 9 
positive samples,small patches of P-glycoprotein positive cells 
were detected. These would have been probably missed in using bulk
techniques and they appeared to be of crucial importance in the
development of MDR phenotype.
Kaposi's Sarcoma:
Significant P-170 expression has been found in untreated tumors 
from 10-12 skin biopsies in patients with Kaposis sarcoma 
(Schwartsmann et al.,1989).
32
Neuroblastoma:
Goldstein et al.(1990) reported high levels of mdrl expression in 
5/18 patients with neuroblastoma, but only 3/31 untreated patients 
with the disease. Corrias et al., (1990) showed no amplification 
in 34 patients with neuroblastoma, using southern blotting 
procedures and in gel renaturation.
Ovarian Carcinoma:
Advanced nonresponsive ovarian cancer was found to overexpress
P-170 in 2/5 cases (Bell et al.,1985; Bourhis et al.,1989). 
Another study (Bell et al.,1985b) reported 3/15 tumors expressing 
P-170, the P-170 positive patients failed to respond to
chemotherapy, as opposed to none of the 35 untreated ovarian 
carcinomas were positive for P-170. Similarly, Sikic's group found 
11/33 Vs 8/50 untreated ovarian carcinomas, as well as 5/15 
previously treated breast cancers expressing high levels of P-170 
mRNA. Two MABs (C219 and JSB1) were used to identify P-170 in 
frozen tissue from the genital tract of 14 women with benign 
gynecological conditions (Finstad et al.,1990). P-170 was noted in
half of the analysed samples. It was suggested from this study
that if epithelial ovarian cancers are derived from the surface
epithelial cells of the ovary, a small proportion of the cancers 
might be expected to retain the phenotype found in non-cancerous 
tissues and to express P-170.
Breast Carcinoma:
Significant P-170 expression has been detected by immunohisto- 
chemical staining in three samples from patients with breast 
cancer, who had either received an anthracycline or a vinca 
alkaloid in treatment. However, patients who had received either
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alkylating agents, antimetabolities, or hormonal agents showed 
little or no expression of P-170 (Schneider et al.,1989). 
Significant MDRl mRNA expression was also detected in 25/49 primary 
breast samples from untreated patients using Northern and Dot 
Blotting procedures, (Keith et al.,1990). Also, Verelle et
al.(1991) confirmed the presence of P-170 in 17/20 tumors; 3 of
these patients had confimed metastases in which the highest levels 
of P-170 were noted.It was concluded from this study that 
pretreatment evaluation of P-170 expression may be of prognostic 
value in patients with locally advanced breast cancer. However, 
Jungsil Ro et al., (1990) and Merkel et al.(1989) found no
significant levels of P-170 in breast cancer at any stage. It was 
concluded that it is possible that acquired resistance may play an 
important role in the failure of locally advanced breast cancer.
It can be noted from the above data on P-170 expression in breast 
cancer, that the results are not consistent from one investigator 
to the next. In order to evaluate fully the role of P-170 in 
clinical resistance it is necessary to develop sensitive
reproducible assays which also must be able to discrimate between 
normal and neoplastic tissue (Dalton et al.,1991).
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1.8 Alternative Mechanisms Involved In MDR.
Although the study of MDR has mainly focused on P-170 expression, 
an increasing number of biochemical and molecular mechanisms have 
been described in MDR selected cell lines. These findings have 
resulted in the designation of MDR phenotype as "classic" (denoting 
P-170 mediated MDR), or "atypical" MDR (At-MDR) in which cells 
appear to possess other mechanisms of MDR. The two best 
characterised additional mechanisms observed in cells that are 
multiply drug resistant are changes in the expression of activity 
of enzymes involved in detoxification pathway (in particular 
Glutathione-S-Transferase, GST) and alterations in the nuclear 
enzyme Topoisomerase 11 (Topo 11). Several MDR lines which do not 
express P-170 show patterns of cross resistance significantly 
different from the classical MDR phenotype. (Haber et al.,1989 ;
Weber et al.,1989). GST is a multifunctional phase 11
detoxification enzyme that catalyses the conjugation of
electrophilic substances and endogenous xenobiotics to the
tripeptide thiol Glutathione (GSH), forming stable secretable 
metabolites, and prevents oxidative damage through intrinsic, 
organic peroxidase activity. Alterations in the activity of GST 
and GSH-related enzymes have been identified in several cell lines 
associated with cross resistance to alkylating agents. (Tew et 
al.,1986; Lewis et al.,1988; Saburi et al.,1989 ;Durse et
al.,1990). Certain isoenzymes of GST may protect cells against the 
damage caused by free radicals, which may be an important 
determinant in the cytotoxicity of anthracyclines (Bradley et 
al.,1988). Comparison of cloned MDR P388 mouse leukemia cells with
cloned wild type parental cells showed increased expression of GST,
and more rapid onset of repair, but no evidence for enhanced drug
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efflux in the resistant variant (Deffie et al.,1988 a,b). In 
addition, the doxorubicin selected MDR human breast cell line, 
MCF-7ADRr, possesses an amplified and overexpressed MDR1 gene 
(Fairchild et al.,1987). It also shows a seven-to twelve-fold 
increased selenium dependent-GSH peroxidase activity and a 45 fold 
increased GST activity , the latter resulting from the increased 
expression of a single, anionic(n)isoenzyme of GSH (Mimnaugh et 
al.,1989). This could possibly suggest that GSH peroxidase or GSH 
may have independent activity in conferring cellular resistance to 
adriamycin. Transfection and expression of cDNA clones of the GSTtt 
isoenzyme in drug sensitive MCF-7 cells that do not overexpress 
P-170, conferred extremely low level (1-2 fold) resistance to 
alkylating agents, but no increase in resistance to natural 
products such as adriamycin (Moscow et al.,1989b). Thus, the role 
of GST in MDR involving non-alkylating agents is not very clear. 
However, work involving the gamma-glutamylcysteine synthetase 
inhibitor buthionine sulfoximide (BSO) suggests that the GSH system 
may have a role in addition to that of P-170 in the conferring of 
MDR. The addition of BSO results in a five to seven fold increase 
in cellular sensitivity to adriamycin MCF-7ADRr cells (Durse et 
al.,1989); an effect was also noted, but to a lesser extent by 
Ford and Hait (1989) where only a 1.5 fold increase in the 
sensitivity of 200 fold doxorubicin resistant MCF7-ADRr cell line 
was seem. A particularly interesting study has been reported in 
which three distinct cell lines were established from a patient 
with small cell lung cancer (De Vries et al.,1989) at different 
stages of disease, (from sensitive to completely resistant to 
chemotherapy). Progressive increases were seen in levels of 
glutathione, GSH, and catalase; cell surface P-170 
immunofluoresence staining was only evident in the most resistant
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of the in vitro cells. In these studies, BSO enhanced adriamycin 
and cis-platin cytotoxicity (but not X-ray induced cytotoxicity). 
However, in the SCLC cell line H69AR a marked decrease in the 
level of GSH was noted. The activity of three enzymes 
(GSH-S-transferase, GSH-reductase and gamma-glutamyl
transpeptidase) were elevated while the selenium -dependent and 
independent GSH -peroxidase activities were unchanged. The 
consequences of these changes resulted in an 6-fold reduction in 
H69AR cellular GSH levels. This pattern of resistance is different 
to that reported for other SCLC cell lines, however it has not 
been conclusively proved that thes changes link with the mechanism 
of resistance (Cole et al.,1990). These researchers established 8 
small cell lung cancer lines, from treated and untreated patients. 
None of the cell lines showed detectable levels of P-170. There 
was however a 50 fold range in the total activity of 
glutathione-S-Transferase (8-409nm CDNB/min/mg) and a four fold 
range in the activity of glutathione peroxidase (10-40 nm cumene 
HjOj/min/mg). The activity of glutathione-S-transferase measured 
is mainly due to the n isoform. The effect of ethacrynic acid, a 
potent inhibitor of GSH was investigated and no modulation of MDR 
was noted. In tranfection studies by Fairchild et al.(1990) it was 
shown that transfection of GST7r in an expression vector (pMTP) is 
insufficent to confer resistance to adriamycin in cells that lack 
P-170. Another study was undertaken to acertain if GSTtt could be 
acting in a synergistic effect with P-170 to alter MDR. Using the 
MCF7ADRr cell line and vectors expressing full cDNA for GSTtt and 
mdrl. it appeared that GST7T does not alter patterns or levels of 
MDR in MCF7ADRr cells. In a study by Keith et al.(1990) all breast 
tumor samples with the exception of one showed low or undetectable 
levels of GSTtt. Also, the leukemia samples generally had low
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levels of GSTtt. However, both colon tumors and a large proportion 
of head and neck tumors had high levels of GSTtt mRNA levels. 
Expression of mdrl and GSTw genes in 35 advanced neuroblastomas 
have been reported by Bourhis et al.(1990). No co-ordinate 
expression between the two genes was found. GSTtt and MDR1 
expression failed to be significantly related to the response of 
the primary tumor at the first induction treatment, however in 
subsequent studies and on the occasion of metatasis, a significant 
relationship was noted between combined expression of MDR1 and GSTtt 
genes and tumor response in neuroblastoma patients. It is 
interesting to note that the high levels of GSTtt have been apparent 
in tumors that are intrinsically resistant. This could be a 
possible indication that GSTtt is an important factor in the 
development of intrinsic resistance. To date GSTtt has been mainly 
implicated in the MDR phenotype, Recently a number of reports have 
emerged that show elevated levels of other isoforms. Evidence of 
over expression of GSTp class subunits in human breast carcinoma 
have been found (Schisselbaurer et al.,1991), and GSTtt in addition 
to GSTa and GSTp in patients have been found with malignant 
lymphoma (Ringborg et al.,1991).
One specific atypical MDR phenotype involving cross resistance to a 
variety of natural product antitumor drugs, but not to 
Vinca-Alkaloids has been the reduction of DNA Topoisomesase 11 
(Topoll) (Beck et al.,1989). The topoisomerases are enzymes that 
catalyse the breaking and rejoining of DNA required for genomic 
unwinding and are necessary for DNA replication. Much attention 
has been focussed on the role of topoisomerase 11 in drug 
resistance because it is believed to be a target for many DNA
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intercalating and non-intercalating drugs such as doxorubicin, 
mitoxantrone, etoposide, tenoposide and 4'-(9-acridinylamine)- 
methanesulfona- m-aniside (Chen et al.,1984). Alteration in the 
quantity or function of Topoisomerase 11 has been suggested as a 
possible mechanism for cellular resistance to this group of drugs 
(Ross et al.,1988). Several MDR cell lines are characterised by 
decreased levels of Topisomerase 11 activity in the absense of 
P-170 expression or changes in drug accumulation, (Pommier et 
al.,1986; Charcosset et al.,1988; Deffie et al.,1989; Zwelling et 
al.,1989;De Jong et al.,1990). The decreased enzyme level could be 
due to a number of factors. During the enzymatic modification of 
the topological state of the DNA, Topoll binds to the DNA to form 
a enzyme DNA reaction intermediate. Many of the chemotherapeutic 
compounds are DNA intercalative drugs and they interfere with the 
action of the action of the enzyme by trapping the enzyme, 
covalently bound to the 5' end of the DNA break, thus reducing 
intracellular concentration of Topo 11. Also, a number of
investigators have suggested that the enzyme in resistant cells is 
of a much higher activity, despite the reduced quantities 
(Capranico et al.,1990). There has also been a suggestion by 
Cunningham (1991) that DNA Topoisomerases might be involved in 
oncogenesis. Inherited susceptability to a wide range of neoplasia 
(Li-Fraumeni syndrome), was shown in studies of one cancer prone 
family,whereby an intriguing association with an abberent c-raf-1 
gene and the inheritance of a radioresistant phenotype in their non 
cancerous fibroblasts was found. Additionally a p53 germline 
mutation is evident in Li-Fraumeni syndrome. Also the fact that 
topoisomerases are preturbed by in vitro serine/threonine kinases 
similar to raf encoded proteins (which conveys radioresistance), 
indicates a possible role for topoisomerases in the advent of
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carcinogenesis. It has been found that topoisomerases can introduce 
error into the DNA,particularly but not exclusively, when perturbed 
by activators. This malfunction has been implicated in mutation, 
sister chromatid exchanges, chromosome stickiness, fragmentation 
of tumor DNA and tumor promotion. The fact that it has now been 
established that Topoisomerase 11 is required for chromosome 
condensation (Adachi et al.,1991), this implies any alterations in 
levels of Topo 11 could have a drastic effect on the natural 
function of the cell. Multifactorial resistance tends to be a 
common enough finding. Ganapathi et al.(1989) characterised a 
series of L1210 cells selected for progressively incresaed 
resistance to doxorubicin. These cell lines displayed increased 
expression of P-170 in addition to reduced Topoisomerase 11 
mediated clevage of DNA. Reduced levels of DNA Topoisomerase 11 
have been evident in a number of multidrug resistant cell lines, 
FM3A breast carcinoma (Hong et al.,1990), A549/CPT and HT29/CPT 
(Sugimoto et al.,1990), CCRF-VMl human leukemic (Danks et 
al.,1988), SCLC and Non SCLC (Danks et al.,1988) P388 Leukemia
cell (De Isabella et al.,1990) and SCLC GLC4/ADR (De Jong et 
al.,1990). Much emphasis in this area is now given to models of 
topoisomerase gene regulation, such as altered rates of 
transcription. Kaufman et al.(1991) added additional confirmation 
of the presence of hypermethylation in atypical MDR cell lines, 
this could open new avenues for therapeutic intervention. For 
example, treatment with azacytidine which inhibits DNA 
methylation, might up regulate the expression of Topoisomerase 11 
resistant (presumably hyper methylated) cells sensitive to 
antineoplastic agents. However, the clinical use of Topoll 
directed agents may be limited, particulary in the treatment of 
intrinsically resistant tumors (Kaufmann et al.,1991). Screening of
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bacterial gyrase inhibitors has identified quinolone analogues that 
induce Topoll mediated strand breaks in eukaryotic cells by 
enhancing the rate of Topoll -DNA aduct formation. Given their 
unique structure and novel mechanism of action, it will be 
interesting to see whether these agents have any unique antitumor 
activity. The concept of tailoring drugs against Topo 11 mediated 
MDR has been also highlighted by Baguley et al.(1990) and Beck et 
al.(1989).
Many other mechanisms of resistance have been suggested as 
important features of MDR cells. Certain of these changes appear to 
occur only in conjunction with mdrl gene expression. This is an 
indication that the other genes which may be part of the six gene 
amplicon localised to chromosome 7q21-31, are well associated with 
MDR cells. Amplification been a hallmark of MDR cells, the 
overexpression of other genes that are part of this amplicon is not 
surprising. For example, Sorcin, a 22 Kda anionic calcium binding 
protein, has been shown to be overproduced in vincristine 
resistant mouse cells (Meyers et al.,1985, 1987) and in L1210 cells 
selected for MDR with VP-16, VM2 6, adriamycin , dactinomycin or 
vincristine (Roberts et al.,1989). However it is unclear if sorcin 
itself plays a role in the establishment, maintenance or patterns 
of MDR. Other low molecular weight cytosolic proteins are uniquely 
expressed in MDR, such as a 21Kda protein found in colchicine 
resitant KB cell lines (Shen et al.,1986) and a 20Kda protein 
phosphorylated to a greater extent in MCF7-ADRr cells exposed to 
phorbal esters (Fine et al.,1988). The significance of these 
proteins in MDR is unknown. Similarly, several membrane proteins 
unique to MDR cells have been observed in addition to P-170, such 
as an 85-Kda glycoprotein in K562/ADM cells (Hamada et al.,1988)
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and a 150 Kda protein immunologically distinct from P-170 (Me Grath 
et al.,1988). Numerous biochemical changes have been implicated in 
MDR. Decreased levels of epidermal growth factor were reported in 
an MDR variant of human KB cells with reduced tumorigenicity 
(Takano et al.,1989). Alterations in the monophosphate shunt have 
been reported (Yeh et al.,1987) in an adriamycin resistant variant 
of a human breast carcinoma, MCF-ADRr. In this same cell line
alterations in the phase 1 cytochrome P450 enzymes such as aryl 
hydrocarbon anhydroxylase (Ivy et al.,1988), and an increased 
activity of the drug activating enzyme DT-diaphorase and Glucuronyl 
transferase (Cowan et al.,1986) have been observed. Induction of 
the enzyme Thymidylate Synthase (Chu et al.,1991) has been noted in 
Human breast MCF-7/ADR cell line and in the colon cancer cell line 
DLD-Ad, this was following exposure to adriamycin ,with concomitant 
resistance to 5-Flurouracil noted. A number of studies are now 
noting the alteration of a number of varied enzyme systems in 
resistant cells. Redmond et al.,(1991) in the study of human
colorectal tumors noted alterations in glutathione, glutathione 
transferase and peroxidase, and the DNA repair enzyme
O^-alkylguanine-DNA-Alkyltransferase. All of these showed 
significant increases in tumor tissue levels when compared to 
normal tissue from the same patient. The significance was highest 
for glutathione peroxidase. Increased expression of 0®- 
alkylguanine-DNA-alkyltransferase has been noted in two other
systems also,a human melanoma cell line (Egyhazi et al.,1991) and 
human brain tumors and biopsies (Tuma et al.,1991).
It is assumed that these changes have a significant regulatory or 
functional role rather than being simply a coincidental result of 
the selection procedure. The large number of changes highlighted
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give an indication of the complexitity of the MDR phenotype.
The permutations and combinations of mechanisms of MDR are indeed 
extensive. It may be of clinical importance to ascertain the 
normal levels (of the above stated enzymes) in various tissue 
types, and whether these levels change significantly from tumor 
tissues to normal tissue. These changes, if highlighted could be 
exploited to prevent the emergence of resistance by the development 
of drugs that would act as first line targets against these 
enzymatic alterations. Therefore, numerous avenues exist to further 
establish the regulatory mechanisms for MDR and for exploring the 
molecular and biochemical basis for alternative forms of MDR.
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1.9. Pharmacological Reversal of MDR.
A major goal in experimental as well as clinical studies in the MDR 
area,is that of reversal of MDR with compounds that are not too 
toxic in vivo. Therefore, many investigators have focused on the 
pharmacological reversal of MDR. Through the identification of 
agents that can reverse resistance it is hoped to introduce these 
agents to clinical situation and to gain a further understanding of 
the mechanisms of MDR. The chemosensitizers described to date can 
be grouped into nine categories :
1. Calcium Antagonists.
2. CaM antagonists.
3. Non toxic antracyclines and Vinca Alkaloid analogues.
4. Steroid and Hormonal analogues.
5. Miscellaneous cationic compounds.
6. Cylosporins.
7. Antisense oligonucleotides.
8. Anti-MDR antibodies conjugated with toxic agents.
9. Agents that can alter At-MDR, Topoisomerase 11 resistance.
(See section 4.9. and 4.10. for more comprehensive details)
Although these compounds only share broad structural similarities, 
most are extremely lipophilic, and those in the first five groups 
are heterocyclic, amphipathic substances. This suggests that there 
is more than one specific receptor site for circumvention agents, 
which have unique, although as yet poorly defined, structural 
requirements for efficent binding and circumventing ability (Ford 
et al.,1990). MDR cells are not normally resistant to cis-platin,
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but it is interesting to note that calcium channel blockers (Onada 
et al.,1989; and Ikeda et al.,1987) as well as hyperthermia may 
reverse cis-platin resistance (Bates et al.,1990; Manouri et 
al.,1989).
Verapamil,the compound that has been most used to date in in vitro 
and in vivo studies has been found to be extremely cardiotoxic. 
Plasma concentrations of verapamil have not been monitored, because 
the cardiovascular therapeutic effects are easily measurable and 
titratable. Usual plasma concentrations for treatment of angina 
are 150-500jL/g/ml (0.4-1.2^M) (Anderson et al.,1982). Clinical
toxicity begins to occur with concentrations greater than these and 
are characterized by atrioventricular blocks and hypotension. The 
plasma concentration required to produce an MDR sensitizing effect 
is in the 2-6/jM range. Thus, the concentration that is required to 
produce an effect in vivo possesses potentially life threatening 
cardiovascular effects. Therefore, more potent and less toxic 
chemosensitizing agents than verapamil were investigated in this 
thesis. Verapamil was used as a 'standard' chemosensitizing 
compound, also because it has been proven to be effective in the 
reversal of P-170 mediated resistance. A number of other compounds 
were studied to ascertain their circumvention effect on a panal of 
MDR cells, nifedipine, chloroquinine, quinine, quinidine, caffeine 
and aspirin. Nifedipine is a calcium channel blocker, which has 
less calcium antagonizing ability than verapamil, but its potency 
would be higher, it has been found that it is possible to obtain 
clinically non-toxic levels of nifedipine and it has been proven 
effective in a number of in vitro systems (Ramu et al.,1984 ;
Tsuruo et al.,1983a). Chloroquinine, a lysosomotropic agents, has 
been tested on a number of in vitro systems and proven to be
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effective (Shiraishi et al.,1986; Zamora et al.,1988; Beck et 
al.,1988). It has as yet not been studied in vivo but its 
structure, pharmacology and metabolic pathways indicate that it may 
be suitable. Quinidine and Quinine have been shown to be non-toxic 
in vivo and both have used in in vivo studies (Tsuruo et al.,1984;
Zamora et al.,1988). Caffeine another lysosomotropic agent has not
been investigated as a circumvention agent previously, it was 
chosen for study due to the large volume of data available on 
achievable in vivo levels. Finally, aspirin was chosen because it 
fits into the mould that has been outlined as the essential 
requirement for a circumvention agent. It is an extremely
lipophilic, cyclic amphiphathic substance and it has also been
shown to have an effect on intracellular calcium levels (Flescher 
et al.,1991). It has been noted however by a number of 
investigators that the calcium levels do not alter in resistant 
cells during the circumvention process (Naito et al.,1989). Despite 
this, due to the diversity of compounds already tested and proven 
to wholly or partially reverse resistance, aspirin was 
investigated on a number of MDR cell lines. There would be 
enormous clinical implications if a compound like aspirin was to 
prove effective in reversing resistance, due to the volume of data 
available on its mode of action and its synergistic effects.
A tremendous amount has been learnt about MDR at the molecular, 
biochemical, and cellular levels, but little yet has been 
translated into clinical gains. However much of the data now 
emerging from studies of the clinical expression of P-170 and its 
relevance to drug resistance in humans, suggests that there will 
be a role for chemosensitizers in cancer chemotherapy. Such 
circumvention strategies may be effective in intrinsic or acquired
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drug resistance. However even if P-170 associated MDR proves to be 
a relevant and reversible cause of drug resistance, numerous 
questions remain to be answered before effective clinical 
chemosensitization may be achieved. Such factors as absorption, 
distribution, metabolism and toxicity, the effect of the
chemosensitizing agent on chemotherapeutic drug toxicity to normal 
tissues expressing high levels of P-170, and the most effective 
regime, all still remain to be studied in vivo. When to
administer the chemosensitizing agent in a regime of therapy is 
another important consideration, should it be administered with 
first line chemotherapy the ward off the development of resistance 
or should it be administered in cases of relapse in second line 
chemotherapy. Clinicans are very wary of the former regime because 
if a standard chemotherapy has proved effective in the treatment of 
a certain tumor type, there is a certain conservatism in the 
readiness to change. However, the addition of a chemosenstizing 
agent in first line therapy in the treatment of Ehrilich ascites 
(adriamycin resistant) in mice, has been proven to increase the 
life span rather than treatment of a recurring tumor with 
chemotherapy and chemosensitizing agent (Tsuruo et al.,1985). 
Clinical drug resistance however, may be so complex that the
likehood of a drug that effects only one mechanism of resistance is
small. It must be noted, that renal cell carcinoma and colonic 
carcinoma express high levels of P-170 and these tumors are 
resistant to virtually all classes of chemotherapeutic agents, 
including those not classified as MDR drugs. Indeed, multiple 
mechanisms of resistance are much reported (See section 1.9 for 
details). This would should be taken into account in the design of 
regimes of therapy incorporating chemosensitizing agents. Future 
regimes may need to include combination chemosensitizers or the
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rational use of drugs to circumvent the likely causes of 
resistance. This approach is definitely not simple. For example, 
Kramer et al.,(1988) used a combination of buthioine sulfoximide 
(BSO) a potent inhibitor of GSTtt, with verapamil (a known
chemosensitizing agent of P-170 mediated resistance), on the 
MCF7-ADRr cell line (That is known to have altered P-170 and GSTtt
levels in its resistant variant) . It was found that the
combination of the two agents could completly reverse resistance, 
whereas each agent individually could not. It was found that the 
combination of BSO and verapamil in the absence of adriamycin was 
extremely toxic to tumor cells. Futhermore otherwise non-toxic 
doses of verapamil were found to be lethal to animals receiving BSO 
(at non toxic levels) in their drinking water. These finding 
emphasize the complexity involved in reversal of multiple
mechanisms of resistance. Findings to date definitely provide
promise for potential clinical applications in the future. The
further study of circumvention agents in animals an man and the
rational search or design of novel chemosensitizers with improved 
activity should define the importance of MDR to clinically 
resistant cancer.
1.10. Aim of This Thesis.
The aim of the research described in this thesis was to select a 
range of Multiply-Drug-Resistant human tumor cell lines (by 
adaptation in progressively increasing concentrations of
adriamycin) and to characterize these cell lines using
pharmacological, biochemical, biophysical and genetic criteria. 
Cross resistance profiles would then be ascertained for each of the 
cell lines, as this can be a first indication as to the mechanisms
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of resistance. An assessment was also undertaken of clonal 
variation in drug sensitivity; sensitivity of the cells to
standard subculture procedures; sensitivity to standard freezing 
procedures; and resistance above the parental cell line to
sonication. Possible involvement of overexpression of P-170 in the 
variants was investigated by the techniques of Western Blotting, 
Immunofluorescence and by transfection with antisense 
oligonucleotides. An antisense oligonucleotide, (18mer), which was 
specific for 18 bases downstream of the mdrl gene promoter was used 
to test the inhibition of P-170 expression, with an adriamycin
toxicity assay as the endpoint to the assay. Transfection 
techniques were investgated and optimized with a view to 
transfection of the complete cDNA for the mdrl gene. The aim of 
this aspect of the study was to compare the characteristics of an 
"adapted" cell line to that of a transfected "cloned" cell line. 
Due to the long time period involved in the development of 
"adapted" cell lines development of resistant cell lines by
transfection procedures is certainly less troublesome. Whether or 
not transfected cell lines are as adequate of the in vivo situation 
as lines adapted to resistance by exposure to drugs in vitro 
remains to be determined.
HSRs and DMs are a common cytogenetic manifestation in MDR cells. 
A number of the adapted cell lines were studied for the presence of 
DMs to ascertain if the number of DMs is representative of the 
degree of resistance.
Several of the cell lines chosen were derived from human non small 
cell lung carcinomas (DLKP, SKMES-1, SKLU-1, and DLRP) since
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resistance mechanisms in these tumors are relatively poorly 
studied. This research also covered cell lines of ovarian . (OAW42) 
and cervical origin (HEP-2). A particular emphasis in this thesis 
is investigation of "circumvention agents" which might be useful in 
the clinical reversal of resistance at pharmacological doses.
The investigation of the biochemical, biophysical and genetic 
characteristics highlighted above will add to our knowledge of the 
basic biochemical alterations and the mechanisms of resistance in 
MDR cells and could be relevant in the design of new regimes of 
therapy and circumvention.
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ICHAPTER 2
MATERIALS AND METHODS
51
2.1. Ultrapure HjO.
A Milli-Pore milliQ ultrapure water system or an ELGA UHP system 
was used to purify all water used for preparation of media and 
reagents. These systems consist of a reverse osmosis system, MilliQ 
or double distilled apparatus with two prefilters to remove ionic 
and non-ionic solutes, followed by two-ion exchange filters, a 
carbon filter and a 0.22pm cellulose acetate filter. The quality of 
water is monitored by an on line conducting meter, with the 
specifications of 10-18 megaohms/cm resistivity as the acceptable 
standard.
2.2. Glassware for Cell Culture.
Media and reagent glassware, plus bottlecaps (separately) were 
soaked in a non-toxic detergent RBS-25, at 2% (v/v) in warm water. 
1-2 hours later bottles were scrubbed manually and rinsed 
thoroughly in warm water, rinsed three times in reverse osmosis or 
double distilled water followed by a final rinse in ultrapure I^O. 
Glassware containing waste medium from cells was autoclaved and 
rinsed with tap water, and washed and dried as above. All glassware 
was dried and autoclaved before use.
2.3. Sterilisation.
Water, glassware and solutions of thermostable compounds were 
sterilized by autoclaving at 120°C for 20 min. at 15 p.s.i. 
pressure. Temperature labile chemicals (eg. chemotherapeutic drugs, 
enzymes) were filter sterilized through 0.22pm sterile disposable
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filters (millipore millex-gv, for low binding of protein). Growth 
medium was sterilized via a Bell filter (Gelman G.1423S).
2.4.1. Growth Medium.
Liquid DMEM (Gibco 042-02501) media were prepared from concentrated 
10X stock solutions of basal media and were diluted before use with 
ultrapure HjO. MEM a (Gibco 041-24561M) was purchased in IX form 
and HAMs F-12 was made up from powdered media. HAMs F-12 contains 
many labile components, thus the stability of the components is 
greatly increased on lyophilization. Powdered HAMs F-12 (Gibco 
074-1700) was reconstituted in 95 % total volume with ultrapure H20 
and 1.176g/L sodium bicarbonate added, the pH was adjusted 0.3-0.2 
pH units below the desired pH (pH 7.5). The total volume was 
brought to 5 litres and filter sterilized through a Gelman Sterivex 
unit equipped with a peristaltic pump. Medium was collected in 
500ml sterile bottles and stored at 4°C for up to 3 weeks. All 
medium was supplemented with 2mM L-glutamine and other components 
(see table 2.1 for details). All media were supplemented with FCS 
or NBCS at a concentration of 5-15 % depending on the cell line 
(see Table 2.2 for details). Before use, all media were sterility 
checked. 5-10 mis of medium was dispensed into sterile universals 
and incubated at 37°C for 3 days. Antibiotics were not used during 
routine cell culture. 1 ml Penicillin/Streptomycin (Gibco 
043-05140H) and 250/j1 Fungizone Gibco ( 043-05290) per 100 mis of 
growth medium were used for all large scale animal cell culture.
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TABLE 2.1. Growth Medium and Supplements 
(per 500ml basal media)
Media
Component
DMEM MEM-a DMEM/HAMs:F12 
(50:50)
2mM L-Glutamine 
Gibco 043-05030
5ml 5ml 5ml
1M Hepes * 
Sigma H-9136 10ml 5ml 10ml
7.5% NaHC03 
BOH 30151
6ml 6ml 6ml
* Hepes :4- (2-hydroxyethly) -piperazineethanesulfonic acid.
2.4.2. Assay Medium.
Assay medium was prepared by the mixing of DMEM and Ham-F12 in the 
proportion 50mls50ml, measured out exactly using a 10ml pipette,the 
addition of 5% FCS, 1ml of L-Glutamine, 1ml Penicillin/Steptomycin 
and 250pl Fungizone.
2.5.1. Cell Lines.
All cell culture work was carried out in class II downflow 
recirculating laminar flow cabinet (Microflow, Holten or Cytoguard 
- which is specially designed for handling chemotherapeutic
agents). See table 2.2 for details of cells cultivated. Cell lines
2 2 were grown in 25 cm flasks (Cell Cult 32025) or 75 cm flasks
(Costar 307S) in the recommended medium. Routinely cells were fed
every 2-3 days, or when a pH change was observed, (i.e. phenol red
color change in media); on reaching confluency cells were
subcultured.
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Table 2.2. CELL LINES.
Cell Line Growth media 
% FCS
Details of 
Cell Type
Source
HEP-2 DMEM/HAMs F12 
5% FCS
Human Larynx 
Carcinoma
ATCC 
CCL 23
OAW42 DMEM 
10% FCS
Human Cyst-
Adenocarcinoma
Ovary
ECACC
8507310
SKMES-1 DMEM/HAMS F12 
5% FCS
Human Lung 
Squamous Cell 
Carcinoma
ATCC 
HTB 58
SKLU-1 DMEM/HAMs F12 
5% FCS
Human Lung 
Adenocarcinoma
ATCC 
HTB 57
DLKP DMEM/HAMs F12 
5% FCS
Human Lung 
Squamous Cell 
Carcinoma
G.Grant. 
NCTCC,DCU
DLRP DMEM/HAMS F12 
10% FCS
Human Lung 
Squamous Cell
B.Gregory 
NCTCC,DCU.
CHOKI HAMS F12 
5% FCS
Chinese Hamster 
Ovary
MDR-Sensitive
ECACC 
CCL 61
CHrC5 MEM-c* 
5% FCS
Chinese Hamster 
Ovary
MDR-Resistant
V.Ling.
LTK- DMEM 
5% FCS
C3H/Mouse Areolar 
Fibroblast
ECACC
85011432
NIH3T3 DMEM 
5% NBCS
NIH Swiss Mouse 
Embryo Fibroblasts 
Clone D4.
ECACC
85111801
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2.5.2. Large Scale Cell Culture.
Cells required for RNA and protein analysis were required in
Qnumbers in excess of 10 cells. For this purpose Roller bottles 
were used. Bellco roller bottles were used with an internal surface 
area of 670 cm were washed, (section 2.2) dried and autoclaved. 
Firstly roller bottles were rinsed with about lOmls of growth 
medium (containing 5% FCS and 1ml of penicillin streptomycin) and 
and then innoculated with 5X105 cell/ml of the required cell type. 
The roller bottle was then left at 0.25 r.p.m. for 24 hours and 
then increased to 0.75 r.p.m. The roller bottle was fed every 2-3 
days until confluency.
2.5.3. Subculture of Cell lines.
Animal cells grow in monolayer attached to the bottom of culture
vessels. Upon reaching confluency, cells were enzymatically removed
using 0.25% Trypsin (Gibco 043-05090) 0.01% EDTA in PBS-A (Oxoid
BR14a). Solutions were prewarmed to 37°C. Waste medium was removed
from the cells which were then rinsed with PBSA or Trypsin/EDTA ,
for every lOmls of growth medium on the cells 2mls of trypsin
solution was used. 2ml of Trypsin/EDTA was added and incubated with
the cells for 10-15min, at 37°C. Once a single cell suspension
was obtained, medium containing FCS, which contains an inhibitor
of trypsin, was added (An equal volume of the trypsin originally
added). The cell suspension were then transferred to a sterile
universal (Sterlin 128A) and centrifuged at l,000rpm for 5min. The
cell pellet was then resuspended in 5ml of growth medium and a
3 4count obtained (section 2.5.4) Cells were then diluted to 10 -10
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per ml of growth medium, this figure is dependent on the cell
2line. 10ml of cell suspension was added to 25cm flasks and 20ml
2to 75cm flasks. Cells were then incubated at 37°C.
2.5.4. Cell Counting.
A sample of a single cell suspension was applied with a Pasteur
pipette to a Weber haemocytometer such that it was held in the
counting area between the slide and the coverslip. The enclosed
3area below the coverslip and the 16 squares is 0.1mm . All those
cells found in the 16 squares of the four courner grids were
counted, cells lying on any two of the four outer lines were also
counted, and the total number, X, was estimated, an average of
4the four corner grids was calculated and multiplied by 10 . This 
gives the number of cells per ml of solution. Cell viability was 
estimated by the addition of an aliquot of cell suspension to 
trypan blue dye (Gibco 525) ratio 4:1, Those cells that take up the 
blue dye are non-viable.
2.5.5. Mycoplasma Detection.
Mycoplasma examination of cell lines was carried out using a 
fluorescent staining method, specific for DNA (Chen,1977). An 
indicator cell line NRK was used and medium from cells was added 
for testing. NRK cells were grown overnight on sterile coverslips 
in 1ml of medium at 10^ cells/ml, at 37°C, 5%C02. 2ml of growth 
medium from cell lines to be tested were then added to individual 
coverslips and incubated for a further 4 -5 days at 37°C and 5% 
C(>2 . Cells were then rinsed twice in PBSA, rinsed once in Carnoys
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fixative (Appendix of solutions 6.1.1) /PBSA (l:l),and then fixed 
in Carnoys fixative for 10 min. The coverslips were removed and 
rinsed thoroughly in PBS. Hoescht 33258 (Sigma B2883) at 0.05mg/ml 
in PBSA were added to the cells so that they were completly 
covered, and left for 10 min in a light-proof sealed container at 
room temperature. Excess stain was removed by rinsing in water. 
The coverslips were then mounted and sealed onto a glass slide 
(with the cells between the two surfaces). The cells were then 
studied under oil immersion using 405nm light. Definite pinpoints 
of fluorescence in the cell cytoplasm indicated the presence of 
mycoplasma contamination. Contaminated stocks were disposed of and 
fresh cultures were grown up from stock.
2.5.6. Long Term Storage of Animal Cells.
New cell stocks received from the ECACC (European Collection of 
Animal Cell Cultures), ATCC (American Type Culture Collection) or 
any other source were immediately grown up to high cell number and 
then frozen in liquid nitrogen for long term storage. Cells in 
subconfluent exponential phase were suitable for long term storage, 
lml of a 10% (v/v) solution of DMSO (BDH 282166) in growth medium, 
with 25% FCS, was added to lml of cell suspension (at least 2X10^ 
cells/ml) in a slow dropwise manner with continuous mixing. This 
method of freezing was only suitable for the parental cell lines 
see section 2.7.3 for details of the freezing procedure for the 
mutliple drug resistant variants. This was then transferred to 
sterile cryotubes (sterlin 35001). The cells were then slowly 
frozen in the vapour phase of liquid nitrogen for three hours, then 
stored in liquid nitrogen storage containers until required. It is
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necessary to take a number of precautions in the handling of vials 
of cells stored in liquid nitrogen. It is recommended to ware full 
face mask in addition to protective gloves during any contact with 
liquid nitrogen.
2.5.7. Cell Thawing.
The required vial was removed from liquid nitrogen and thawed 
rapidly at 37°C. The thawed cell suspension was transferred to a 
sterile universal with growth medium and centrifuged at l,000rpm 
for 5min. The cell pellet was resuspended in 5ml of growth medium 
and transferred to a 25cm flask. The cells were then incubated at 
37°C for 24 hours. The cells were then refed with 10ml fresh 
culture medium.
2.6.1. Safe Handling of Cytotoxic Drugs.
There are two principal risks in the handling of cytotoxic 
drugs-one definite and one potential. The definite risk results 
from the fact that a number of cytotoxics are extremely irritant 
and produce harmful local side effects after direct contact with 
skin or eyes. The potential risks stem from the knowledge that some 
cytotoxic drugs are proven carcinogens. Cytotoxics drugs must be 
treated with the utmost care in the laboratory in the initial 
stages of reconstitution and the handling of drug containing 
culture medium. Generally in handling cytotoxic drugs, double 
gloves, and face masks are worn, and all work involving cytotoxics 
is performed in a 'Cytoguard' laminar air flow cabinet. All liquid 
waste is treated with hypochlorite followed by autoclaving, all 
plastic disposable waste that had come in contact with cytotoxics
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are rinsed three times, and subsequently autoclaved. Any 
reconstitution vials or syringes that would have been in contact 
with concentrated cytotoxics drugs were incinerated through 
'Bioburn 'limited. Initially it was noted that the reproducibility 
of some of the toxicity assays was particularly bad, indicating 
instability problems with the drugs. The stability of each drug was 
ascertained by storing a number of aliquots in different ways and 
comparing these to the results of a toxicity assay preformed with 
the drug on the day of reconstitution of the original vial. In 
general, dissolving the drug from powder formulation with water for 
injection is advisable, followed by further dilution in medium 
containing 10% FCS (The protein concentration present is thought to 
stabilise the drug). Secondly, any of the drugs stored frozen at 
-20°C can only be thawed five times, activity of the drug on 
subsequent freezing is markedly reduced. Table 2.3 summarizes the 
finding of these results.
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Table 2.3. Storage of Cytotoxic Drugs.
Drug Presentation Storage Special comments
Adriamycin
10mg/50mg
Parmatalia
powder
-20°C,2mg/ml 
or 20pg/ml
Can be stored at -20°C 
for 6 months.Light 
sensitive.
Cis-platin
10mg/50mg
Lederle
powder
room temp, for 
6 months 
lmg/ml,5mg/ml 
quantities.
Do not refrigerate or 
freez as a ppt.forms, 
Light sensitive.
VP16/VM2 6
lOOmg
Lederle
powder
Store 3 months 
at -20°C,
6 month at-40°C 
lmg ,lOmg 
quantities.
5-Fluorouracil 
250mg/10ml powder 
Farmatalia
Store between 
10-30°C,
2 5mg/ml,2.5mg/ml 
quantités
Sensitive to light 
stable for 12 months.
Vincristine 
lmg/2mg vials of 
solution 
Lederle
-20°C in 10pg/ml 
or 20pg/ml 
quantities.
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2.6.2. Adaptation of MDR Variants.
Initally, a toxicity assay (section 2.7.1) with Adriamycin was 
preformed to ascertain the concentration of drug at which there was 
5% survival of each cell line. ADR was added at the relevant
concentration,cells were grown at that concentration until they
appeared healthy and attaining high numbers, the drug concentration 
was then doubled. This process was continued, doubling drug
concentrations where the cells appeared fit enough to do so. See
table 2.4 for details of adaptation.
2.6.3. Obtaining of MDR Variants by Mutagenesis followed by 
Adaptation.
It was cited in the literature that mutagenesis was a suitable 
method for the adaptation of MDR variants (Debenham et al.,1982). 
This method involved the treating of the cells with a point mutagen 
Ethyl Methanesulfonate (Sigma M8024) at a concentration of 25/jg/ml 
for 18 hours followed by three days preselection period, the cells 
were exposed to ADR at lpg/ml. The selection then proceeded as in 
section 2.6.2. Only one cell line was adapted by this method, 
HEP-2B.
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Table 2.4. Cell Lines Adapted To Resistance.
Cell Line Initial ADR 
Concentration 
t/jg/ml)
Final ADR 
Concentration 
(pg/ml)
HEP-2A 0.05 1.65
HEP-2B 0.1 1.55
DLKP-A 0.05 2.45
SKMES1-A 0.025 0.95
SKLU1-A 0.05 0.525
OAW42-A 0.05 0.85
DLRP-A 0.025 0.1
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2.7.1. Toxicity Assays - 24 well plate.
The cells were pretreated as follows : Cells growing in 10 mis of
2media (Table 2.2) in 25 cm flasks were trypsinised and set up at 
106cells /75cm2 flask, 2 days prior to the assay and fed the 
following day. Cells were plated at a concentration of 2X10^ 
cell/ml in 500pl per well. Exactly 24 hours later drug dilutions 
were added (2 X final concentration in 500pl) to triplicate wells 
(Costar 3524 ). The plates were then incubated for 7 days and the 
cell growth was determined by two procedures. Both procedures 
involved firstly removing drug medium, rinsing three times in PBSA 
and staining for exactly 10 min with 500ul 0.25% crystal violet 
(Sigma C 3886) (Matthews et al.,1987). The stain was then removed 
and the plates washed five times in distilled water, the plates 
were then allowed to dry for 24 hours. Procedure 1 involved 
reading the plate by image analysis, Yielding number of colonies 
and the area covered by the cell in mm . Procedure 2 involved the 
elution of the crystal violet with glacial acetic acid (500pl per 
well), transfer to quaduplicate wells of a 96 well plate and 
reading at 570nm (using 620nm as reference wavelength) in an ELISA 
reader. It is necessary to include a control to allow for non 
specific binding of the crystal violet to the plastic. This 
involved adding the crystal violet (500pl/well) to four wells, not 
containing cells. After 10 min the plate was rinsed five times in 
H 2 O and dried overnight: 500pl of glacial acetic acid was then
added and O.D. were measured as described above.
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2.7.2. Toxicity Assay - 96 well plate.
Cells were plated into 96 well plates (Griener 6621160),5,000 cell 
per well in lOOpl assay medium. To one column of the plate only 
medium was added. This acted as the blank in the subsequent 
reading of the plate. After 24 hours incubation at 37°C,5%C02, 
lOOpl of drug dilution (2X final concentration) was added to each 
well, in replicates of eight, for each drug dilution. Control 
wells had 100/jI of medium added only. Plates were incubated for a 
futher 6 days with drug after which the end point was determined by 
the acid phosphatase method (Connolly et al.,1986 ; Martin et 
al.,1991). Medium was removed from the wells and rinsed with lOOpl 
PBSA. lOOpl of p-nitrophenyl phosphate substrate containing buffer 
(Appendix of Solutions 6.1.2.) was added to each well. It was 
found necessary to make up the solution freshly each time before 
use, Air bubbles were eliminated. The plate was then incubated at 
37°C in 5% CC> 2 for the standard incubation time of 2 hours, after 
which it was read in a dual beam ELISA plate reader at 405nm 
(reference wavelength 620nm). If the colour obtained was slight 
the plate could be reincubated for a further time to give increased 
sensitivity. Otherwise the reaction could be stoped by the addition 
of 50pl of IN NAOH to each well, in addition to stopping the 
reaction the color is further developed by the addition of NAOH.
2.7.3. Cell Freezing Experiments.
It was found that when the MDR variants were frozen in the 
conventional manner that the cell recovery after thawing had 
decreased,in addition to a loss in resistance. Cell freezing 
experiments were preformed by the 96 well plate - toxicity assay
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(section 2.7.2). Cells were pretreated at a density of 2X10® 
cells/75cm flask and allowed to grow to 75% confluency trypsinized 
and counted, a toxicity assay was carried out on the cells before 
freezing. The cells were then frozen at varying cell densities 
(106, 2.5X106, 5X106, 1X107), varying serum (10%, 20%, 50%,
100%) concentration, varying concentraton of cryoprotectant agent 
DMSO (10%, 20%) (Sigma D8386) or Glycerol (10%, 20%) (Sigma G9012). 
The cells were frozen for six weeks. On thawing a viability count 
was ascertianed by Trypan blue viability. The cells were allowed 
to grow for seven days in the absence of drug, then a toxicity 
assay was preformed to estimate the level of resistance. The
7optimum procedure found suitable for all the MDR variants was 10 
cells, 10% DMSO, and 50% FCS.
2.7.4. Trypsin Sensitivity Assay.
2Two days before the experiment, the cells were removed from 25cm 
flasks by incubation with 0.05% EDTA (Sigma E9884) for 7min, and 25
2 5cm flasks were set up at a concentration of 5X10 cells/flask. The
cells were fed the next day and the assay was set up on day three.
Five different procedures of cell removal were investigated:
Scraping in PBSA; 0.025%EDTA for 7 min; 0.05%EDTA for 7min;
Trypsin(0.25%)/EDTA(0.02%) and Trypsin (0.25%). Adriamycin
sensitivity assays were the preformed as in section 2.7.1 and
2.7.2.
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2.7.5. Cloning Efficiency Assay.
Pretreated cells were plated at lOOcells /500pl per well in a 24 
well plate, adriamycin at varying concentrations were added 24 
hours later. The plates were incubated for 10 days at 5%C02 at 
37°C, then stained for exactly 10 minutes with 0.25 % crystal 
violet, dried thoroughly and colony number quantified by image 
analysis.
2.7.6. Circumention Assays.
Pretreated cells (Section 2.7.1) were plated at 2X103 cells/lOOpl 
per well and then adriamycin and circumvention agent (CA) added 24 
hours later. All circumvention assays were carried out in the 96 
well plate assay (section 2.7.2). Both adriamycin and circumvention 
agent were added at 4X final concentration in a final volume of 
25pl. Verapamil (Sigma V4629), quinidine (Sigma Q3625), caffeine 
(Sigma C1778), quinine (Sigma Q1625) and nifedipine (Sigma N7634) 
were made up in PBSA (lmg/ml stock), chloroquinine (Sigma C6628) in 
0.9% NaCl (lmg/ml stock), nifedipine and aspirin (lOOmg/ml) were 
made up in water for injection (lOmg/ml stock). Both generic 
aspirin ("Soluble Anadin" International Chemcial Co.Ltd., Island 
bridge, Dublin 8) and Standard Aspirin (Sigma A3160) were studied. 
The assay was incubated for 6 days , cell growth quantified and the 
resistance modulating ratio (RMR) of each agent calculated.
IC50 of Adriamycin alone 
RMR = ------------------------
IC50 of Adriamycin + CA
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2.8. Immunofluorescence.
P-170 is recognised by a number of monoclonal antibodies (See 
tables 2.5. and 2.6.). C219 (Centocor) a monoclonal antibody to
the internal moiety of the P-170, was used in this study. Cells 
were trypsinized and diluted to 10 cells/ml. 50pl of this 
suspension was added to each well of a Dynatech multi-well slide 
and incubated at 37°C, 5% CO2  overnight. The slides were
incubated in 100mm petri dishes (Griener 633185). The following day 
slides were rinsed three times, with 2ml of PBSA, fixed and 
permeabilised in acetone (pre cooled at - 20°C) for 20min. Slides 
were then air dried. 20pl of primary antibody, C219 (5pg/ml) was 
added. C219 was incubated overnight at 4°C. After the incubation 
time slides were rinsed three times in PBSA (10 minutes per rinse). 
20/jl of FITC-labelled second antibody (Sigma F3008) was added to 
each well and incubated in a dark, 37°C,5% COj enviroment for one 
hour. Slides were then rinsed three times in PBSA, excess PBSA 
was removed with filter paper. Slides were then mounted in 
glycerol/DABCO (Aldrich D2,780,-2)(lmg/ml)(Johnson et al.,1982) ,
sealed with nail varnish and viewed under a Nikon fluorescent 
microscope.
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Table 2.5. P-170 Specific Monoclonal Antibodies
Antibody Cell line used 
in immunisation
Epitope Reference
Hamster
C219
C494
C32
CHOCHrC5
and
CEM/VLB(500)
Recognises
internal
epitope
Kartner et 
al., 1985
265/F4 CHOCHrCS Recognises
external
epitope
Lathan et 
al., 1985
JSBl CHOCHrC5 Recognises
internal
epitope
Scheper et 
al., 1988
Human
MRK16
MRK17
K562/ADM Recognises
internal
epitope
Hamada et 
al.,1986
32G7
9A7
1F10
CEM/VLB(100)
Recognises
internal
epitope
Danks et 
al.,1985
HYB-612
HYB-241
HYB-195
SH-SY5Y/VCR
and
P3X63Ag8.653
Recognises
external
epitope
Hamada et 
al.,1986
MS. 2 K562/DOX Recognises
external
epitope
Marie et 
al. ,1991
MDR-AB1 N.K. N.K. Krishan et 
al.,1991
Murine
Moabl7F Murine 3T3 
transfected 
with human 
mdrl qene
Recognises
external
epitope
Dr. D. Ring 
Cetus
Corporation
1991.
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Table 2.6. Description and source of cell lines used 
for MAB production.
Cell Line Description/Comments Reference
CHOCHrB30 Chinese Hamster Ovary 
Colchicine - resistant
Kartner et al., 
1983.
CHOCHrCS Chinese Hamster Ovary 
Colchicine - resistant
Kartner et al., 
1983.
K562/ADM Human Myelogenous 
Luekemia - Adriamycin 
Resistant
Tsuruo et al., 
1985.
CEM/VLB.100 
CEM/VLB.500
Human leukemia 
Vinblastine resistant 
100 and 500 fold from 
parental cell line
Beck et al., 
1979.
SH-SY5Y/VCR Human neuroblastoma 
Vincristine Resistant
Biedler et al., 
1988.
P3X63Ag.653 Human Myeloma cell line Kearney et al., 
1979.
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2.9. GENETIC METHODOLOGY.
2.9.1. Table 2.7. Listings of Plasmids
Plasmid Source Selective Marker
pSV2NEO
PLW4
pHaMDRla 
(Full MDR1 
cDNA)
Beatson Inst. 
Glasgow
Beatson Inst. 
Glasgow
Ira Pastan
Neomycin/Geneticin 
Chloroamphenicol
AMP
2.9.2. Calcium Chloride Transformation of Bacterial Hosts with
Recombinant Plasmid DNAs.
Transformation is the process of uptake of DNA by bacteria. The 
calcium chloride method of bacterial transformation was described 
by Mandel et al.,(1970), and the bacterial host for all 
transformation was E.Coli C600. From an overnight culture of C600 
in LB medium, 10ml was innoculated into 100ml of fresh LB medium 
and incubated at 37°C until an O.D. of 600nm of 0.4 - 0.5 was 
attained. Cells were then centrifuged at 9,000 r.p.m. 5 min ,4°C 
(in a GSA rotor head of a Sorvall RC-5B refrigerated centrifuge) 
resuspended in 10ml cold 30mM CaCL2 and chilled on ice for 20min. 
To 100/il 'competent cells', O.lfjg of recombinant (covalently closed 
circle) plasmid DNA was added and the mixture chilled on ice for 
60min. The cells were heat shocked for 5 min at 37°C, and removed 
immediately to ice. To each lOOpl 'transformed cells', 1ml of LB 
medium was added and the cells incubated at 37°C for 1-2 hours. 
This period was allowed for the expression of the antibiotic 
resistance encoded by the recombinant plasmid. Samples of lOOpl 
were then plated on LB agar containing the selective antibiotic 
(Concentration lOOpg/ml). The plates were allowed to dry, and
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incubated overnight at 37°C. The efficiency of transformation was 
calculated and was usually 1X106 transformants per pg DNA.
2.9.3. Small Scale Purification of Plasmid DNA.
10ml cultures of the plasmid containing strains were grown in LB 
medium for 18h at 37°C with shaking. The selective drug for the 
plasmid in question (see Table 2.9. for details) was included at a 
concentration of lOOpg/ml in the LB medium. The cells were 
harvested in 30ml Sorvall tubes by centrifugation at 10,000 
revs/min in an SS-34 Sorvall rotor. The cells were washed once 
with TE (lOmM Tris, ImM di-Sodium EDTA, pH 7.4) and centrifuged in 
the same manner. The supernatant was discarded and the pellet 
drained. The pellet was resuspended in 0.25ml of 25% (W/V)sucrose 
in 0.01M Tris-HCl, pH 8.0 and transferred to an Eppendorf tube. To 
this was added lOOpl of freshly prepared Lysozyme (Sigma L6876) 
solution (25g/L in 0.25M Tris-HCL, pH 8.0) and 0.25M EDTA, pH 8.0. 
The mixture was kept on ice for 15min and the 500pl of Triton 
lysing mix (2% Triton X 100 in 0.05M Tris-HCL, 0.0625M EDTA,pH 
8.0) was added. After a further 15min on ice, centrifugation was 
preformed at 26,000 revs/min at 4°C in an eppendorf tube and 0.75ml 
of phenol- chloroform (25:24) was added. This was then mixed and 
spun in a microfuge for 3min at 2,000 rpm. Upper Aqueous phase was 
removed to a new tube and to this was added 1/10 of a volume of 20% 
sodium acetate firstly, followed by 2X volume of 100% ethanol. This 
was kept at -70°C for 20 min. This was then spun at 2,000 r.p.m. 
in a microfuge for 15 min. The supernatant was discarded and the 
pellet was dried under a 60 watt lamp for 20 min, then dissolved 
in lOOpl TE buffer. This was then passed through a Sephadex G50
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fine column to further purify the plasmid. This DNA suspension was 
then suitable for transfection experiments or transformation.
2.9.4. Large Scale Plasmid Isolation-Cleared Lysate Procedure.
Large amounts of recombinant plasmid DNA (l-2mg) was obtained using 
the cleared lysate procedure of Maniatis et al,(1982). Selective 
agent was added to both the starter culture and the large scale 
preparation to maintain selective growth of only those bacteria 
harbouring the required recombinant plasmid. 2.5ml of the 
overnight starter culture (10ml) was innoculated into 500ml of LB 
medium (contained in a 1L baffled flask) and incubated at 37°C 200 
rpm, for 18 hours. The cells were harvested by centrifugation in 
250ml tubes for lOmin at 16,000 r.p.m. in a GSA Sorvall (RC-5B) 
rotor. The supernatant was discarded and the pellet thoroughly 
drained of excess liquid, it was then resuspended in 3ml of a
solution containing 25% (w/v) sucrose in 0.05M Tris-HCl, pH 8.0 and 
transferred to a 30ml Sorvall centrifuge tube. To this was added 
lml of a freshly prepared Lysozyme solution (25g/L in 0.25 M 
Tris-HCl, pH 8.0) and lml of 0.25M di-SODIUM-EDTA, pH 8.0. This 
mixture was allowed to stand on ice for 15 min, then 7ml of triton 
lysing mix was added and the mixture allowed to stand on ice for 15 
min. Cell debris was removed by a clearing spin at 20,000 r.p.m. 
in a SS-34 Sorvall rotor for 45 min at 4°C. 9.5ml of supernatant
was decanted into a silanized glass universal. lg of Cesium
cloride (Sigma C3032) was added per ml of cleared lysate, together 
with 500^1 of ethidium bromide (lOmg/ml). When the cesium chloride 
had fully dissolved, the mixture was centrifuged at 5,000 r.p.m. 
for 15 min, this causes any proteinaceous material to collect at
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the surface, this material wag removed and the remaining lysate was
transferred to heat sealable Beckman ultracentrifuge tubes and
centrifuged at 42,000 r.p.m. for 40 hours at 15°C in a 70iTi fixed 
angle rotor. Chromosomal (upper) and the plasmid (lower) DNA bands 
were visualised using ultraviolet light. The plasmid band was 
extracted with a syringe and transferred to an acid washed glass 
universal. The ethidium bromide was extracted from the recovered 
fraction by addition of 1 volume of CsCl- saturated isopropanol. 
The upper, isopropanol was then removed and the procedure repeated
until the lower layer was colourless. The plasmid fraction was
then dialysed against TE buffer for 4 hours to remove the CsCl. 
The plasmid fraction was then extracted with phenol, saturated 
with 1M Tris-HCL (pH 7.6) shaken vigorously for 30 sec. The 
aqueous layer was recovered using a pasteur pipette and transferred 
to a 30ml corex tube (DuPont). A 10% volume of sodium acetate and 
two volumes of cold absolute ethanol were added and the mixture 
stored at -70°C for 2h to precipitate the plasmid DNA. DNA was
recovered by centrifugation at 20,000r.p.m. for 30 min in a SS-34
Sorvall rotor at 4°C. The pellet was washed in 80% ethanol to 
remove residual salt and then air dried under vacuum. The pellet
was dissolved in TE and stored at -20°C until required.
2.9.5. Quantification of DNA by Spectrophotometric Methods.
An aliquot of the DNA to be determined was diluted in TE buffer and 
the O.D. at 260nm and 280nm taken. An O.D. of 1 at 260 nm 
wavelength corresponds to 50 pg/ml for double stranded DNA. The 
ratio of 260nm to 280nm gives an estimate of the purity of the 
DNA,and should be 1.8 for pure DNA. The concentration of DNA in 
pg/ml was given by the reading at Q.D.260nm X dilution factor X 50.
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2.9.6. Agarose Electrophoresis of Purified Plasmid and
Oenomic DNA.
Isolated plasmid and genomic DNA were checked for quality and
purity using 0.8% agarose gel, 5/jg of sample was placed in loading
buffer (Appendix of buffers 6.1.3.) and run in TBE buffer (89mM 
Tris-HCl, 89mM Boric acid and 2mM EDTA pH 8.0) at 75 V for 4 hours. 
The resultant gel was stained with ethidium bromide, lOOpg/ml and 
visualised under U.V. illumination.
2.10. Cytogenetic Analysis.
Cytogenetic analysis was carried out on HEP-2, HEP-2A, HEP-2B, DLKP
and DLKP-A. Cells were analysed 2 days out of drug. Cells were
6 2 innoculated at 6 X 10 cells per 75 cm flask 21 hours hours prior
to harvesting. For HEP-2 and DLKP colcemid at a final
concentration of 0.02pg/ml was added two hours prior to harvesting,
while with HEP-2A, HEP-2B, and DLKP-A colcemid was added ten hour
before harvesting. This was due to the altered growth pattern of
the drug resistant cell, it is much more difficult to get a good
metaphase yield. Cultures were not trypsinised as a satisfactory
mitotic yield was achieved by vigorous shaking of the flasks. The
resultant cell rich supernatant was decanted, centrifuged and
resuspended in 0.075M KCL, 37°C, parental lines for 25 min, HEP2-A
and HEP2-B for 35min, and DLKP-A for 45 min. The varying time is
differential of the ease at which different metaphases of different
cell lines spread. The cell suspension was centrifuged and the
cell button gently resuspended in cold Methanol-acetic acid
fixative (3:1 (v/v)) for a minimum of 1 hour. A protocol involving
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several washes in fixative was found to improve chromosome spread. 
Air dried preparations were prepared by applying one or two drops 
of concentrated cell suspension to a clean glass slide. Staining 
was with either conventional Giemsa or Giemsa-Trypsin 
(Seabright, 1971).
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2 .11. Transfection Techniques.
2.11.1. Calcium Phosphate Transfection Technique.
Cells were pretreated as described in section (2.7.1) to ensure the
cells were in exponential stage of growth. Cells were trypsinized
6 2and replated at a density of 1X10 /25cm flask and incubated at 
37°C for 24 hours. Day 2 involved the preparation of the CaPO^ 
precipitate (Graham et al.,1977). To 40pg/ml of donor DNA in 900pl 
O.lmM EDTA, l.OmM Tris-HCL, pH 8.0 lOOpl of 2.5M CaCL2 was added 
and mixed thoroughly. This DNA solution was added slowly with
continuous mixing to 1ml of 2 X HBS (See appendix of buffers
6.1.4.). This solution was mixed immediately by vortexing and 
allowed to stand at room temperature for 30 minutes to allow time 
for the DNA/CaPO^ preciptate to form. Then 500pl of this solution 
was added to each flask containing 5ml of growth medium. It is 
necessary to ensure the DNA precipitate is spread evenly throughout 
the flask, the flask was then incubated at 37°C for 3 hours and 
then gently mixed again and then left incubating for 20 hours 
without disturbing, this time period allows for absorption of the 
DNA calcium phosphate precipitate. After the 23 hours total 
incubation time the precipitate was washed from the flask and 
selection free medium added (see section 2.11.6 for selection 
details). In all experiments a control transfection was preformed 
by the replacement of the DNA by T.E. buffer, this allows for the 
quantification of spontaneous mutants for the particular selected 
phenotype.
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2.11.2. Calcium Phosphate Transfection Procedure with
Facilitators.
The effect of an number of facilitators on the efficiency of the 
CaPO^ assay was investigated, to try and increase transfection 
frequency. These included chloroquinine, PEG 6000 and DMSO. The 
transfection technique was as described in section 2.11.1, but an 
additional agent was added either pre or post addition of the 
calcium phosphate precipitate.
It was necessary to optimise the concentration of each of the 
facilitators, this involved preforming a toxicity assay with the 
relevant agent (as described in section 2.7.1). It was noted from 
literature that a certain amount of cell kill was required with 
treatment of the cells with facilitators to increase the 
transfection frequency. The cell kill required for each of the 
agents to be effective as a transfection agent was as follows: 
Chloroquinine -30% kill, DMSO -10% kill, Peg 6000 -10% kill (see 
section 3.9 for further details). Pretreatment with Peg 6000 for 
two minutes was used prior to the addition of the CaP04 
precipitate. The concentration varied depending on the cell line 
in question (see section 3.9.4). Pretreatment with chloroquinine 
for 3 hours prior to addition of the CaP04 precipitate was 
investigated, the concentration of chloroquinine varied with the 
cell line under study (see table 3.9.2a for details) DMSO exposure 
for 4 minutes was investigated both pre and post addition of the 
CaPO^ .
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2.11.3. Polybrene/DMSO Transfection Procedure.
This procedure was highlighted by Morgan et al.(1986). As in the 
case of the facilitators highlighted in section 2.11.2 
approximately 10% kill of the combined effect of polybrene/DMSO is 
necessary before an efficent transfection occurs. Thus toxicity 
assays were set up (as highlighted in section 2.7.1) with three 
different concentration of each agent (10/20/30 pg/ml polybrene 
(Sigma H9269) and 10/20/30% DMSO) to ascertain the optimum combined 
affect of Polybrene and DMSO necessary to achieve the necessary 10% 
kill regiured for transfection. The transfection was preformed by 
the addition of the appropriate Polybrene concentration, in the 
presence of the DNA to be transfected to the cells for 6 hours at 
37°C, the cells were then washed twice in PBSA followed by the 
addition of the appropriate DMSO concentration for 4 minutes. The 
cells were washed twice in PBSA and replaced in growth medium (see 
section 2.11.6 for details of selection procedures).
2.11.4. Electroporation Toxicity Assay.
Survival curves for any cell line to be electroporated were set up 
varying voltages and ¡uF to observe the effects of electroporation 
(Potter et al.,1984) on healthy cells in the absense of DNA. It 
has been observed that a 30% kill is required for successful 
transfection. Pretreated cells were trypsinised and washed twice 
in sterile PBSA and counted. To each cuvette 200pl TE buffer and 
5X106 cells /600pl PBS were added. The cuvettes were kept on ice 
for 5 minutes prior to electroporation. One control cuvette was 
kept on ice while the other was kept at 37°C to account for cell 
death due to drop in temperature. Electroporation was carried out
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on each cuvette at a different set of conditions. After 
electroporation the cells were kept on ice for a further 10 minutes 
and a viability assay preformed (see section 3.7.1 and 3.7.2) on 
the cells to ascertian the affect of the varying electroporation 
conditions.
2.11.5. Transfection of Plasmid and Genomic DNA 
By Electroporation.
Cell in exponential growth phase were trypsinized, washed 2X in PBS
to remove and residual medium and counted. 200pl DNA/TE and 600pl
6 2cells in PBS (5x10 for 75cm flask) were added to each cuvette and
placed on ice for 5 minutes. The suitable electroporation
conditions, as decided from section 2.11.4., were set (/jF and
voltage) and the pulse discharged. After electroporation the cells
were left on ice for a further 10 minutes and then added to the 
culture flask with fresh culture medium (see section 2.11.6 for 
details of selection period).
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2.11.6. Selection Procedures for Transfected DNA.
Most gene transfer experiments are monitored by the transformation 
of cells from one phenotype to another. This usually involves the 
use of selective medium for a specific biochemical marker. It is 
thought that in many cases, a period of expression in non-selective 
conditions is necessary prior to selection. This is known as the 
preselection time. It varies markedly depending on the gene been 
transfected.
Table 2.8. Selection Procedure for Transfected DNA.
Donor DNA Preselection Time Selection agent 
Concentration pg/ml
PLW4 3 days Chloroamphenicol
pSV2NEO 1 day Geneticin 
400-1000pg/ml 
(Over four days)
pHAMDRlA 3 days Colchicine 20ng/ml 
increase to 
40/50ng/ after 3 
weeks
A9/NIH3T3 24 hours Ouabain 10~® M
CHrC5 3 days 0.075 pg/ml 
Adriamycin
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2.11.7. Transfection of Antisense Oligonucleotides.
The sequences of the oligomers used in this study were 
d5'(GTC CCC TTC AAG ATC CAT)3' Antisense oligomer.
d5'(ATG GAT CTT GAA GGG GAC)3' Sense oligomer.
These sequences represent the first 18 bases in the human mdrl
coding sequence. Oligomers were made and purified by Dr.Mike
Powell, Delta Biotechnology. I acknowledge the co-operation of Dr.
Becky Shaddaux for the computer search showing uniqueness of the
2above nucleotides for P-170. Cells were set up in 25cm flasks at
a density of 4X10^ cells in 3 mis of culture medium. All culture
medium was made up with 10% FCS that had been previously heat
treated at 65°C for 15 minutes to elimate serum nucleases.
Oligomers were added for three days to the culture medium at a dose
of 80pg on the first day and 40 pg on the second and third days.
After pretreatment the cells were trypsinized and plated at a 
3density of 2X10 /lOOpl in 96 well plate. An adriamycin toxicity 
assay was preformed as in section 2.7.2., using a four day 
incubation instead of 7 to test for the down regulation of P-170. 5 
assays were set up for each cell line, a control adriamycin 
toxicity profile, antisense and sense without oligomer present in 
the toxicity assay, and antisense and sense with oligonucleotide 
present in the toxicity assay. The assays were set up in the 
presence and absense of oligomer to ascertain the stability of the 
down regulation event. Oligomers were added at a concentration of 
40pg each of the four days of the toxicity assay.
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2 .12 . Protein Analysis by Western Blotting.
2.12.1. Purification of Cell Membranes.
Cell membranes were prepared by sonication followed by differential
Ocentrifugation, (Ronchi et al.;1989) 10 cells were trypsinized and
washed three times in cold PBSA. The cell were then placed in
lysing buffer (appendix of buffers, 6.1.5.). The cells were then 
sonicated as highlighted in section 3.5.2., sonication time is
dependent of the cell line in question. The cells were checked 
microscopically for the appearance of cell lysis. The cells were 
then spun at 7,000 r.p.m. for 15 min. The supernatant was then 
recovered, with care been taken not to dislodge the pellet. This 
supernatant was the loaded onto a sucrose cushion, 15 ml (appendix 
of buffers 6.1.6.), and spun at 37,000 r.p.m. in an SW28 rotor of 
a Beckmann ultracentrifuge, for 90 min. The membrane enriched 
fraction collects at the interface of the sucrose and the lysis 
buffer. This was removed carefully, volume was raised to 10ml with 
washing buffer (appendix of buffers 6.1.7.) and centrifuged at
36,000 r.p.m. for 40 min at 4°C. The pellet was then resuspended 
in storage buffer (appendix of buffers 6.1.8.) and frozen at 70°C. 
The samples were then freeze dried.
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2.12.2. Quantification of Membrane Protein -
Pierce Bincincboninic Acid (BCA) Protein Assay.
This is a highly sensitive reagent used for the determination of 
protein concentration. It combines the well known reaction of 
protein with Cu++ in an alkaline medium (yeilding Cu+) with a 
highly sensitive detection reagent for Cu+ namely bincinchonic acid 
(Smith et al.,1985).
Two pre-formulated reagents were supplied :-
Reagent A :Base reagent which containes sodium carbonate ,sodium 
bicarbonate, BCA detection reagent and sodium tartarate in 0.2N 
NaOH.
Reagent B :4% (w/v) copper sulphate.
The BCA protein assay working reagent was made up by mixing 50 
parts of reagent A with one part reagent B. The working reagent 
was stable at room temperature. Two different protocols were 
followed; one involved incubation at 37°C for 30 min for expected 
protein concentrations of 0.2-1.2 mg/ml and the other used 
incubation at 60°C for 30 min for expected protein concentrations 
of 0.05-0.25 mg/ml. In both cases a standard BSA stock solution 
2mg/ml was prepared and appropriate dilutions were made to give the 
range of standards required. Then 0.1ml of each standard or 
unknown protein sample was pipetted into a testube and 0.2ml of BCA 
working reagent was added. For blanks, 0.1ml of diluent was used. 
The tubes were incubated at the selected temperature and absorbance 
readings taken at 562nm. All samples and standards were made up in
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duplicate. This method has several advantages over other protein 
assays such as the Lowry assay. These include the very small 
amount of sample required for this assay ; there is only one step 
involved in the assay, which reduces operational error ; and the 
working reagent can be stored for 1 week at room temperature.
2.12.3. Western Blotting of Membrane Proteins.
Following protein analysis of the cell membranes by the BCA method
Smith et al.(1985) suitable quantities of membrane proteins
0.6pg/pl were separated of 7.5% SDS polyacrylamide gels in a
discontinuous method, according to the method of described by
Lamelli (1970). Using the "midget" system of vertical
2 2electrophoresis a 7cm X 8cm gel was made as follows. 15ml of
resolving gel was made by mixing 5ml acrylamide stock (Appendix of
buffers 6.1.9.), 6.8ml distilled HjO and 3.0ml 1.875M Tris-HCL, pH
8.8. To this solution of 10% (W/V) SDS, 7.5pl TEMED, and 50 pi 10%
(W/V) ammonium persulphate was added. The gels were cast
immediately in two gel cassetes, each comprising a plastic plate, 
2two 0.75cm spacers and a aluminium oxide plate mounted against the
vertical core of the unit, and allowed to set, (appromiately 30
min). A stacking gel, 5ml, was prepared by mixing 0.8ml of stock
acrylamide, 3.6ml distilled H20 and 0.5ml 1.25 M Tris-HCL buffer
pH 6.8, 50pl 10 % (W/V) SDS and mixed well. To this was added
5.0pl TEMED and 17pl 10% (W/V) ammonium persulphate. This was
carefully poured on top of the resolving gel and a comb of the
appropriate thickness inserted. The amounts of resolving and
ostacking gel stated above were sufficent for two 0.75mm thick 
gels.
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Separated proteins were visualised by staining with Commassie Blue 
Brillant Dye R-250. Western blotting of separated proteins was 
achieved by the method of Towbin et al.(1979) using a Biorad 
Transblot apparatus. Membrane proteins were transferred to 
Hybond-C (Amersham,PLC). The Western blots were placed in blocking 
buffer (3% (w/v) BSA, 15mM NaN3 in PBSA ) overnight at 4°C. Test 
antibody, (monoclonal antibody C219, Centicor diagnostics or 
polyclonal antibody from mouse immunised with CHrC5 cells) was 
diluted with 2% (w/v) BSA, 0.1 % (v/v) Tween 20 in PBSA and
incubated for 2 hours at 37°C. Western blots were washed in 
washing buffer (lOmM Tris; 150mM NaCL; 0.5% (v/v) Tween 20, pH 
7.5) and second antibody, alkaline Phosphatase-conjugated 
anti-mouse IgG (Sigma A-1902) was added. Western blots were again 
washed and developed in substrate consisting of 0.1% (V/V)
Nitroblue tetrazolium, NBT (Sigma N-5514), in 10mm Tris-HCL, pH 8.9 
5mg/ml 5-bromo-4-chloro-3-phosphate (BCIP), in N,N'
-dimethylformamide (Sigma D-8654), 1.0M magnesium chloride in
distilled H20 and 0.5M Tris -HCL,pH 8.9. The addition of substrate 
gave rise to the development of blue/purple dots for positive 
antibody recognition. In all case a negative control strip 
untreated with test antibody was included, to ascertain any 
backround staining.
2.12.4. Determination of Protein Size.
Protein size was ascertained by the running of prestained molecular 
markers (Sigma MW SDS-Blue, and Sigma MW SDS-200) these are 200Kd, 
116kd, 96Kd, 66Kd, 45Kd, and 29Kd.
8 6
SECTION 3
RESULTS
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3.1. Establishment of 7 Novel Multidrug-Resistant Human Cell Line
Variants, and Investigation of their Cross Resistant Profiles.
Seven new multi-drug resistant variants of six established human 
cell lines were established, as described in section 2.6.1 and
2.6.2. To ensure the adriamycin selected cell lines were 
collaterally resistant to other drugs and representative of the in 
vivo situation, they were assayed for sensitivity to 
chemotherapeutic agents from a number of different drug 
classifications. The drugs included in this study were adriamycin, 
an anthracycline antibiotic; VP16 and VM26 both semisynthethic 
derivatives of podophyllotoxin; Vincristine (Oncovin) a vinca
alkaloid; Cis-platin, a nonclassical alkylating agent which 
consists of a complex of chloride and ammonium ions with platinum; 
colchicine an antimitotic agent and 5-Fluorouracil, an 
antimetabolite (See appendix 6.2 for drug structures). Resistance 
to 5-fluorouracil is not a usual observation in MDR cells. The 
instability of a number of the chemotherapeutic drugs was evident 
from initial toxicity assays, it was necessary to optimise storage 
procedures for each drug to ensure reproducibility of experimental 
data. (See section 2.6.1. for correct handling of
chemotherapeutic drugs). The following tables represent the IC50 
(nM) of the MDR variants and are the mean of two experiments, the 
assay procedure used was the acid phosphatase (unless otherwise 
stated). In the acid phosphatase procedure, 8 replicate wells 
were studied and in the 24 well assays, 3 replicate wells were
studied; the results presented in the following tables are the
IC50nM ascertained from a toxicity profile for each agent (See 
appendix 6.3 for sample calculation of IC50 nM). Data presented 
are the mean of two experiments ± standard derviation.
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3.1.1. Cross Resistance Patterns of DLKP and DLKP-A at 
Different Levels of Resistance.
DLKP-A, a squamous cell carcinoma of the lung, was the cell line 
that adapted to resistance most readily. Subsequent experiments 
designed to investigate the clonal variation of parental cell line 
DLKP (Section 2.7.5) showed that a resistant population was evident 
that accounted for approximately 4% of the total population. 
DLKP-A resistant variants were analysed at three different levels 
of resistance, 0.8pg/ml, 1.75/ug/ml and 2.45pg/ml of adriamycin.
The time period for selection was as follows :
0.05pg/ml - 0.8 pg/ml ADR November 1989 - September 1990.
0.8 pg/ml - 1.75pg/ml ADR October 1990 - December 1990.
1.75pg/ml - 2.45pg/ml ADR January 1991 - March 1991.
DLKP-A was found (Table 3.1.3, 3.1.2) to be cross resistant to all
the agents tested, with highest cross resistance noted to the 
podophyllotoxins and vincristine. A very interesting phenomenon is 
noted in the most resistant variant of DLKP-A (2.45) whereby a 
lower fold resistance to vincristine is noted. With all the agents 
(other than vincristine) an increase in resistance to the test 
agent is noted as the adriamycin selected concentration increases. 
A surprising finding is the resistance to 5-FU, which is not 
normally noted with the classical MDR phenotype.
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Table 3.1.1. Cross resistance patterns of DLKP and DLKP-A at 
different levels of resistance.
IC50nM
Drug
DLKP DLKP-A
(0.8)
DLKP-A
(1.75)
DLKP-A
(2.45)
ADR 16.55+3.68 2216±82.5 4995.5±320.5 6834±377
VP16 42.47+6.8 1444±112.1 1521.0±127 1486±76.5
VM26 84.76±7.17 708±54.13 1035.0±127 1256±98
VCR 0.83+0.01 56+2.6 88.0±029 33+3.54
C-PT 1433+200 3499±233.65 5500.0±300 7510±550
5-FU 6571±499. 5 13064+1614 15372.5±768.5 19215±1537
COLH 17±0.32 45+2.376 70.7±5.885 114±7.14
n=2 Data= Mean + S.D.
Table 3.1.2. Fold resistance of the DLKP-A MDR variants 
relative to the control cell line DLKP.
Drug DLKP-A
(0.8)
DLKP-A
(1.75)
DLKP-A
(2.45)
ADR 133.9 301.84 412.93
VP16 34 35.81 35.00
VM2 6 8.35 12.21 14.82
VCR 67.46 106.02 39.75
C-PT 2.44 3.8 5.24
5-FU 1.98 2.34 2.92
COLH 2.64 4.15 6.405
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SKMES-1 and SKMES1-A.
The SKMES1—A selection at the initial stages proceeded very slowly. 
Looking at the clonal population of the parental cell line (section
3.4. figure 3.4.4) a resistant population is not as evident as in 
the case of DLKP.
The time period for selection was as follows:
0.025/ig/ml - 0.30/jg/ml November 1989 - September 1990.
0.3 pg/ml - 0.55pg/ml October 1990 - December 1990.
0.55 pg/ml - 0.95pg/ml January 1991 - March 1991.
At the later stages of selection the cells adapted very well to 
increases in drug concentration, it is presumed that a more 
resistant population had become dominant. As with the case of 
SKMES1—A, OAW42-A was initially very slow to adapt to resistance. 
No clonal variation was noted in the parental cell line (Figure 
3.4.2).
The time period for selection was as follows:
0.05pg/ml - 0.25pg/ml November 1989 - September 1990.
0.25pg/ml - 0.65pg/ml October 1990 - December 1990.
0.45pg/ml - 0.85/jg/ml January 1991 - March 1991.
Both OAW42-A and SKMES1-A were selected to almost the same level of
adriamycin resistance (0.85pg/ml and 0.95pg/ml ADR) respectively, 
but varying patterns of cross resistance are very evident. SKMES1-A 
shows a greater diversity in cross resistance , with highest levels 
of resistance to podophyllotoxins and vincristine. Low levels of
3.1.2. Cross Resistance Patterns of OAW42,OAW42-A,
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resistance were noted to both C-PT and COLH with no cross 
resistance noted to 5-FU. OAW42-A cross resistance patterns are 
unusual in that highest level of resistance is noted to Cis-Platin 
with low level resistance to VP16, VM26 and VCR.
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Table 3.1.3. Cross resistance patterns of OAW42, OAW42-A,
SKMES-1 and SKMES1-A.
IC50nM
Drug
OAW42 OAW42-A
(0.85)
SKMES-1 SKMES1-A
(0.95)
ADR
VP16
VM26
VCR
C-PT
5-FU
COLH
26.36+1.7 
33.10+4.5 
82.99+9.9 
1.23±.09 
583.3 ±16.7 
6917.2 ±614 
31.7 ±3.9
1812±138 
187±21.2 
233+17.41 
3.5±0.3 
5349±283.35 
7095±84.55 
33±2.54
24.8±0.9 
66.0±3 
54.1±11.42 
1.6+0.235 
1333±166.7 
4188±730.5 
21±3.37
3026±156 
1514±46.74 
759±34.3 
28±2.99 
6800±200 
7801±576.48 
82±13.77
Table 3.1.4. Fold resistance of OAW42-A and SKMES1-A relative 
to the parental cell lines.
Drug OAW42-A SKMES1-A
ADR
VP16
VM26
VCR
C-PT
5-FU
COLH
68.7 
5.67 
2.87 
2.84 
9.17 
1.025 
1.04
122.01
22.9
14.04
17.5 
5.1 
1.86 
3.9
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DLRP and DLRP-A.
SKLU1 was extremely slow to adapt to even low levels of resistance. 
The selection was initiated at 0.05pg/ml, it was necessary to 
restart the selection 4 times as the cells died for no apparent 
reason. However, after 9 months they reached O.lOjug/ml level of 
adriamycin resistance. This selection behaved differently in that 
the cells appeared to senese, the cells were not dividing rapidly 
but the pH of the medium was changing, indicating metabolic 
activity.
The time period for selection was as follows :
0.05pg/ml - 0.1 pg/ml November 1989 - July 1990.
0.1 pg/ml - 0.35pg/ml July 1990 - November 1990.
0.35pg/ml - 0.55pg/ml December 1990 - March 1991.
DLRP-A selection was extremely slow, as with SKLU1-A , the 
selection was restarted a number of times (8 in total), the cells 
also appeared to remain dormant for long periods, often months at 
the time. The selection proceeded after 18 months in culture from 
0.025pg/ml to O.lpg/ml. The resistance patterns of these cell lines 
were different to the others (Tables 3.1.5 and 3.1.6) fold 
resistance to adriamycin was noted for DLRP-A with slight fold 
increases in resistance for VP16, VM26 and 5FU. SLKU1-A shows 
level cross resistance to VCR and colchicine, 5.023 and 3.824 
respectively, with very low levels of cross resistance noted for 
VP16, VM26 and 5FU.
3.1.3. Cross Resistance Patterns for SKLU-1, SKLU1-A,
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Table 3.1.5. Cross resistance patterns for SKLU-1, SKLU1-A,
DLRP and DLRP-A.
IC50nM
Drug
SKLU-1 SKLU1-A
(0.55)
DLRP DLRP-A
(0.1)
ADR 14.87±1.63 1508±55 6. 1±1.48 132.4±5 . 5
VP16 84.94±11.9 136±13 54.4±8.95 79.9±3.395
VM26 97.44±12.16 147±22.1 50.5±1.423 89.1±3.81
VCR 0.43±0.078 2.16±0.24 0.24±0.05 0.235 ±0.013
C-PT 1450.0 ±150 1946 ±86.4 1266.3±100.3 1214.5 ±86
5-FU 4265.1 ±465 6571 ±576 108.3±0.822 203.7 ±3.803
COLH 15.15±2.11 58 ±5.14 8.5±1.005 9.64±0.624
Table 3.1.6. Fold resistance of SKLU1-A and DLRP-A relative
to the respective parental Lines.
Drug SKLU1-A DLRP-A
ADR
VP16
VM26
VCR
C-PT
5-FU
COLH
101.41
1.599
1.5
5.023
1.32
1.54
3.824
21.70
1.46
1.77
0.988
0.958
1.88
1.132
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and HEP-2B, at Two Resistance Levels.
HEP-2A was selected in a stepwise manner by the increase in 
concentration of adriamycin over 14 months (September 1988-November 
1989) from 0.05pg/ml to lpg/ml adriamycin. It was subsequently 
selected to 1.65pg/ml of Adriamycin from December 1989 to March 
1991. The selection appeared to slow down and the cells were not 
adapting well in the presence of drug from October 1990-March 1991. 
HEP-2B was selected initially by exposure to ethyl methyl sulfonate 
(25pg/ml for 18 hours) it was selected over 11 months from 
0.05pg/ml to lpg/ml (From December 1988-November 1989). It was 
subsequently selected to 1.55 pg/ml (from December 1989-March 
1991); as with HEP-2A, the cells appeared to go through a crisis 
stage whereby the cells were not doubling for months at the time, 
they may possibily have been because they had reached their 
threshold point as regards levels of adriamycin resistance 
attainable. HEP-2A and Hep2B were both analysed at two levels of 
drug resistance. The toxicity profiles for HEP-2A and HEP-2B at 
0.65pg/ml ADR were performed using the 24 well plate assay (see 
section 2.7.1 for details).
Both HEP-2A and HEP-2B show progressive increase in resistance to 
all agents tested (except 5-FU and colchicine) with increased 
resistance to adriamycin and generally very similar cross 
resistance patterns. Highest levels of resistance was noted to the 
vinca alkaloid vincristine, with lower levels of resistance noted 
to VP16, VM26, C-PT and COLH. Due to the long period of time 
required for the HEP-2B selection it cannot be concluded that
3.1.4. Cross Resistance Patterns of HEP-2, HEP-2A
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initial chemical mutagen treatment on HEP-2B had a role in the 
development of adriamycin resistance.
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Table 3.1.7. Cross resistance patterns of HEP-2,HEP-2A
and HEP-2B, at two levels of resistance.
IC50nM
Drug
HEP-2 HEP-2A
(0.65)
HEP-2A
(1.5)
HEP-2B
(0.65)
HEP-2B
(1.5)
ADR
VP16
VM26
VCR
C-PT
5-FU
COLH
19.8±2.3 
62.1±5.3 
102.113.1 
1.1±0.1 
1833.2±145 
6135.4+380 
24.9±11
1740±123 
134+12.5 
204± 6.7 
15.4± 1.3 
N.D. 
6900±279 
N.D.
3744+137 
248±11.9 
458±17.5 
18.1±2.52 
6020+487 
6570+514 
130±11
1650±114 
154±103 
240+ 89 
24.1+ 2.3 
2356±216 
7900±645 
N.D.
3973±78.1 
260± 7.6 
502+ 8.3 
24± 1.2 
6151± 314 
7 686±154 
136±13
N.D. = Not done
Table 3.1.8. Fold resistances of HEP-2A and HEP-2B relative
to the parental Line.
Drug HEP-2A
(0.65)
HEP-2A
(1.5)
HEP-2B
(0.65)
HEP-2B
(1.5)
ADR 87.87 189 83.33 200.6
VP16 2.16 3.99 2.47 4.18
VM26 1.99 4.48 2.35 4.91
VCR 14.1 16.45 21.9 21.8
C-PT N.D. 3.28 1.28 3.35
5-FU 1.12 1.07 1.287 1.25
COLH N.D. 5.22 N.D. 5.46
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3.2.1. Stability of Drug Resistance in the Selections.
The genetic stability of the MDR phenotype is an important 
parameter too ascertain, additionally it is a factor that needs to 
be considered in the design of experimental procedures. The 
stability of the drug resistant phenotype was studied by removing 
cells from drug and subculturing in drug free medium for up to 
three months. The stability of all the MDR variants was studied 
using the Acid Phosphatase toxicity assay procedure.
The variants were analysed at the following levels of resistance:
DLKP-A - 2.0 pg/ml ADR.
HEP-2A - 0.85 pg/ml ADR.
HEP-2B - 0.85 pg/ml ADR.
SKMES1-A - 0.75 pg/ml ADR.
SKLU1-A - 0.40 pg/ml ADR.
OAW42-A - 0.65 pg/ml ADR.
All the variants appeared to be stable after 3 months in the 
absence of drug, signifying a genetically stable population. In 
all cases a very slight decrease in IC50 was noted after the 3 
month drug free period. An interesting observation was noted in 
the case of OAW42-A (figure 3.2.5) where the most resistant 
population (approximately 8%) which was growing at 2pg/ml ADR, at 1 
month in drug free medium, was not evident at the 2 month and 3 
month assay time. This possibly indicates the genetic instability 
of a small subpopulation of OAW42-A.
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3.2.1. : Stability of Drug Profile of HEP-2A (0.85 ug/ml ADR ) in the 
Absence of drug for 1 month,2 months ond 3 months.
A —  A  1 Month. 
A  —  A  2 Months. 
O  O  3 Months.
0.000 2.0000.500 1.000 1.500
Adriomycin Concentration (ug /m l).
3.2.2. : Stability of Drug Resistance of HEP-2B (0.85ug/m l ADR) in the 
Absence of Drug for 1 month, 2 months ond 3 months.
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3.2.3. : Stability of Drug Profiler of DLKP—A (2p g /m l) in the Absence of drug 
for 1 month,2months and 3 months.
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0.000 0.500 1.000 1.500 2.000
Adriomycin Concentration (p g /m l).
3.2.4. ¡Stability of the Drug Resistant Profile of SKMES1-A (0 .75 jjg /m l) 
in the Absence of drug for 1 month,2 months ond 3 months.
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3.2.5. : Stability of the Toxicity profile of 0AW42-A (0 .65u g /m l)
in the absence of drug for 1 month,2months and 3 months.
0.000 0.500 1.000 1.500
Adriomycin Concentration (ug /m l).
3.2.6. : Stability of the Toxicity Profile of SKLU1 —A(0.4ug/m l ADR)
in the absence of drug for 1 month , 2 months and 3 months.
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3.3. Sensitivity of the MDR Variants to Standard 
Freezing Procedures.
An initial observation that MDR cells were slow to recover from 
standard freezing procedures and their drug pattern appeared 
altered, led to the study of various cyropresevation procedures for 
MDR variants. The conditions altered were cell number, percentage 
FCS and percentage cryoprotectant. The aim of this experiment was 
to optimise freezing procedures for the MDR variants that improved 
percentage viability and recovery of drug resistance after 
freezing. The acid phosphatase assay was used for all assays 
(except for those presented in figures 3.3.8 and 3.2.9., where a 
cloning efficiency assay was set up to look at clonal distribution 
after freezing).
All the MDR variants were found to be susceptible to standard 
freezing procedures of 10® cells per ml /10% FCS, with HEP-2A and 
HEP-2B showing the most marked sensitivity (See figures 3.3.1. to
73.3.9.) 10 cells per ml/50% FCS proved to be the optimum
conditions which favoured high cell viability after revival and 
maintainance of the drug resistance phenotype. Control freezing 
experiments were carried out with the parental cells lines, (see 
graph 3.2.7 for an example) it was noted that viability increased 
with increased percentage FCS but the drug resistant profiles did 
not alter depending on freezing procedure. Additionally alteration 
in the cyroprotectant (10%, 20% and 30%) DMSO and (10%, 20% and
30%) glycerol did not alter viability and drug profile on thawing 
(Data not shown).
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Table 3.3.1. Cell Viability After Freezing
Freezing
Conditions DLKP-A HEP-2A HEP-2B OAW42-A SKMES1-A SKLU1-A
106cells/10%FCS 69 61 58 72 73 62
106cells/25%FCS 75 64 67 79 81 73
106cells/50%FCS 84 71 68 83 85 77
107cells/10%FCS 76 68 64 75 66 65
107cells/25%FCS 81 75 78 85 87 79
107cells/50%FCS 91 88 83 90 93 80
Data = Percentage viability determined by trypan blue vital dye.
1 0 4
30
20-
1 0 -
O  —  O  DLKP-A Before Freezing.
• ----- •D L K P -A  106 Cells / 2 5 *  FCS,After Freezing
A ----- A  DLKP-A 107 C e lls /5 0 *  FCS,After Freezing
0.000 0 .500  1.000 1.500 2.000 2.500 3.000
Adriomycin Concentrotion(ug/m l)
3.3.1.: The Effect of Cell Number and % FCS on Freezing of DLKP-A.
O  O  H EP -2A  Before Freezing
• ------•  HEP-2A106Cells/25XFCS
A  —  A  HEP-2A107Cells/50XFCS.
3.3.2.
1 2 3
Adriomycin Concentration (u g /m l).
:The Effect of Cell Number and % FCS on Freezing of HEP—2A.
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3.3.3. :The Effect of Cell Number and % FCS on Freezing of HEP-2B.
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O -— O 0A W 42-A  Before Freezing. *
•  —  9  0AW 42-A 106 C e lls /2 5 *  FCS. 
A  — A 0A W 42-A  107 C e lls /5 0 *  FCS,
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Adriamycin C oncentration(jjg /m l).
3.3.4. :Effect of Cell Number and %FCS on Freezing of 0AW42-A.
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30 
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0.000 0.250 0.500 0.750 1.000 1.250 1.500 1.750 2.000
Adriomycin Concentration (u g /m l).
3.3.5. : Effect of Cell Number and fcFCS of Freezing of SKMES1 -A . 
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3.3.6. rEffect of Cell Number and &FCS on Freezing of SKLU1—A.
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3.3.7.:Effect of Cell Number ond SKFCS on Clonal Variation After Freezing. 
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3.3.8.: Effect of Cell number ond SKFCS on Clonol Variotion a fter Freezing. 
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3.3.9. : The Effect of Cell Number ond XFCS on Clonol Variation
of HEP-2B After Freezing.
1
O ----- O HEP-2 Before Freezing.
• ----- •  HEP-2 106 Cells/105SFCS.
4 ----- A HEP-2 106 Cells/50 S6FCS.
A —  A HEP—2 107 Cells/50i6FCS.
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3.4 Clonal Variation in the MDR variants.
Our observation of reduced drug resistance of MDR variants 
following freezing by the earlier procedure (10^ cell/ml 10% DMSO), 
suggested that our variants since they were not cloned, might 
contain subclones with different levels of drug resistance, with 
the more resistant subpopulation being also more sensitive to 
cryopreservation procedures. Such clonal variation should, if it 
exists, should be taken into account in assessing results obtained 
from these variants. We therefore decided to evaluate the possible 
existence of clonal variation in some of our variants. Clonal 
variation was estimated by the plating of 100 cells per well in a 
24 well plate and exposing to varying concentrations of adriamycin, 
followed by incubation for ten days. Colony number was counted by 
image analysis. Heterogenity in the level of drug resistance was a 
feature of all the MDR variants tested (figures 3.4.1 to 3.4.5). 
The clonal variation results for DLKP-A and SKMES1-A, indicate the 
existence of several subpopulations with different adriamycin 
sensitivity, and also a marked survival above the final selective 
concentration of adriamycin, indicating the presence of a 
resistant population.
The presence of two different populations in terms of drug 
resistance was also implied in OAW42-A, HEP-2A, HEP-2B and SKLU1-A, 
with a sharp decline in colony survival followed by a plateau in 
colony survival over a range of higher drug concentrations, 
indicating the presence of a highly resistant population. In the 
case of OAW42-A, there is 90%-100% survival up to 0.75pg/ml ADR, 
between 0.75pg/ml and l.Opg/ml ADR survival decreases to 50%, the 
survival then plateaus out to 35% at 1,5/ig/ml ADR, 26% survivaal at
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2/ig/ml and 8% survival at 3/jg/ml. In SKLU1-A an initial decrease 
in survival to 80% at 0.05/jg/ml is evident, this indicates the 
presence of approximately 20% of the population that is extremely 
sensitive to drug. The drug profile plateaus at approximately 70% 
survival up to 0.5pg/ml ADR. A sharp decline from 70% to 10% 
survival from 0.5/jg/ml to l.Opg/ml ADR is observed, indicating the 
presence of resistant population in SKLU1-A accounting for 
approximately 5% of the population. In HEP-2A and HEP-2B there is 
approximately 90% survival up to 1.5pg/ml of adriamycin, a sharp 
decline is noted between 1.5pg/ml and 2pg/ml of ADR , with a
reduction in survival of HEP-2A to 50% and HEP-2B to 25%. The 
slighty different results obtained for HEP-2B compared to HEP-2A in 
the Western blot analysis could possibly be explained by the 25% 
difference noted between HEP-2A and HEP-2B in the clonal variation 
at a concentration of 2pg/ml adriamycin. However, we would expect 
the difference in clonal variation of HEP-2A and HEP-2B at 2pg/ml 
to make an impact on all our other experimental data, but no other 
biochemical and pharmacological difference are evident between 
HEP-2A and HEP-2B.
I believe that it is valid to attribute these results to clonal
variation in sensitivity rather than to some trivial explanation 
eg. Cell cycle specificity ; one reason for this assertion is the 
quite different individual patterns exhibited by the different 
variants. However, to show this definitely would require cloning of
cells and demonstration of different sensitivity levels. Time did
not allow inclusion of this experimental work.
1 1 0
The possible significance of populations with different levels of 
resistance is addressed in the discussion. I will also propose a 
hypothesis to explain how the more sensitive population (eg 
SKLU1-A) cells sensitive to adriamycin at O.lpg/ml adriamycin) can 
survive at the selective drug concentration (e.g.SKLUl-A 
0.55pg/ml).
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3 .4 .1 . :Clonal Variation of DLKP ond DLKP-A.
O  OOAW42.
•  —  •  OAW42-A (O.S5ug/m l).
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3.4 .2 . : CLonal Vorioiion of 0AW42 ond 0AW 42-A.
1 2 3 4
Adfiom/cin Concentration (u f/m t) .
3 .4 .3. rClonal Voriolion of H E P -2 .H E P -2A  ond HEP -2B .
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Adriomycin Concentration (u g /m l).
3.4.4. :Clonal Variation of SKMES-1 and SKMES1—A.
• -----•  SKLU1
O  OSKLU1-A
0.000 0.500 1.000 1.500 2.000 2.500 3.000
Adriomycin Concentration (u g /m l),
3.4.5. :Clonal Variotion of SKLU—1 and SKLU1-A
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3.5.1. Sensitivity of MDR Variants to Subculture Procedure.
During the adaptation process, it was noticed that the cell being 
grown in drug took some time to recover from the standard 
Trypsin-EDTA subculture procedure. When this was replaced by 
scraping in PBS A, or by a very short treatment with Trypsin -EDTA 
or EDTA alone, cell growth in drug appeared to improve 
significantly. To investigate this phenomenon further each of the 
MDR variants was subcultured by different methods and a toxicity 
assay performed (Figures 3.5.1, 3.5.3, 3.5.5., 3.5.6., 3.5.7 and
3.5.8.). Additionally, control experiments were performed on DLKP 
and OAW42 to evaluate if this phenomenon is specific to MDR cells 
(Figure 3.5.2. and 3.5.4). The adriamycin toxicity curves for the 
parental cells were independent of subculture procedure, whereas in 
all the MDR variants tested subculture procedure affected 
adriamycin sensitivity. The extent of affect noted was very varied 
with the most pronounced noted in DLKP-A, HEP-2A and HEP-2B and a 
lesser affect noted with SKMESl-A, SKLU1-A and OAW42-A. Sub 
culture in 0.05% EDTA or 3 minute exposure to Trypsin/EDTA was the 
subculture method ultimately chosen for the MDR variants. The 
sensitivity of the MDR variants to T.V. is a possible indication 
of degradation of the membrane located P-170 glycoprotein with 
increased exposure to trypsin.
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3.5.1.: Effect of Different Subculture Methods on Adriamycin Toxicity to DLKP-A Cells.
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Adriamycin Concentration (u g /m l).
3.5.2. :Effect of Different Subculture Procedures on Adriamycin Toxicity to DLKP CEIIs.
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3 .5.3. :Effect of Different Subculture Methods on Adriamycin Toxicity to OAW42-A cells.
O  O Scroping.
•  —  #  Trypsin.
A  —  A T .V .
▲ —  ▲ EDTA 0.05%. 
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3.5.4.:Effect of Different Subculture Methods on OAW42 cells (P64).
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3.5.5. :Effect of Different Subculture Methods on Adriamycin toxicity 
To SKMES1-A Cells (0.55 u g /m l ADR).
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3.5.6.:Effect of Different Subculture Methods on Adriamycin Toxicity 
to SLKU1-A (0 .4u g /m l ADR).
117
%
 S
UR
VI
VA
L.
1 0 0  
90 
80 
70 
60 
50 
40 
30 
20 
10 
0
0.000 0 .500 1.000 1.500 2.000 2.500
Adriomycin Concentration (u g /m l) .
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During the preparation of the purified membrane fraction for 
Western blotting. It was noticed that the resistant variants were 
consistantly more resistant to sonication. During the sonication 
process microscopic examination was used to monitor cell lysis. The 
criteron for complete sonication was the lysis of majority of the 
cells, care must be taken not to over sonicate the cells as this 
can lead to membrane degradation. The time required for the 
resistant cells to lyse was definitely longer than there parental 
counterparts (See table 3.5.2 for details).
The increase in the sonication time and frequency required for all 
the MDR variants was noted in comparison to their respective 
parental cell lines. This observation is somewhat contradictory to 
our finding that MDR resistant cells are generally more sensitive 
to freezing and standard subculture procedures. The increase in 
sonication required for lysis of the resistant cells could be 
indicative of altered lipid composition of the resistant cells 
rendering them more mechanically sturdy rather than a P-170 related 
property.
3.5.2. The Varying Sonication Required for MDR Variants and their
Sensitive Counterparts.
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Table 3.5.2. The Varying Sonication Required for MDR variants
and their Sensitive Counterparts.
Cell Line
Sonication 
no.of pulses 
Hz
CHOK1 23 X -61
CHrC5 24 X -81
DLKP 10 X -81
DLKP-A 27 X -72
SKMES1 17 X -80
SKMES1-A 29 X -80
OAW42 13 X -70
OAW42-A 23 X -77
SKLU-1 13 X -67
SKLU1-A 25 X -71
HEP-2 18 X -85
HEP-2A 25 X -81
HEP-2 B 26 X -82
1 2 0
3.6. Protein Analysis of P-170 by Western Blotting.
The presence of immunoreactive P-170 was investigated by Western 
blotting of purified membrane fractions of the MDR variants. The 
extraction procedure involved initial sonication to disrupt the 
cell membrane followed by differential centrifugation in order to 
obtain a purified plasma membrane fraction (see Section 2.12.1, 
figure 3.6.1.) One interesting observation was that the MDR 
variants required more sonication before cell lysis was obtained 
(See Table 3.5.2. for details). Immunoreactive P-170 expression 
was highest in CHrC5, DLKP-A (Figure 3.6.2) and SKMES1-A (Figure 
3.6.3) with lower level expression in OAW42-A, HEP-2A and HEP-2B 
(Figure 3.6.4.). No expression of P-170 was noted in SKLU1-A 
(Figure 3.6.5). The presence of a second band was evident at 70KD 
M.W. in CHrC5. The significance of this band is unknown, it 
could signify the expression a related membrane glycoprotein or a 
degradation product. DLRP-A was not investigated.
1 2 1
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Figure 3.6.1. CHrC5 Membrane Proteins.
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Figure 3.6.2. Western Blot CH0C5 (*), CHOK1, DLKP-A and DLKP.
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Figure 3.6.3. Western Blot of SKMES-1 and SKMES1-A.
(*) Correction : CH0C5 in Figure 3.6.2. should read CHrC5
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Figure 3.6.4. Western Blot of HEP-2, HEP-2A, HEP-2B,
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Figure 3.6.5. Western Blot of SKLU1 and SKLU1-A.
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3.7. Immunohistochemical Detection of P-170.
The monoclonal antibody used for P-glycoprotein detection was C219 
antibody (see tables 2.5 and 2.6 for details), which recognises an 
epitope lying in a cytoplasmic domain, 2 0 0  amino acids long, of 
the C-terminal region of the P-glycoprotein polypeptide. The 
positive control cell line used was CHrC5 (Figure 3.7.1). Three 
different patterns of staining was noted. Firstly, a pattern with 
numerous positively stained cells with fluorescence that appeared 
to be very even, was seen in CHrC5 and DLKP-A (Figure 3.7.2). 
Secondly, scattered positively staining cells indicating the 
presence of a very heterogeneous population with varied expression 
of P-170 was seen for SKMES1-A (Figure 3.7.4), HEP-2A (Figure 
3.7.6), HEP-2B (Figure 3.7.7) and OAW42-A (Figure 3.7.8). Finally, 
no positive cells at all were seen in SKLU1-A. In initial 
immunohistochemical studies, photo-bleaching of the FITC 
fluorescence was a problem, this was overcome by the use of DABCO 
(l,4-diazobicylo-(2,2,2)-Octane) incorporated into the mounting 
buffer (Johnson et al.,1982). In the negative control slides of 
the parental cell lines, it was only possible to obtain 
photographs of DLKP (Figure 3.7.3.) and SKMES-1 (Figure 3.7.5.), 
the backround fluorescence was judged to negligible on the 
remaining parental cell lines.
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Figure 3.7.1. Immunofluorescence of CHrC5 Cell Line (X250)
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3.8. Cytogenetic Alterations in DLKP-A, HEP-2A and HBP-2B.
The presence of double minute (DM) chromosomes and homogeneously 
staining regions (HSRs) both indicative of gene amplification, are 
the most common cytogenetic mainfestation of MDR. Cytogenetic 
analysis was performed on three of the resistant cell lines and 
their parental counterparts, looking for the presence of double 
minute chromosomes. 1 0 0  cells were scored for each of the variants 
analysed type and the number of double minute chromosomes reported 
per metaphase spread analysed.
Additionally, on analysis of the slides a number of hugely abnormal 
spreads were encountered, with vast cytogenetic damage evident. The 
number of abnormal spreads noted per 1 0 0  metaphases is reported. 
(Note : No abnormal spreads were counted in the DM chromosome 
analysis)
Table 3.8. : Cytogenetic Evidence of MDR.
Cell Line % of Cells With DMs % of Cells with High 
degree of chromosome 
damage0 1 2 3 >4
DLKP 97 3 2
DLKP-A 6 6 8 6 7 3 18
HEP-2 98 1 1 1
HEP-2A 53 34 8 1 4 23
HEP-2B 61 28 7 1 3 29
Double Minute chromosomes are a definite cytogenetic feature of 
DLKP-A (Figure 3.8.2), HEP-2A (Figure 3.8.5) and HEP-2B (Figure
3.8.7.), with little evidence of DM present in either of the 
parental cell lines DLKP (Figure 3.8.1) and HEP-2 (Figure 3.8.4). A 
ring chromosome was noted in DLKP-A (Figure 3.8.2) in addition to 
double minute chromosomes, it has been reported that ring 
chromosomes signify a transition stage between DM chromosomes and
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HSR's (Barker et al.,1982). In HEP2-A (figure 3.8.5) a large number 
of DHs are evident in addition to a long chromosome, it is thought 
that this could be a HSR, further work with G-banded preparations 
is required to ascertain if HSRs are a definite karyotypic feature 
Of HEP-2A.
A large number of abnormal chromosomal spreads were noted for all 
the resistant variants analysed (Table 3.8.1), 18 for DLKP-A, and 
23 and 29 respectively for HEP-2A and HEP-2B. An extended period 
of time in hypotonic solution in order to achieve nuclear lysis, 45 
minutes for DLKP-A, 35 minutes for HEP-2A and HEP-2B as Opposed to 
25 minutes for the parental cell lines * This indicates an 
alteration in the composition of the nuclear membrane.
1 3 2
tFigure 3.8.1. G-Banded DLKP Metaphase Spread.
133
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Figure 3.8.2. DLKP-A Metaphase Showing the Presence of DM 
Chromosomes and a Ring Chromomsome(*),
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Figure 3.8.3. DLKP-A Abnormal Metaphase, Spread Showing Numerous 
DMs, Abnormal Breakages and Chromosome 
Condensation.
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Figure 3.8.4. HEP-2 Metaphase spread.
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Figure 3.8.5. HEP-2A Metaphase Showing Numerous DMs Ascentric 
Fragments and HSR.
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Figure 3.8.6. HEP-2A Abnormal Metaphase Spread Showing
Chromosome Condensation and Chromosome Breakage.
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Figure 3.8.7. HEP-2B Metaphase Spread Showing Numerous Faintly 
Stained Double Minute Chromosomes.
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Figure 3.8.8. HEP-2B Abnormal Metaphase Spread With Ascentric 
Fragments Chromosome Condensation and Chromosome 
Breakage.
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3.9. Optimization of Transfection Techniques.
A number of transfection techniques were optimised with a view to 
transfection of the MDR phenotype, with the pHAMDRla vector which 
encodes for the complete cDNA for the mdrl gene and also with 
genomic DNA from a number of resistant cell lines. The techniques 
studied were that of CaPO^ alone and in the presence of a number of 
facilatators which included chloroquinine, DMSO and PEG 6000. Also 
the novel transfection procedure involving polybrene/DMSO treatment 
was investigated in addition to electroporation. Other parameters 
included the investigation of the required concentration of DNA 
necessary for transfection.
3.9.1a. Investigation of the Effect of DNA Concentration on 
Transfection Frequency into Different Recipient 
Cell Lines.
Varying DNA concentration in the CaPO^ method of transfection 
(Table 3.9.1a) shows that with an increase in DNA concentration a 
subsequent increase in transfection frequency occurs. The ease at 
which the mouse cell lines (LTK- and A9) are transfected in 
comparison to human tumor cell lines is clear. On repeating of 
this experiment higher concentrations of DNA were included to 
ascertain if higher transfection frequencies were achievable,the 
results are shown in table 3.9.1b.
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A very large, dense CaP04  precipitate was noticable at the higher 
concentrations of DNA (40 and 50pg), thus use of concentrations of 
DNA this high is not suitable for transfection purposes. It was 
decided that a total concentration of 20pg of DNA was suitable for 
further transfection experiments as firstly the precipitate was the 
correct texture and the transfection frequencies were quite high. A 
general requirement for the calcium phosphate procedure to be 
efficient, is the precipitate must be fine and opaque, this was an 
observation by Debenham et al.(1982). Two factors are thought to 
determine the quality of the precipitate, the quantity of the DNA 
present and the pH of the TE buffer used in the preparation of the 
CaPO^ precipitate. Table 3.9.1c. summarises an experiment to 
investigate the optimum pH of the TE buffer. The pH of the TE was 
varied from 6.9-7.5 then a CaPO^ precipitate was formed as 
described in section 2 .1 1 .1 . and the precipitate examined 
microscopically. The optimum pH of the TE buffer pH 7.0-7.1. The 
number of transfectants was scored by the staining of the plates 
with 0.25% crystal violet after the relevant selection time (See 
section 2 .1 1 .6 ), and then manually counting the number of stained 
colonies.
1 4 2
Table 3.9.1a. Investigation of the effect of DNA concentration 
of PLW4 plasmid, on transfection efficiency into 
different recipent cell lines.
Cell line 
DNA
Conc.pg
HEP-2 SW1088 LTK~ A549 A9
1 7.5±2 . 1 4.1 ± 0 .9 14.210.9 0 15.610.6
5 15.6±0.6 9.7±0.8 17.811.6 4.910.2 17.212.3
1 0 17.4±1.8 13.212.6 24.113.7 9.311.6
15 18.7±2.3 13.910.9 45.214.5 9.912.6 19.411.3
2 0 2 1 .3±3.3 12.411.7 64.612.1 11.512.3
6 2n=5 ; Data =no.of tranfectants per 10 cells/lOOmm culture 
dish ± S.D.
Table 3.9.1b. Effect of the concentration of PLW4 DNA 
on transfection frequency.
Cell line 
DNA
conc.pg
HEP-2 SW1088 LTK" A549 A9
5 5.711.2 0 14.611.4 1 . 2  1  1 . 6
1 0 14.312.4 3.3 11.6 23.512.3 8.9 1 1.2 3.4 11.3
2 0 23.410.9 6.3 10.9 46.210.8 9.7 1 0.9 9.8 12.6
40 15.610.6 5.6 10.5 42.310.7 6.3 1 0.7 --
50 13.311.4 2.4 11.2 15.611.6 3.121 1.9 1 . 2  1 1 . 6
6 2n=5 ; Data =No.of transfectants 10 cells/lOOmm culture dish 1 S.D.
Table 3.9.1c. Investigation of the effect of the pH of TE buffer 
on the formation of the CaPO^ precipitate.
pH of TE Microscopic observations
6.9 Very fine crystals, small clusters
7.0 Crystals slightly larger, opaque
7.1 Crystals still fine, opaque
7.2 Crystal size increasing, opaque
7.3 Medium sized crystals, opaque
7.4 Large crystal visible with naked eye
7.5 coarse large crystals, uneven lumps
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3.9.2. Transfection using CaPO^ Plus Chloroquinine.
Chloroquinine (a lysosomotropic agent) + CaP04  has been proven to 
enhance the transfection frequency above CaP04  alone. It has been 
found that 30% kill due to chloroquinine is necessary to see 
enhanced efficiency of transfection. A toxicity assay was performed 
on a number of cell lines to acertain the concentration of 
chloroquinine to cause 30% kill.
Table 3.9.2a Experiment to establish concentration of 
chloroquinine required for transfection.
Cell Line Chloroquinine
Concentration
IC30
RPMI-2650 180pg/ml
HEP-2 124pg/ml
LTK- 173/jg/ml
SW1088 163pg/ml
n=3
3.9.2b. Transfection of pSV2NEO by CaP04  plus chloroquinine.
Cell Line 
Transfection
RPMI-2650 HEP-2 LTK SW1088
CaP04 17.612.3 19.210.7 47.213.2 12.41 2.3
CaP04
+CHQ
28.411.73 25.612.5 U.C.>100 13.612.5
6 2n=3 ; Data=No.of transfectants 10 cells/lOOmm ± S.D. 
U.C.= uncountable.
Chloroquinine enhanced the transfection frequency 
substantially particularly in the case of LTK .
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3.9.3. Transfection of pSV2NE0 and PLW4 by CaPO^ Plus DMSO.
DMSO has been found to increase transfection frequency. As with 
chloroquinine a certain degree of cell kill is reported to be 
necessary before DNA is transfected efficiently, 10% in the case of 
DMSO. A preliminary experiment showed that treatment of any of the 
cell lines with 30% DMSO solution for 4 minutes produced 
approximately 10% kill. In the literature DMSO has been used both 
before and after the CaP04  precipitate has been added. Both these 
parameters were investigated.
Pre-treatment of the cells before transfection with 30% DMSO proved 
to be a very effective transfection procedure for all the cell 
lines and the two plasmids tested. It was a much more effective 
strategy than treatment with DMSO after transfection.
Table 3.9.3. Transfection of pSV2NEO and PLW4 by CaP04  plus DMSO.
Cell line 
Transfection
RPMI LTK- HEP2 A549
pSV2NEO
CaP04
14.3±2.3 45.6±3 . 6 2 1 .1 ±2 . 1 16.7+2.9
pSV2NEO B.T. 
CaPO4+30%DMSO
41.2±4.7 U.C.
> 1 0 0
29.2±2.9 29.2±3.5
pSV2NEO A.T. 
CaPO4+30%DMSO
33.2+1.2 77.5±4 . 2 33.1±3.7 25.2±3.9
PLW4
CaP04
32.1+3.4 49,8±5 . 6 27.5±4.5" 18.22+2.9
PLW4 B.T. 
CaPO4+30%DMSO
45.2±2.9 94 . 2±2 . 3 36.7±3.9 23.2+6.7
PLW4 A.T.
CaP04+30%DMSQ
29.2±3.4 65.2+2.8 29.4+2.1 24.1±3. 9
n = 3 for all experimental data, but for "  n =2.
Data = No. of transfected colonies 10® cells/lOOmm2  dish ± S.D. 
B.T. = Before Transfection 
A.T. = After Transfection
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Procedure.
The mechanism of action of PEG 6000 is unknown but it is thought 
that it perturbs the cell membrane on several levels. It has been 
suggested that PEG may induce various structural changes in the 
bulk liquid phase adjacent to membrane surfaces. It has found been 
to be an extremely effective method of transfection (Sutherland et 
al.,1984). A preliminary experiment showed that PEG 6000 at a 
concentration of 0.5g/ml is suitable for transfection purposes. As 
with DMSO a concentration which yielded about 10% kill is necessary 
for transfection.
Peg 6000 was found to substantially increase the tranfection 
frequency of the human cell lines (RPMI, HEP-2 and A549) and for 
the mouse cell line LTK-, over CaP04  alone. The results obtained 
for each of the plasmids PLW4 and pSV2NEO were found to be very 
similar.
Table 3.9.4. Investigation of the effect of Peg 6000 on CaP04  
transfection frequency.
3.9.4. Transfection of pSV2NEO with the PEG-6000 and CaPO^
Cell Line 
Transfection
RPMI-2650 LTK- HEP-2 A549
CaP04  pSV2NEO 
CaP04  + PEG 6000
18.2±2 . 1  
59.3±2 . 6
45.112.7
U.C.
22.211.4
63.410.7
18.211.9
35.112.3
CaP04  PLW4 
CaP04  + PEG 6000
22.1±4.6
53.1±6.1
49.112.9 
U.C.>150
25.811.8
65.114.5
27.214.7
41.213.4
6 2n=3 ; data = no.of transfectants per 10 cells/lOOmm dish ± S.D.
1 4 6
3.9.5. Transfection with Polybrene/DMSO.
Transfection with polybrene/DMSO has been found an effective 
procedure for the transfection of a number of cell lines. The 
optimal concentration of polybrene and DMSO in combination needed 
to be ascertained, 1 0 % kill was required to achieve an enhanced
transfection effect. The results of a preliminary experiment to
optimize concentration of polybrene/DMSO are summarised in table
3.9.5a.
The efficiency of transfection with the Polybrene/DMSO procedure 
appears to be less than with CaP04  + Peg 6000, however its
efficiency is higher than just CaP04  alone.
Table 3.9.5a Optimisation of Polybrene/DMSO concentration 
required for transfection.
Polybrene: 
pg/ml :
DMSO
%
Cell line 
IC10
1 0  : 1 0 A549
2 0  : 30 LTK
30 : 1 0 RPMI
2 0  : 30 HEP-2
These conditions were then used in the transfection of pSV2NE0.
Table 3.9.5b Investigation of the frequency of Transfection 
with Polybrene/DMSO compared to CaPO^.
Cell line 
Transfection
RPMI-2650 LTK- HEP-2 A549
CaP04
Polybrene/
DMSO
18.6±0.9 
24.1±2.6
37.9+2.6 
97.4±9 .1
19.4+1.2
38.4+3.4
12.712.7
14.211.8
6 2n=3; Data=No. of transfectants per 10 cells/lOOmm dish ± S.D.
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3.9.6a. Transfection of pSV2NE0 by Electroporation.
The technique of electroporation has been developed to a large 
extent in the past three years (Potter et al.,1984). This technique 
is a lot less cumbersome than any of the transfection technique 
highlighted so far in this study. It involves the perturbation of 
the cell membrane by an electric current, allowing for the uptake 
of DNA. In the initial experiments a range of voltages and
capacitances were studied. These experiments were performed in
2 525cm flasks seeded at 5X10 cells per flask.
Table 3.9.6a Effect of varied voltage on transfection frequency 
of pSV2NEO at fixed capacitance of 25pF.
Cell Line 
Voltage
HEP-2 DLKP CHOK1 SKMES1 SKLU1
500 25+1.2 17±2 . 3 33+4.6 18±3.2 913.4
750 37±2.5 35±3.4 72±3.9 39±3.4 1412.5
1 0 0 0 52±3.5 61±7 .1 U.C.>100 4114.5 2113.7
2 0 0 0 48+3.9 69±6.1 U.C.>100 4912.7 1612.4
5 2n=3; Data=Number of transfectants per 5X10 cells/25cm flask 1S.D.
For all the cell lines increased voltage up to 1000V resulted in 
increased number of transfectants.
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3.9.6b. Effect of Capacitance on the Number of Transfectants.
It has been found that voltage affects the levels of transfection; 
this experiment was performed to investigate if increase in 
capacitance either affects cell survival or transfection 
efficiency. A preliminary experiment showed that varying of 
capacitance from 0 to 25pF did not cause any alteration in cell 
survival for CH0K1, NIH3T3, DLKP, HEP2 and LTK~ (data not shown). 
The next experiment was performed to ascertain if an affect on
transfection efficiency was noted. This experiment was performed
6 2 using 10 cells in 100mm culture dishes with pSV2NEO the
transfected plasmid at 1500 voltage, 25/jF capacitance.
Table 3.9.6b Effect of capacitance on transfection frequency.
Cell Line 
Capacitance fjF
CHOK1 NIH3T3 DLKP HEP-2
1 36±2 . 8 39±2.5 16+2.9 2 1 ±2 . 6
5 37±3.9 43±4.1 19+2.4 19±3.5
25 39±2.7 40±2.7 19+3.1 2 2 +1 . 8
6  2n=3 ;Data=Number of transfectants per 10 cell/lOOmm dish ± S.D.
Capacitance does not affect the efficiency of transfection for any 
of the cell lines tested.
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3.9.7. Transfection of Genomic DNA.
A number of experimenta were performed to optimise the transfection 
of genomic DNA with a view to transfection of genomic DNA from 
resistant cell lines. Co-transfection was the procedure adopted 
whereby the genomic DNA was transfected in the presence of plasmid 
DNA. The procedure of co-transfection allows for an internal 
standard within each experiment so that if plasmid DNA is taken up 
it is an indication that the genomic DNA has been also. 
Transfection of genomic DNA is much more difficult because the DNA 
must be integrated into the chromosome into a suitable position 
before expression can occur.
It can be seen from table 3.9.7 that it is possible to get stable 
expression of genomic DNA from mouse to a human recipient looking 
for expression of ouabain resistance. However, regardless of which 
procedure was attempted it was not possible to transfect genomic 
DNA encoding MDR, (resistance to adriamycin). The reasons for this 
are unknown, possibly an incorrect selection time was being used in 
these experiments. Judging by the transfection results from the 
plasmid DNA for those experiments, it seems as if genomic DNA was 
taken up but not expressed, probably due to insertion of the 
genomic DNA in a unsuitable chromosomal position, or DNA 
degradation before insertion.
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Table 3.9.7. Summary of Genomic Transfections
DNA Recipient 
Cell Line
Transfection
Procedure
Selection Results 
per 1 0 ® cells.
1.RPMI+pSV2NE0 RPMI CaP04 Geneticin 23/10®
2.RPMI+pSV2NEO A9 CaP04+PEG 6000 Geneticin 0/10® 
HAT 0/10®
3.RPMI+pSV2NEO A9 Polybrene/
DMSO
Geneticin 0/10® 
HAT 0/10®
4.A9 +pSV2NEO RPMI CaP04 Geneticin 10/10® 
Geneticin+ 
Ouabain 6/10®
5.A9 +pSV2NE0 RPMI CaP04+PEG 6000 Geneticin 30/10® 
Geneticin+ 
Ouabain 11/10®
6 .LTK~+pSV2NE0 RPMI CaP04 Geneticin 35/10® 
Geneticin+ 
Ouabain 12/10®
7-LTK~+pSV2NE0 RPMI CaP04+PEG 6000 Geneticin 45/10® 
Geneticin + 
Ouabain 30/10®
8 .LTK~+pSV2NE0 RPMI Polybrene/
DMSO
Geneticin 29/10® 
Geneticin+ 
Ouabain 21/10®
9.CHrC5+pSV2NEO LTK“ CaP04+PEG 6000 Geneticin 44/10® 
Geneticin+ADR 
(O.lpg/ml) 0/10®
10.CHrC5+pSV2NEO LTK~ Polybrene/
DMSO
Geneticin 41/10® 
Geneticin+ADR 
0.075pg/ml 0/10®
11.CHrC5+pSV2NEO lt k“ Electroporation 
1000 V 
25 pF
Geneticin 61/10® 
Geneticin+ADR 
0.075/i/ml 0/10®
12.CHrC5+pSV2NEO NIH3T3 CaP04+Peg 6000 Geneticin 56/10® 
ADR(0.075 0/10® 
Hg/ml)
13.CHrC5+pSV2NEO NIH3T3 Electroporation 
2000 V 
2 5 pF
Geneticin 58/10 
ADR(0.075pg/ml) 
0 /1 0 ®
14.CHrC5+pSV2NEO NIH3T3 Electroporation 
1500 V 
25 pF
Geneticin 42/10 
ADR (0.075pg/ml) 
0 /1 0 ®
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3.9.8. Transfection of pHAMDRla Plasmid Encoding the full cDNA for
the mdrl Gene.
pHAMDRla encodes the full cDNA for the mouse mdrl gene (Me Lachin 
et al.,1990). This was transfected into NIH3T3, HEP-2 and DLKP 
with a view to comparing the multidrug resistance profiles of a 
transfected gene and a selected cell line. The initial experiments 
were done on NIH3T3 cell line to ascertain the concentration of 
colchicine required to start the selection, the preselection 
period required and the optimal transfection technique.
Table 3.9.8a. Experiment to estimate optimal voltage for
transfection of NIH3T3 at constant capacitance 
of 25pF.
VOLTAGE 
( V )
NIH3T3 
% SURVIVAL
0 1 0 0 ±1.3
0 (ice) 98.2 ±0. 7
50 95.2 ±1.9
1 0 0 96.5 ±2.4
500 94.3 ±2.4
750 81.2 ±1.7
1 0 0 0 69.2 ±1 . 6
1500 68.4 ±2.3
2 0 0 0 49.2 ±1.9
2500 36.2 ±2.7
Voltage to be used in subsequent experiments 1000 V or 1500 V.
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3.9.8b. Experiment to Estimate Optimal Transfection of pHAMDRlA 
into NIH3T3.
The aim of this experiment was to establish the correct 
concentration of colchicine to use for selection of transfectants 
(to eliminate backround), and to ascertain the preselection time 
required for pHAMDRlA (Table 3.9.7).
At a concentration of colchicine of 5-15ng/ml the backround number 
of colonies was too high, 2 0  ng/ml colchicine was chosen as a 
suitable concentration for initial selection of transfectants. 
Transfection frequency very found to be very low . Three different 
transfection procedures were investigated to try and increase 
transfection frequency, CaPO^ + PEG 6000, CaPO^ + Chloroquinine and 
electroporation at 2000V, 25pF Capacitance.
Table 3.9.8b. Investigation of optimal transfection of
pHAMDRla with NIH3T3 as the recipent cell line.
Colchicine Cone, 
(ng/ml)
Control
no
Plasmid
Preselection Time (Hours)
0 24 48 72 96
5 63 ±5.2 61±2.8 72±2.7 69±2.1 — .
1 0 60 ±4.8 65±4.9 7 5±7.5 6 8 ± 2  . 1 79±2.1 72±2.1
15 16 ±2 . 1 19±3.8 25±2 .4 2 1 ±2 .4 2  0 ±2 . 1 24±3.4
2 0 0 3±2. 6 1 1 ± 1 . 2 9±1.2 1 2 ±0 .5 1 1 ±2 . 1
30 0 0 0 0 0 0
n=3; Data=Number of transfected colonies depending on preselection 
time and colchicine concentration, ± S.D.
1 5 3
3.9.9. Investigation to Increase Transfection Frequency, and 
Obtain Transfectants for Toxicity Assays.
Transfection frequency was found to be very low for experiment
3.9.8b. A number of different transfection procedures were
investigated to try to increase transfection frequency, CaPO^ + PEG
6000, CaPO^ + Chloroquinine and electroporation at 2000V, 25pF
2Capacitance. This experiment was in triplicate in 75 cm flasks;one 
was stained and counted (the results are presented in Table 3.9.8) 
the other two were grown up further for use in toxicity assays.
Table 3.9.9. Investigation to Increase Transfection Frequency, 
and to Obtain Transfectants for Toxicity Assays.
Transfection Method Transfection frequency 
NIH3T3 /106  cells.
CaP04 +PEG 6000 35
2 g/ml
CaP04 + Chloroquine 41
150pg/ml
Electroporation
2000V, 25pF 62
n=l; Data=Number of transfectants per 
106 cells/7 5cm2  flask.
Electroporation at 2000V proved to be the most efficient, even 
though initial cell death was 50%. Electroporation at 2000V, 25pF 
was the transfection procedure used for the transfection of HEP-2 
and DLKP. The transfection frequencies were 26/10® cells for HEP-2 
and 31/10® cells for DLKP. Cells were grown to varying 
concentration of colchicine resistance (For details of selection 
procedure see section 2 .1 1 .6 .) and their drug resistance profiles 
analysed. HEP-2 transfectants were analysed at 40ng/ml colchicine
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resistance, DLKP tranfectants at 50ng/ml (Tables 3.9.12. and 
3.9.13.), and NIH3T3 at 30ng/ml and 50ng/ml resistance (Tables
3.9.10. and 3.9.11.). Results are presented in the form of IC50 
nM. It is noted that with a increase in resistance to colchicine 
that a concomitant increase in resistance to each of the test 
compounds is observed. The highest fold resistance was noted for 
adriamycin, vincristine, colchicine and VP16, with low level 
resistance to 5-FU and cis-platin. Both HEP-2pHa40 and DLKPpHA50 
showed diverse patterns of resistance, with DLKPpHA50 showing 
marked resistance to adriamycin, 39.62 fold resistance as compared 
to 4.04 fold resistance for HEP-2pHA40. In addition DLKP-A was 
much more resistant to vincristine 33.58 fold compared to 3.5 fold 
for HEP-2pHA50. Resistance to the other test compounds was quite 
similar with substantial resistance to VP16 noted for both the cell 
lines. The cross resistant profiles of the three transfected cell 
lines are not at all comparable. This is possibly indicative of the 
fate of the pHAMDRIA DNA on entering the cells and the number of 
copies of pHAMDRla integrated into the genome. In addition point 
mutations in the P-170, caused by colchicine exposure may give rise 
to altered patterns of resistance.
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Table 3.9.10. Cross resistance patterns of NIH3T3
NIH3T3pHA30 and NIH3T3pHA50.
Cell line 
Drug
NIH3T3 NIH3T3
pHA30
NIH3T3
pHA50
COLH 10.82±1.034 223.8±41.9 317±41.14
ADR 95.05±12.77 2047.2±214 4047±367.8
VCR 2.75±0.36 27.1±4 33.9±0.39
5-FU 949.5 ±476 1633.1±135 3163±328.4
C-PT 899.2 ±33.35 2216.6±83.9 6228±299.4
VP16 67.97±8.49 1563.1±50.9 2208±169.9
n=2 ; Data= IC50nM, mean ± S.D.
Table 3.9.11. Fold resistance of the NIH3T3pHA30 
and NIH3T3pHA50 relative to the 
parental control.
Cell Line 
Drug
NIH3T3pHA30 NIH3T3pHA50
COLH 20. 7 29.29
ADR 21.53 42.59
VCR 9.85 12.3
5-FU 1.72 3.332
C-PT 2.47 6.93
VP16 22.99 32.48
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Table 3.9.12. Cross Resistance Patterns of HEP-2pHA40
and DLKPpHA50.
Cell line 
Drug
HEP-2 HEP-2pHA40 DLKP DLKPpHA50
COLH 24+1.55 190±7.2 26+3.34 276110.9
ADR 2 2 ±1 . 8 6 89±11.4 2710.52 10701103
VCR 1.13±0.17 4±0.73 1.3110.14 4414.36
5-FU 4022±569 15779±5019 80321557 2281913728
C-PT 1233+133 2433±300 13991333.5 40001300
VP16 144±3.6 3150+286.4 11918.1 2693+438
n=2 ?Data =IC50nM, Mean ± S.D.
Table 3.9.13. Fold Resistance of HEP-2pHA40 and DLKPpHA50
Relative to the parental Controls.
Cell line
Drug
HEP-2pHA40 DLKPpHA50
COLH 7.9 1 0 . 6
ADR 4 .04 39.62
VINC 3.5 33. 58
5-FU 3.9 2.85
C-PT 1.97 2 . 8
VP16 21.87 2 2 . 6
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3.10. Transfection of Antisense and Sense Oligonucleotides.
A direct role for the evaluation of the role of P-170 
overexpression as a mechanism of resistance was studied by the 
transfection of antisense and sense oligonucleotides, using an 
18mer (for details see section 2.11.7.) which codes for 18 bases 
down stream of the mdrl promoter. After culturing for three days 
in the presence of oligomers, the expression of P-170 was assessed 
by an adriamycin toxicity assay (4 Day); the stability of the 
altered sensitivity was ascertained by the assaying in the presence 
and absence of oligomer.
No change in adriamycin resistance was seen after culture with 
sense oligomers for any of the resistant variants , for example 
figure 3.10.8 DLKP-A. Only one of the parental cell lines cultured 
in the presence of antisense oligomer showed a decrease in IC50 
SKMES1-A (Figure 3.10.9) possibly indicating the presence of low 
level P-170 expression in the parental cell line. In all the MDR 
variants tested putative reduced expression of P-170 protein 
(measured as increased adriamycin sensitivity) with antisense 
oligomers was noted, but to markedly varying degrees. The greatest 
degree of altered resistance was noted for CHrC5 (Figure 3.10.1.), 
the resistant control cell line. A reduction in IC50 by 3-4 fold 
was noted for DLKP-A (Figure 3.10.7), SKMES1-A (Figure 3.10.11), 
HEP-2A (Figure 3.10.17) and HEP-2B (Figure 3.10.19). Reduced 
resistance but to a lesser extent, was noted in OAW42-A (Figure 
3.10.13), with a reduction in IC50 of approximately 1.6 fold. 
Only a very slight alteration in the IC50 of SKLU1-A (Figure 
3.10.15) was noted.
158
1 0 0
90
80
70
60
50
40
30
20
10I
0 *
0 1  2 3 4 5 6 7 8 9  1 0
Adriomycin Concentrotion (u g /m l)
3.10.1 .¡Effect of Antisense Oligomers on CHrC5.
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3.10.5.¡Effect of Antisense Oligonucleotides on DLKP.
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3 .10 .8 .¡Effect of Sense Oligonucleotides on DLKP-A.
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3.10.13..Effect of Antisense Oligonucleotides on the Adriomycin toxicity of 
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3.10.14.: Effect of Sense Oligonucleotides on the Adriomycin Toxicity of 
0AW42-A (0.85 ug/m l ADR).
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3.10.16.¡Effect of Sense Oligonucleotides on the Adriomycin toxicity 
of SKLU1 -  A (0 .55ug /m l ADR)
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3.10.18. :Effect of Sense Oligonucleotides on the Adriomycin Toxicity 
of HEP-2A (l.5 u g /m l ADR).
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3.11. Circumvention of MDR.
Novel chemotherapeutic agents and combination chemotherapies have 
resulted in promising new protocols for the treatment of recurrent 
and drug-resistant malignancies. These regimes allow for increased 
therapeutic efficacy but are often limited to a specific tumor type 
or to specific cytotoxic agents.
Verapamil, quinine, quinidine, chloroquinine, nifedipine, aspirin 
and caffeine were studied for their efficacy in the reversal of 
resistance. The emphasis of this study was on compounds and 
concentrations that can be used in vivo situations, with little or 
no toxicity noted to normal tissue. Initially toxicity assays (See 
tables 3.11.1a. and 3.11.1b.) were performed with each of the 
agents to ascertain non toxic dose levels to use in circumvention 
assays (see table 3.11.1c.). This concentration of agent was then 
incorporated into an adriamycin toxicity assay to look at the fold 
reversal in IC50 due to the presence of circumvention agent. 
Results presented are the mean of two experiments, S.D. were ± 10% 
(data not presented), the results are presented in the form of IC50 
of adriamycin in the presence and absence of circumvention agent 
(C.A.), RMR signifies Resistance Modifying Ratio.
IC50nM ADR
RMR = -------------------
IC50 nM ADR + C.A.
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Table 3.11.1a. IC50nM of the Circumventions Agents.
Cell Line 
IC50nM
HEP-2 HEP-2A HEP2B DLKP DLKP-A SKMES1 SKMES1A
Verapamil 27,034 31,789 29,000 32,032 36,670 25,431 26,254
Nifedipine 80,854 82,006 81,946 74,123 69,623 58,217 62,163
Chloroquine 44,482 39,162 44,217 62,188 60,943 52,165 51,179
Caffeine 200823 2 1 1 1 2 2 187124 175129 162456 131129 146358
Quinine 382479 412345 398721 356783 367582 321456 335671
Quinidine 46789 47435 45983 51256 53198 53458 53987
Gen.Aspirin 
(mg/ml)* 3.6 3.94 4.52 7.15 6.98 4.95 5.23
Std.Aspirin 
(mg/ml)* 11.24 9.76 6.58 7.45 8.17 7.99 7.45
Table 3.11.1b. IC50nM of Circumvention Agents.
Cell Line 
IC50nM
OAW42 OAW42-A SKLU-1 SKLU1-A
Verapamil 35,416 34,324 25,129 26,485
Nifedipine 45,176 39,326 53,764 51,129
Chloroquine 53,176 59,125 47,359 45,916
Caffeine 189746 173129 169723 154123
Quinine 299876 304678 334567 329876
Quinidine 51,673 49,897 35,347 367113
Gen.Aspirin 
(mg/ml)* 7. 64 7.01 3.94 4.76
Std.Aspirin 
(mg/ml)* 14.12 13.38 6.75 6.24
*These figures are given in mg/ml rather than nM, since all the 
components of the generic aspirin preparation are not known, it was 
impossible to convert to a molar concentration (This can however be 
done for standard aspirin, using a molecular weight of 180.2).
It is noted from the above tables that there is no marked 
difference in IC50 for any of the circumvention agents comparing 
the sensitive parent to the resistant cell line.
171
Table 3.11.1c. Concentrations of agents used in
circumvention assays.
Circumvention
Agent
Concentration
Verapamil 1  pg/ml
Nifedipine 4.5 ¡jg/ml
Quinine 50.0 pg/ml
Quinidine 2 . 0  ijg/ml
Chloroquinine 2 . 0  pg/ml
Std.Aspirin 0 . 1  mg/ml
0.25mg/ml
0.5 mg/ml
Generic Aspirin 0 . 1  mg/ml
0.25mg/ml
0.5 mg/ml
Caffeine 25.0 pg/ml
1 7 2
Circumvention results are shown in tables 3.11.2. to 3.11.7.
CHrC5 and CH0K1:
Verapamil proved to be the most effective agent producing a RMR in 
CHrC5 of 14.9. It must be noted that this was the highest level of 
reversal for any of the agents tested on all the cell lines. This 
is consistent with findings from the literature that verapamil is 
extremely effective in the reversal of P-170 mediated mechanism of 
resistance. Quinidine, a stereoisomer of verapamil, plus generic 
and standard aspirin (at a concentration of 0.25mg/ml) proved 
effective in reversal of resistance with a RMRs of 4.39, 3.44 and 
3.915 respectively. Generic aspirin at a concentration of 0.5mg/ml 
and quinidine both induced a reversal of resistance in parental 
cell line CH0K1.
DLKP and DLKP-A :
The circumvention results for DLKP-A were very surprising in that 
every compound tested appeared to cause a reversal effect, with the 
most prominent effect noted for standard (0.25 mg/ml) and generic 
aspirin at concentration of 0.25mg/ml. Generic aspirin was noted to 
cause a 2.375 RMR on the parental cell line DLKP.
SKMES-1 and SKMES1-A:
The most effective compound for the reversal of Adriamycin 
resistance in SKMES1-A was verapamil. High levels of P-170 have
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been detected in SKMES1-A, this possibly explains the enhanced 
effect of verapamil. Quinine and generic aspirin both produced low 
level circumventing activity in SKMES1-A.
HEP-2, HEP-2A and HEP-2B:
Quinidine was found to be the most effective agent for the reversal 
of resistance to HEP-2A and HEP-2B with a 3.3 and 3.5 fold 
respective reversal of resistance. Verapamil proved to be an 
effective circumvention agent producing a RMR of 2.4 for HEP-2B, 
and 1.96 for HEP-2A. Nifedipine and verapamil both resulted in 
similar fold reversal of resistance of 2.85 and 2.82 respectively. 
Standard aspirin at a concentration of 0.25mg/ml proved to be the 
next most effective agent in these cell lines.
OAW42 and OAW42-A :
Both standard aspirin and verapamil were noted to affect the 
toxicity profile of the parental cell line OAW42. In Addition 
nifedipine had marked affect with a RMR of 2.85.
SKLU1 and SKLU1-A :
Quinidine was the most effective circumvention agent for SKLUl-A , 
with a 2.69 fold reversal of resistance. In addition quinine and 
generic aspirin in both produced clinically relevant RMRs.
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Table 3.11.2 Effect on IC50 of Circumvention Agents on
CHOK1 and CHrC5.
Cell line 
Agent
CHOK1 CHOK1
+
(RMR)* CHrC5 CHrC5
+
(RMR)
Verapamil 45.99 27.59 (1 .6 6 ) 7579 507.7 (14.9)
Quinidine 55.2 21.03 (2.62) 8003 1819 (4.39)
Nifedipine 49.67 31.27 (1.58) 6273 4433 (1.4)
Chloroquinine 46.21 40.98 (1.127) 7594 7012 (1.08)
Std.Asp (0.1) 44.59 37.26 (1.19) 7322 3012 (2.4)
(0.25) 51.64 31.34 (1.64) 7216 2097 (3.44)
Gen.Asp.(0.1) 49.21 40.12 (1 .2 2 ) 6776 3642 (1 .8 6 )
(0.25) 55.27 47.23 (1.17) 7521 1921 (3.915)
(0.5) 48.71 2 1 . 1 2 (2.306) 7921 4726 (1.676)
* RMR-Resistance Modulating Ratio.
Table 3.11.3 Effect on IC50 of Circumvention Agents on 
DLKP and DLKP-A.
Cell line 
Agent
DLKP DLKP
+
(RMR) DLKP-A DLKP-A
+
(RMR)
Verapamil 5.33 6 . 43 (0.828) 5749 1648 (3.48)
Quinidine 6.9 4. 59 (1.5) 5748 1548 (3.71)
Quinine 4.04 4.49 (0.899) 5546 1703 (3.25)
Nifedipine 5.7 7.783 (0.73) 5751 1924 (2.98)
Caffeine 5.23 5.1 (1.025) 5654 2595 (2.17)
Std.Asp.(0.1) 4.599 3.863 (1.191) 5745 1769 (3.24)
(0.25) 3.86 1.287 (2.99) 5726 958.5 (5.97)
Gen.Asp.(0.1) 5.702 4.921 (1.158) 5699 2818 (2 .0 2 )
(0.25) 5.138 2.163 (2.375) 5546 1326 (4.18)
Table 3.11.4 Effect on IC50 of Circumvention Agents 
on SKMES-1 and SKMES1-A.
Cell line 
Agent
SKMES-1 SKMES-1
+
(RMR) SKMES1-A SKMES1-A
+
(RMR)
Verapamil 
Quinidine 
Quinine 
Nifedipine 
Std.Asp.(0.25) 
Gen.Asp.(0.25)
8.279
10.85
9.014 
8.83
9.014 
7.827
10.67
9.04 
6.99
8.4 
6.43 
2.876
(0.77)
(1 .2 )
(1.29)
(1.04)
(1.39)
(2.72)
2808
2802
2627
2842
2911
2678
715.67
1810
866.9
2 0 1 2
1804
1246
(3.9)
(1.54)
(3.03)
(1.4) 
(1 .6 ) 
(2 .2 )
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Table 3.11.5. Effect on IC50 of Circumvention agents
on HEP-2,HEP2-A and HEP-2B.
Cell Line
HEP-2 HEP-2(RMR) HEP-2A HEP-2A(RMR) HEP-2B HEP-2B(RMR)
Agent - + — + — +
Verapamil 12,7 8 .3(1.5) 3975 2018(1.96) 4121 1701 (2.4)
Quinidine 11.9 9.2(1.3) 4021 1213(3.3) 3896 1124 (3.5)
Quinine 11.03 10.5(1.05) 3929 2844(1.38) 4314 3809 (1.5)
Nifedipine 12.75 9.9(1.28) 3819 2930(1.30) 3946 2466 (1.6)
Chloro-
Quinine 13.06 13.0(1.06) 3655 1788(2.04) 3843 2231 (1.7)
Std.Asp
(0.25) 12.51 6.63(1.88) 3707 2382(1.55) 4065 2621 (1 .6 )
Table 3.11.6. Effect on IC50 of Circumvention Agents on 
OAW42 and OAW42-A.
Cell line 
Agent
OAW42 OAW42
+
(RMR) OAW42-A OAW42-A
+
(RMR)
Verapamil 12.5 6.439 (1.94) 2163 767 (2.82)
Quinidine 7.95 7.727 (1.028) 2071 1814 (1.14)
Quinine 8.28 4.78 (1.732) 2231 1446 (1.54)
Nifedipine 7.54 6.439 (1.17) 2235 784 (2.85)
Chloroquinine 8.79 8.34 (1.05) 2388 1457 (1.63)
Std.Asp.(0.1) 11.41 7.175 (1.59) 2126 1755 (1 .2 1 )
(0.25) 7.727 3.216 (2.4) 2698 1113 (2.42)
Gen.Asp.(0.25) 9.014 5.335 (1 .6 8 ) 2132 1048 (2.03)
Table 3.11.7. Effect on IC50 of Circumvention Agents on 
SKLU-1 and SKLU1-A.
Cell line 
Agent SKLU-1 SKLU-1
+
(RMR) SKLU1-A SKLU1-A
+
(RMR
Verapamil 9.75 7.48 (1.3) 1338 1146 (1.17)
Quinine 8.23 8 . 0 1 (1.027) 1568 690 (2.27)
Quinidine 7.73 6.62 (1.168) 1356 503 (2.69)
Nifedipine 7.23 6.59 (1.097) 1315 901.8 (1.46)
Chloroquinine 6.923 5.42 (1.227) 1501 1406 (1.13)
Gen.Asp.0.25 6.521 3.55 (1.836) 1547 832 (1.85)
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CHAPTER 4
DISCUSSION
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4.1. General Discussion.
Resistance of cancer cells to chemotherapeutic agents may be an 
inherent property of a tumor, or may develop during the course of 
treatment, perhaps due at least in part to the mutagenising 
effects of the drugs used in initial chemotherapy (Shoemaker et 
al.,1983; Kees, 1987). Two theories have been put forward to 
account for the development of cellular drug resistance. The first 
suggests that the tumor population is very heterogenous with
populations of cells present that vary in biological properties and
their drug sensitivity. It is thought that as treatment proceeds 
the sensitive cells will be preferentially destroyed but the 
primarily resistant population will not be affected and will expand 
to repopulate the tumor ; so after an initial period of regression 
tumor growth will continue as before. The second theory suggests 
that the resistance is acquired as a result of the appearance,
during treatment, of mutant tumor cells which are unaffected by
the administering cytotoxic drug. By a process of natural 
selection these resistant cells will then proliferate and come to 
dominate the tumor population. In the past few years, analysis of 
mechanisms MDR and the biochemical properties of resistant cells 
has much improved our understanding of drug resistance in human 
cells, particularly in relation to development of in vitro 
resistance. Yet little of this knowledge has been transformed into 
clinical gains in the form of alterations in standard 
chemotherapeutic regimes.
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The major focus of this thesis was to develop a number of multiply 
drug - resistant cell lines of different tumor origin and to 
characterise these using pharmacological, biochemical, biophysical 
and genetic criteria. A number of lung carcinomas were chosen for 
this study due to the lack of substantial data accumulated on 
mechanisms of resistance in lung tumor cell lines compared to other 
tumor types. Much emphasis was focused on the area of circumvention 
of MDR with the use of compounds like nifedipine, aspirin, caffeine 
and chloroquinine, that could be used in the clinical situation 
without marked toxicity to normal tissue.
The drug adriamycin was chosen as the selection agent due to its 
well documented involvement in the MDR phenotype both in vitro and 
in vivo. It has been used by other researchers for the selection 
of a number of mulitple drug resistance variants of varied tumor 
type, for example; SW-1573, a human lung tumor cell line (Keizer 
et 1989), Colon carcinomas LOVO, DLD1 and SW948 (Toffoli et 
al.,1991); and leukemic T cells B1 (Snow et al.,1991). This drug 
shows marked activity against leukemias and has subsequently proved 
to be one of the most effective of all cytotoxic drugs with 
activity against a wide range of solid tumors including carcinoma 
of the breast, bronchogenic carcinoma, gastric cancers and soft 
tissue sarcomas. The mode of action of adriamycin is still not 
completely understood but at least five potentially cytotoxic 
effects of this agent have been identified :
1.Intercalation : This means that the molecular structure of the 
drug is such that it can insert itself between duplex DNA strands, 
and bind to specific components of the DNA. This results in 
disturbance of various DNA functions and in the case of the
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anthracyclines it seems that DNA and RNA synthesis are inhibited.
2.Membrane Binding : Anthracyclines have been shown to bind to 
various components of cell membranes, leading to altered membrane 
fluidity and changes in permeability to various ions.
3.Free Radical Formation : Free radicals possess an unpaired 
electron and they are often highly reactive towards DNA and other 
biologically important macromolecules. Anthracyclines undergo 
enzymatic transformations which release free radicals within the 
cell and these can cause breaks in the DNA chain, thereby 
preventing mitosis.
4.Metal Ion Chelation : Anthracyclines have the ability to chelate, 
or bind, various metals including copper, zinc and iron. Some of 
the resultant chelates are thought to be cytotoxic.
5.Alkylation : It has been shown that metabolites of the 
anthracyclines act as alkylating agents.
This summary demonstrates the multiple possibilities for cytotoxic 
activity that the anthracyclines possess, though the relative 
importance of these various properties in relation to their 
antitumor effect is unclear.
The selection process differed markedly for each of the selected 
cell lines. DLKP-A was the quickest to develop to resistance. This 
is possibly attributable to a resistant population present in the 
parental cell line that was subsequently selected out. At each 
increase in concentration of adriamycin the DLKP-A cells adapted 
with ease ; an initial slowing in growth rate was evident for the 
first three weeks in the presence of higher concentration of drug 
but generally after that time period the proliferation rate 
increased again. In the case of all the selections a period of at
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least six weeks at each new drug concentration was found to be 
necessary to allow the cells to fully adapt to that level of 
resistance. All the other selections (SKMESl-A, SKLU1-A, HEP-2A, 
HEP-2B, OAW42-A and DLRP-A) proceeded at a much slower rate. The 
DLRP-A and SLKU1-A selections proceeded at an extremely Blow pace. 
It was necessary to restart both these selections a number of 
times; this is possibly indicative of a relatively homogenous
population as regards drug resistance of the parental cell line. It
is evident from looking at the clonal variation of the SKMES-1 
parental cell line that a slightly resistant population 
(approximately 1%) was present. It was thought that this 
population would select out easily as in the case of DLKP-A;
however this was not the case, the SKMESl-A selection proceeded
very slowly at the initial stages. The cells appeared dormant in 
the presence of drug with the pH of the medium altering indicating 
metabolic activity but no cell doubling was noticed. At the later 
stages of selection the cells adapted very well to increases in 
drug concentration. The OAW42-A selection evolved very similarly 
to that of SKMESl-A but no drug resistant parental population was 
evident in OAW42-A. In the cases of the HEP-2A and HEP-2B both 
selections adapted initially quite quickly from 0.05/jg/ml to l^ ig/ml 
adriamycin resistance, but then slowed down markedly so that the 
cells had to be grown in drug free medium for two months. On 
reaching a fold resistance of 189 and 200 (respectively for HEP-2A 
and HEP-2B), the cells reacted very badly to any further increase 
in adriamycin concentration, with a large proportion of the cells 
dying with an increase of 0.2 pg/ml of adriamycin. It is assumed 
that HEP-2A and HEP-2B reached a threshold as regards drug 
resistance. Additionally it could indicate that the DNA damage
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resulting from prolonged periods of growth in adriamycin have 
affected basic cellular survival functions to such an extent that 
any further drug induced DNA damage render the cells non-functional 
as regards basic cellular processes.
The method by which MDR variants are selected is a very important 
factor to consider in the study of MDR in vitro (Yang et 
al.,1990b). To date most investigators have used the prolonged 
exposure of one single agent usually the anthracycline adriamycin 
or certain antimitotic agents (Vinca alkaloids), as the method of 
obtaining MDR variants.How representative this is of the in vivo 
situation is unknown. It must however be noted that some results of 
studies using cell lines in which resistance was induced/selected 
using the conventional method have contradicted those from studies 
using fresh tissue. This factor was particullarly noted (Carulli et 
al.,1990) in the study of haematological maligancies; mdrl 
expression was noted in chronic lymphoblastic leukemia in the in 
vivo situation however this was not noted in the in vitro selected 
cell lines. Future in vitro MDR studies will have to include 
multidrug selections in which drug combinations representative of 
those used in in vivo treatment regimes are used for the in vitro 
selection process. Secondly, the relevance of selection by
prolonged exposure to drug needs to be addressed. In the clinic
patients may develop resistance at relapse after only several
courses of chemotherapy. Therefore in terms of the method of
induction of resistance, the drug resistance induced by a short 
term exposure to antitumor agents may have more clinical relevance 
than that produced by long term exposure.
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the MDR adapted variants and transfected variants.
The phenomenon of multidrug resistance suggests that a wide 
spectrum of structurally and functionally unrelated lipophilic 
drugs are recognised and processed by the molecular system, 
presumably the P-170, which protects MDR cells against toxicity of 
lipophilic substances. On analysis of the toxicity profiles from 
the MDR variants developed in this thesis, there is a consistent 
rank order correlation between resistance to the selecting drug and 
cross resistance to other drugs. However the detailed cross
resistance profile varies among cell lines selected with the same 
drug. This is a consistent finding from the literature whereby 
cell lines are usually cross resistant after selection but the 
order of magnitude of resistance to the different agents is varied. 
Table 4.1. summarises the cross resistance profiles for a number of 
MDR variants, reported in the literature.
4.2. Analysis of the cross resistance profiles of
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Table 4.1. Diversity of collateral resistance in MDR cell lines.
Cell line/Ref. ADR C-PT VLB VCR VP16 COLH
SW-1573/50 1 0 0 . 6 N.D. * 5.5 23 2.3
SW-1573/500 250 0.25 N.D. 540 270 62
SW-1573/10,00 2 0 0 0 0.7 N.D. N.D. 750 2 2 0
(Keizer,1989)
SKVLB1 260 N.D. 2 0 0 0 1 0 , 0 0 0 N.D. N.D.
SKVCR2 510 N.D. 4100 1 , 0 0 0 N.D. N.D.
(Bradley,1989
K562/ADM 527 N.D. N.D. 841 14 N.D.
2780AD 96 N.D. N.D. 357 25 N.D
KBC-4 1 N.D. N.D. 3 6 N.D
(Sato,1991)
SW948-R-6 4.5 1.5 N.D. 2 N.D. N.D
DLS1-R-8 1 1 . 1 1 . 0 N.D. 6 . 8 N.D. N.D
LOVO-R-5 19.3 0.98 N.D. 10.3 N.D. N.D
(Tollifi,1991)
K562-R 850 N.D. 4.0 5.0 N.D. N.D
(Yanovich,1989)
* N.D.-Not Done.
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The data in table 4.1. illustrates the variation obtained in cross 
resistance patterns for a number of MDR selections. An interesting 
observation noted from the drug profiles of the ovarian resistant
cell line SWVLB1 is that the level of cross resistance to 
vincristine greatly exceeds the level of resistance to the 
selecting drug vinblastine (Bradley et al.,1989). Similarly the 
lung carcinoma SW-1573/500 (which was selected with adriamycin), 
shows greater cross resistance to vincristine and VP16 (Keizer et 
al.,1989). None of the MDR variants characterised in our study 
exhibited this characteristic of a higher degree of cross 
resistance to the non selecting drug. It was however noted in the 
cases of the transfected cell lines, for example in the case 
NIH3T3pha50 higher levels of resistance to adriamycin and VP-16 
were evident, HEP-2pha40 was more resistant to VP-16 and 
DLKP-pha50 was more resistant to adriamycin, vincristine, and 
VP16 compared to drug used for selection (Colchicine). DLKP-A was 
the most cross resistant of the MDR cell lines selected in the 
programme described in this thesis (Table 3.1.2), the magnitude of 
cross resistance noted in descending order ADR > VCR > VP16 > VM26 
> COLH > C-PT > 5-FU. With progessively increased selective
concentrations of adriamycin the cross resistance patterns 
increased for all drugs except for vincristine. An increase in the 
fold resistance from 67.46 for DLKP-A at 0.8/jg/ml ADR to 106 for
DLKP-A at 1.75/jg/ml ADR was followed by a decrease in fold
resistance to 39.75 for DLKP-A at 2.45/jg/ml ADR. This could 
possibly signify a gene switching event in the predominant isoform 
of the P-170 produced at latter stages of resistance. A similar 
finding was highlighted by Lothstein et al., (1989) who found that 
a switch from the mdrlb to the mdrla gene product was associated
with an increase in resistance to vinblastine, taxol and adriamycin
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with no detectable increase in the amount of immunoreactive 
P-glycoprotein. (Resistance to 5-FU and cisplatin will be 
discussed relative to all the resistant variants together). 
SKMES1-A also exhibited collateral resistance (Table 3.1.4) with 
highest levels of resistance to VP16, VM26 and vincristine and 
lower levels of resistance to C-PT, COLH and 5-FU. OAW42-A was most 
resistant to cis-platin (Table 3.1.4); cisplatin resistance is a 
very common finding in ovarian carcinoma in vivo. This could 
indicate that OAW42-A is a suitable model for the study of 
resistant ovarian carcinoma. OAW42-A is also resistant to 
VP16,VM26 and vincristine. HEP-2A and HEP-2B (Table 3.1.8.) 
exhibit identical spectra of cross resistance ,being most resistant 
to vincristine, with lower level resistance observed to colchcine, 
VP16, VM26 and cis-platin. The initial treatment of HEP-2B with 
EMS did not alter either the time required for selection or the 
cross resistance profiles. It was reported by Debenham et 
al.,(1982) that prior exposure to EMS accelerated the rate of 
selection ; this was not noted in the case of HEP-2B. HEP-2A and 
HEP-2B reacted very similarly in all the biochemical, 
pharmacological and genetic characterisation, the only exception 
being the lesser reactivity of the HEP-2B in the Western blotting 
procedure. Due to the very close similarities it is suggested that 
despite the differing selection process that the same population is 
selected out in both HEP-2A and HEP-2B. SKLU1-A (Table 3.1.6) 
exhibited low level resistance to vincristine, colchicine and VP16 
with no other marked collateral sensitivity to any other agents. It 
was noted in DLKP-A, HEP-2A, HEP-2B and SKLU1-A that the highest 
level of resistance displayed after adriamycin was to vincristine. 
This was found to be the only correlation in cross resistance
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patterns observed with all the cell lines selected. DLRP-A was 
found not be significantly cross resistant to other drugs, the low 
level of resistance to adriamycin probably accounts for this.
We have shown that a full length cDNA clone for the mouse mdrl gene 
on transfection of pHAMDRla into HEP-2, DLKP, and NIH3T3 can 
efficiently confer resistance to otherwise sensitive cells in 
transfection experiments. On analysis of the cross resistance 
patterns of the transfectants, cross resistance was evident in 
each of the transfectants, however the magnitude of resistance to 
different agents is varied. This observation was also noted by a 
number of investigators (Croop et al.,1987; Schurr et al.,1989, 
Lincke et al.,1990; Yang et al.,1991). Croop et al., (1987) 
examined nine different clones of a transfected cell line for 
collateral resistance to adriamycin, colchicine, daunomycin, 
vinblastine and actinomycin D. A very varied spectrum of 
resistance was noted for all the clones analysed. Diversity in the 
spectrum of cross resistance was observed in the transfected 
NIH3T3pha30, NIH3T3pha50, DLKPpha50 and HEP-2pha40. With 
NIH3T3pha30 and NIH3T3pha50 a concominant increase in resistance to 
each of the test compounds is observed. The highest fold 
resistance was noted to adriamycin, vincristine, colchicine and 
VP16, with low level resistance to 5-FU and cisplatin. Both 
HEP-2pha40 and DLKPpha50 show very diverse patterns of resistance, 
with DLKPpha50 showing marked resistance to adriamycin 39.62 fold 
resistance as compared to 4.04 fold resistance for HEP-2pha40. In 
addition DLKPpha40 was more resistant to vincristine (33.58 fold) 
compared to 3.5 fold for HEP2pha40. Resistance to other compounds 
was quite similar with marked resistance to VP16 for both these
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cell lines. On comparison of the cross resistance patterns it is 
found that DLKP-A and DLKPpha50 are most resistant to the same 
drugs (Adriamycin, Vincristine and VP16) with DLKP-A exhibiting 
higher fold resistance to these drugs.
No similarities are noted in the MDR profile of HEP-2A and 
HEP-2pha50, with HEP-2A most resistant to adriamycin (189), 
vincristine (16.45) and colchicine (5.22) while HEP-2pha50 is most 
resistant to VP16 (21.87), colchicine (7.9) and adriamycin (4.04). 
This could be due to a number of factors. Firstly the mdrl gene 
transfected is the full cDNA for the mouse mdrl gene, and there are 
differences in the cross resistance profiles of the transfection of 
the mouse mdrl gene and the human mdrl gene (Croop et al.,1987). 
Secondly differences in the degree of amplification could be 
evident depending on the particular cell line or transfectant in 
question and this could result in an altered patterns of cross 
resistance. Thirdly, the differing patterns of cross resistance 
could be due to the presence of non P-170 mechanisms of resistance 
in HEP-2A. Further work on the mechanism of resistance in HEP-2A 
is required to answer this question fully. Additionally further 
work on the stability of the transfectants is essential to 
establish if the plasmid has been stably incorporated in the genome 
of the transfected cell lines.
Point mutations in the mdrl gene induced by the action of the 
selecting drug could also account for the lack of homogeneity as 
regards cross resistance patterns in MDR variants and transfected 
variants selected with the same drug under similar selection 
conditions. Independent evidence indicates that the nucleotide 
binding sites in each half of the P-170 are important in drug
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resistance, but the two sites apparently are not identical. 
Inactivation of both binding sites abolishes all activity ,while 
inactivation of either site alone leaves either no activity or only 
a small amount of residual resistance to colchicine, vinblastine 
and actinomycin D (Azzaria et al.,1989). The patterns of residual 
resistance are different depending on which nucleotide binding site 
is mutated. This suggests that both halves of P-170 and possibly 
the nucleotide binding sites themselves are somehow involved in the 
specificity of drug recognition or binding. Indeed the two halves 
might be closely associated with each other in the folded protein, 
such that the integrity of P-170 structure or conformation is 
important. The issue of drug binding and specificity is also 
intriguing in the light of very early observations that MDR cell 
lines are usually most resistant to the drug in which resistance 
was established (Croop et al.,1988; Moscow et al.,1989a ; Shen et 
al,1986). There are as stated above a number of exceptions to this 
general finding (Bradley et al.,1989 ; Keizer et al.,1989). These 
cells are resistant to a whole battery of drugs within the MDR
phenotype, but the pattern of resistance can vary from cell line to 
cell line. Some information on drug specificity comes from the
discovery that P-170 in colchicine-selected human cells differs 
from that in vinblastine-selected or in wild type, drug sensitive 
cells at only a single amino acid residue (Choi et al.,1988;Kioka 
et al.,1989). The 'mutant' protein encoding a preference for 
colchicine resistance has a valine at codon 185 in the P-170
sequence, while the 'wild type' sequence is a glycine at that
residue. When the mutant gene is transfected into drug sensitive 
cells, the cells become relatively more resistant to colchicine 
than vinblastine or adriamycin. Thus residue 185 seems to be 
responsible for preferential resistance to colchicine, and might be
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involved in the specificity of drug interaction with P-170. It is 
hypothesised that alterations of other amino acid residues by point 
mutation may cause preferential resistance to other MDR drugs and 
this could account for the variances noted in spectrum of cross 
resistance to different chemotherapeutic drugs.
The study of MDR by transfection of cloned genes has a number of 
advantages over the use of step wise selection of variants. The 
individual contribution of different members of the mdrl gene and 
related family members to the multidrug resistant phenotype remains 
at present unknown. Cell clones stably transfected with full length 
cDNA for individual members of the MDR family provide an ideal 
system to study the structural and functional features of the 
corresponding MDR protein in an otherwise drug sensitive cellular 
backround. A number of reported alternative mechanism to P-170 
have been reported, including alterations in a number of enzymes of 
the GST family (particullary n ), Topoisomerase 11, DNA Polymerase 
a and fl. One such experiment has been reported (Fairchild et 
al.,1990) with the transfection of the full cDNA for the mdrl gene 
and the GST7T gene individually and comcomitantly. The possibility 
of interaction of the mdrl gene and the GSTtt was investigated by 
transfection into the MCF-7 breast carcinoma cell line. It was 
reported that the transfection of the GSTtt vector alone is 
insufficient to confer resistance to adriamycin. Additionally on
co-transfection of GSTu and the mdrl genes, no alterations in 
resistance patterns was noted above those resulting from
transfection of the mdrl gene alone. These findings leave a number 
of questions unanswered. A possible hypothesis it that the P-170 
works in conjunction with cytosolic transport proteins to pump
drugs out of the cells, although such accessory proteins have not
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yet been identified. Furthermore because GST7T amd mdrl genes are 
both overexpreased in aeveral modela of reaistance, it is apparent 
that there may be several mechanisms of reaistance. There may be 
common factors to the regulation of these two genes. Finally, 
although co-transfection of GSTtt and mdrl genes did not accentuate 
the resistance found on the transfection of the mdrl gene alone, 
indicating that GSTtt may not have a direct role in producing MDR, 
evidence that this enzyme is found elevated in some tumors, 
compared to the normal tissue (Moscow et al.,1989a,b) suggests that 
it may be a clinical marker for carcinogen induced tumors or de 
novo drug resistance. Further transfection studies into different 
cell lines could further evaluate the role of GSTtt in MDR. An 
interesting study would involve the transfection of full cDNA of 
different combinations of the above stated genes and the 
pharmacological, biochemical and genetic alterations noted. 
Experiments of this style might lead to implications of synergistic 
actions of different genes causing specific alterations in 
resistant cells. Cells lines transfected would be very useful for 
the screening of potential circumvention agents. The transfectants 
would be particullary useful for this purpose as individual 
compounds could be tested on a range of transfectants each 
expressing different combinations of mechanisms of resistance. 
However, how representative transfected cell lines are of the in 
vivo situation is difficult to ascertain. They represent model 
systems that can be used to study the effect of different 
combinations of drugs and the screening of potential circumvention 
agents,but owing to the diversity of the MDR phenotype transfected 
cell lines could never be representative of the in vivo situation.
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4.3 Transfection Techniques.
On analysis of the results of the different transfection techniques 
it can be concluded that it is possible to increase the efficiency 
of the CaP0 4  transfection procedure by the addition of facilitators 
PEG 6000, chloroquinine and DMSO. The most efficient procedure for 
the transfection of plasmid DNA was found to be electroporation. 
Generally human cell lines were much more difficult to transfect 
than mouse or hamster cell lines. The most effective procedure for 
the transfection of genomic DNA was found to be CaPO^ + PEG 6000, 
for the transfection of ouabain resistance. Generally it is found 
that it is necessary to optimise transfection techniques for the 
particular cell line in use and DNA being transfected.
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4.4. Resistance to Non-MDR drugs.
Resistance to non-MDR drugs has been noted in a number of the
selected variants and transfected cell lines. This finding has been
attributed to a number of factors. Cancers are thought to 
originate as a result of cellular mutations which allow an 
individual cell or group of cells to escape from normal control
mechanisms. In such an unstable population further mutations are
likely to occur with passage of time and some of these mutated 
cells may carry structural or biochemical abnormalities which 
render them resistant to a broad range of cytotoxic drugs; included 
in this category are non-MDR related drugs. This results in a 
subpopulation of inherently resistant cells. Many cytotoxic drugs 
themselves are mutagenic agents and when drug treatment begins the 
rate of mutation may be expected to increase with the appearance of 
resistant clones. The mutagenic affects of numerous
chemotherapeutic agents has been proven and much documented. The 
mechanism of carcinogensis by antitumor drugs is still a subject to 
intensive research. One theory that has evolved relates to a 
direct action of certain drugs on cellular DNA. The suggestion is 
that agents which attack or bind intimately with DNA in the cell 
nucleus, may not always kill but might cause sublethal damage 
which can cause multiple mechanism of resistance. Support for this 
concept comes from the observation that cancer formation, following 
chemotherapy, in animals and man has been seen mainly with those 
agents that react directly with DNA (Daunorubicin) whereas agents 
which have no direct effect on DNA, such as methotrexate have not 
shown any carcinogenic potential. The second explanation for 
cytotoxic carcinogenesis is immunosuppression. It has been
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suggested that the body is constantly producing small cancers which 
are recognised by the immune system and destroyed by host defences 
at a very early stage in their development: this is the theory of
immune surveillance. If this theory is correct then prolonged
immunosuppression would inhibit host defecnces and allow such 
tumors to grow unchecked. Clear evidence for the development of 
second cancers in man following cytotoxic therapy has now emerged 
from observations on the long term survivors of certain cancers 
(Hodgkins, some childhood maligancies and ovarian carcinoma) who 
received cytotoxics as part of their treatment. Cytotoxic agents 
may be grouped into three catergories; firstly those that have
clearly been shown to be carcinogenic in clinical studies (these
include nitrogen mustard, cyclophosphamide, chloroambucil, melphan 
and nitroureas, procarbazine and thiopea); secondly , agents which 
have demonstrated some carcinogenicity in laboratory tests but not 
as yet in clinical series (these include bleomycin, doxorubicin,
actinomycin D, cis -platin and the vinca alkaoloids); finally, a 
number of drugs, which so far have shown no evidence of 
carcinogenicity in either laboratory or in patients (these include 
5-Flurouracil, methotrexate and cytosine arabinoside). The model 
suggesting a series of mutation affects by carcinogenic agents, 
offers some explanation for the development of multiple mechanisms 
of resistance. If this model is a true representation of events, 
it provides a further argument for adjuvant therapy, in that 
earlier cytotoxic treatment is given the less chance of resistant 
strains having emerged.
Mutagenic affects on a number of genes could be the causative 
reason for resistance to both 5-Fluorouracil and cis-platin. 
Resistance to 5-Flurouracil is an unusual finding in MDR cells, and
194
also in the clinical situation. Three fold resistance over the 
parental cell lines was evident in the case of DLKP-A, 1.86 fold 
resistance for SKMES1-A, 1.88 for DLRP-A and 1.54 for SKLU1-A. 
Increases in resistance to 5-FU is often associated with increases 
in the cellular levels of thymidylate synthetase, which converts 
deoxyuridylic acid to thymidilic acid this is an essential step in 
pyrimidine synthesis. Future studies estimating the thymidylate 
synthetase levels of DLKP-A would indicate if increased levels of 
this enzyme were the causative reason for 5-Fluoruracil resistance 
in DLKP-A. Resistance to Cis-platin is not always observed in the 
classical MDR phenotype. There are numerous reported mechanisms of 
resistance to platinum based drugs; Godwin et al.,(1991) 
implicated the alteration of DNA polymerase ^ in 2780ADM ovarian
carcinoma. Also increases in metallothionein levels have been
reported in H69/C-PT (Kasahara et al.,1991) resistant cells.
Finally increases in the GSTtt has been highlighted by Cho et
al.(1991). To ascertain what mechanism(s) of C-PT resistance 
exists in DLKP-A, OAW42-A, SKMES1-A, HEP-2A and HEP-2B studies
should include assays for the above stated enzymes.
Behavior which may be analogous to the phenomenon of tumor dormancy 
and senesence was noticed in a number of the MDR variants during 
the selection process DLRP-A, SLKU1-A, HEP-2A and HEP-2B. The 
concept of dormancy was invoked to account for the delayed local 
recurrences of tumors after surgical excisions and for the growth
of metastatic tumors a long time after supposedly complete removal
or destruction of primary growth. However this theory has never 
been discussed in terms of selecting of MDR variants in vitro.
Several possible factors could be responsible for induction of the 
dormant state in vivo, such as mechanical, immunological or
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nutritional restraints. Little is known about the dormant state or 
the progression of cell lines or tumor growth from it. Two 
reasonable possibilities are the emergence might be 'triggered' by 
some unidentified extrinsic stimulus or that it might be the 
consequence of the progression of the dormant tumor. However the 
relevance of the dormant period in the MDR variants is unknown. A 
related concept is synchronization of tumor cells as an ingenious 
method of increasing cell kill during cancer chemotherapy. 
Metabolic modulation alters the metabolism of the target tumor cell 
and renders it vunerable to the cytotoxic agent. An example is 
given by Vadlamudi et al. (1971) who treated mice carrying the 
L1210 leukemia with cytosine arabinoside (a specific S phase 
inhibitor) and vinblastine (an M phase inhibitor). When the two 
drugs were given simultaneously, a slight decrease in the
therapeutic effect occurs in comparison to the effects obtained if 
each drug is used alone. A remarkable synergism is observed however 
if vinblastine is given first, followed by ara-C 16 hours later: 
increase in the median survival time exceeds 150%. What happens is, 
the vinblastine arrests the cells in M phase, when its effect 
fades, all blocked but viable cells are synchronized to enter the 
S phase at the same time. In the L1210 system maximum synchrony in 
S phase is achieved about 16 hours after vinblastine injection and 
ara-C has its greatest effect at that time. Synchronization has 
also been reported to be a useful method to overcome natural 
resistance. A good model is the modulation of 5-FU by high dose 
exogenous leukovorin. In the initial protocol, leukovorin was given 
by a two hour infusion at a dose of 500mg/m . Half way during the 
infusion, 5-FU was injected I.V. at the dose of 600mg/m . This
regime was repeated every week for 6  weeks, followed by a two week 
rest period before the six cycles were repeated. This regime
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appeared to be extremely effective with a reported response rate 
above 40% in colon carcinoma (Madejewicz et al..,1984). Again, the 
modulation of 5-FU by previously administered methotrexate is also 
exploitable in chemotherapy ; also the timing of methotrexate 
administration in relation to cytarabine and L-asparaginase is 
important (Bertino et al.,1985). The regime of synchronised 
chemotherapy may be useful in the treatment of MDR tumors, 
particularly if the regime incorporates the use of a 
chemosensitizing agent. The synchronising of the tumor population 
should yield increased efficay of the treatment given and to some 
extent overcome the problems of dormancy.
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4.5. Altered Biochemical and Biophysical Properties of MDR Cells.
The multidrug resistant variants displayed numerous altered
biochemical and biophysical properties compared to their sensitive
counterparts. The observation that MDR cells were sensitive to
both standard freezing and standard subculture methods was an
initial surprising finding, with neither of these previously
reported in literature. It was noted that in all cases the best
7conditions for freezing of MDR variants was high cell number (10 
cells) and high precentage FCS (50%) (See figures 3.3.1 to 3.3.6). 
Further increases in percentage FCS did not alter drug resistant 
profiles after freezing (data not shown). Hep-2A (figure 3.3.2) and 
Hep-2B (figure 3.3.3) proved to be the most sensitive to standard 
freezing procedures with a marked decrease in the IC50 from 
2.5//g/ml to 1.3/jg/ml of adriamycin. The assay procedure used was 
acid phosphatase activity. It was then decided to look also at 
clonal variation of HEP-2A (Figure 3.3.8) and HEP-2B (Figure 3.3.9) 
after freezing as an indication if one particular population of 
cells was most affected by the sub-optimal freezing conditions. It 
was suspected that the most resistant cells were not surviving the 
freezing process. The preferential sensitivity of one population 
of HEP-2A and HEP-2B was not however evident in the results. 
Suboptimal freezing conditions had an overall effect on the
population ; with HEP-2B a decrease of 10% in the survival of the 
most resistant cells (at 3pg/ml Adriamycin) was evident under 
conditions of 10® cells/25% FCS . DLKP-A proved to be less 
sensitive to standard freezing procedures but an interesting 
observation is noted from the profile of the toxicity curve for 
DLKP-A , 10®cells/25% FCS (Figure 3.3.1). At a concentration of
0.5pg/ml adriamycin cells frozen at 10® cells/25%FCS, a 10%
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decrease in survival was noted compared to 10 /50%FCS,additionally 
at a concentration of 1/ig/ml for 10® cells/25%FCS a decrease of 93% 
to 63% was evident. Note, however that these are not clonal 
survival results but acid phosphatase which measures bulk cell 
survival. This provides suggestive evidence that a population of 
DLKP-A is susceptible to freezing, but under optimal conditions of 
increased cell number and percentage FCS it is possible to protect 
this population. Some decrease in IC50 was noted for SKMES1-A 
(1.65/jg/ml to 0.95/jg/ml ; figure 3.3.3), OAW42-A (1.3/jg/ml to
1.075/jg/ml ; figure 3.3.5.) and SKLU1-A (0.6/jg/ml to 0.5pg/ml ;
figure 3.3.6) under suboptimal freezing conditions, however as 
with DLKP-A an increase in cell number and percentage FCS present 
in the freezing medium ,ensured recovery of the MDR phenotype. It 
is noted that the cell lines expressing the highest levels of P-170 
are most susceptable to standard freezing procedure, this would 
indicates the fragility the cell membrane containing high levels of 
of the P-170 glycoprotein. Increased serum protein concentration in 
the freezing medium was found to reduce the sensitivity of the 
cells, it is presumed that the protein and/or other substances 
present in the serum aid in stabilising the cell membrane.
Sensitivity to standard trypsin-EDTA (TV) treatment was a feature 
of a number of the cell lines. The reduction in IC50 of DLKP-A 
(figure 3.5.1) subcultured using scraping compared to T.V. is very 
marked, 1.81//g/ml to 0.72/jg/ml adriamycin. Also, IC50 reduction by 
2 fold is noted in HEP-2A (Figure 3.5.7) and HEP-2B (Figure 3.5.8). 
No adverse affect of T.V. was noted on the adriamycin toxicity 
profiles of SKMES1-A (Figure 3.5.5) and SKLU1-A (Figure 3.5.6) and 
only a slight affect was noted on the OAW42-A (Figure 3.5.3). In 
the cases of DLKP-A, HEP-2A and HEP-2B sensitivity to T.V.
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correlates well with the level of P-170 expression. However, high 
levels of expression of P-170 were noted in SKMES1-A by western 
blotting, and immunofluoresence, but prolonged exposure to T.V.
had no effect on toxicity profiles. This implies that the 
overexpression of P-170 must differ in some way in different cell 
lines ; for example the P-170 glycoprotein could be more protected 
in SKMES1-A, through extensive phosphorylation. Otherwise it 
could indicate that prolonged exposure to T.V. affects other
cellular functions, that subsequently alter drug toxicity
profiles. Barranco et al.(1980) highlighted time dependent changes 
in drug exposure expressed by mammalian cells after exposure to 
trypsin of CHO cells. It was observed that trypsin was shown to 
cause the release of glycopeptides, from the surface of plasma 
membranes. These glycopeptides, synthesized intracellularly and 
transported through the Golgi apparatus to the periphery may have a 
function in the control of cell proliferation. Enzymatic 
alteration of the cell surface can also initiate DNA synthesis in 
contact inhibited cells (Burger,1970 ; Sefton et al.,1970) and can 
cause changes in membrane components, changes that have been 
correlated with the expression of a transformed phenotype (Robbins 
et al.,1979). These findings suggest that exposure to T.V. can 
cause alterations in cell membranes and/or cell surface components, 
which normally act as physical diffusion barriers or receptors and 
thereby affect the transport of drugs into the cells.
The presence of a heterogeneous population as regards drug 
toxicity, is a very evident feature of the multiple drug resistant 
variants selected (Luo et al.,1991). The clonal variation of DLKP-A 
(Figure 3.4.1) is very broad with a large population of resistant
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cells viable above the final selected concentration of adriamycin. 
This accounts for 72% in the case of DLKP-A (1.5) and 81% for 
DLKP-A (2.1). A drug resistant population in DLKP-A is very 
evident with extended growth in the presence of drug up to 3.5/jg/ml 
of adriamycin, with 30% of the population surviving at this 
concentration. Above that concentration the morphology of the 
cells was altered, they appeared large, dark and granular with a 
large number of cellular projections evident. It is doubtful if 
these cells were viable. The presence of a resistant population 
explains why the DLKP-A cell adapted to adriamycin toxicity so 
quickly. Very similar observations were noted with SKMESl-A 
(3.4.4.) , whereby a large population of resistant cells are 
present above the final selective adriamycin concentration,this 
accounts for an 80% survival at 1/vg/ml adriamycin. Cells grew to 
2.5pg/ml adriamycin without displaying any altered morphological 
alterations. On analysis of the toxicity profile of the parental 
cell lines DLKP and SKMES-1 a resistant population was evident in 
both DLKP (4%) and SKMES-1 (1-2%), the increased drug resistance 
above the final adriamycin selected concentration in DLKP-A and 
SKMESl-A could be attributed to the cloning out of the resistant 
sub-population. In OAW42-A (Figure 3.4.2) such a range of clonal 
variation was not noted with a decline in resistance levels very 
evident from 90% to 50% at 0. 75-1. Ojjg/ml of adriamycin. There is an 
indication of two predominant drug resistant populations one which 
is present from 0-0.75/jg/ml of resistance with 90% survival and the 
second from 1/yg/ml Adriamycin (with 50% survival) which gradually 
reduces to 22% at 2.5/jg/ml adriamycin. The same is evident in 
HEP-2A, HEP-2B (Figure 3.4.3) and SKLU1-A (Figure 3.4.5) where a 
sharp decrease in the level of resistance occurs. This decline in
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the level of drug resistance is very evident in HEP-2B where a 
decrease in resistance from 8 8 % to 24% occurs between 1.5pg/ml and 
2 /jg/ml of adriamycin.
During the preparation of cell membranes from the sensitive cell 
lines for western blotting procedures, it was consistently found 
that the resistant variants were slower to lyse on sonication. In 
view of our earlier results on sensitivity to cryopreservation and 
to TV, this finding was surprising. This could indicate altered 
lipid composition of the plasma membrane increasing the fluidity of 
the membrane, making it more resistant to mechanical force. Little 
is known about differences in the lipid composition of cells
sensitive and resistant to anticancer drugs. In mouse leukemia 
P388 cells Ramu et al.,(1983) have found a greater triglyceride and 
sphingomyelin content along with a lower phophatidylcholine (PC)
content than in the sensitive parental cell line. In contrast no 
major differences in the content of neutral lipid, phospholipid or 
ganglioside family was found by Holleran et al.(1986) while Tapiero 
et al.,(1986) have found a greater PC to sphingomyelin and PC to 
phosphatidylethanolamine ratios in resistant than in sensitive
cells. Finally Wright et al, (1985) have found a greater 
sphingomyelin, cardiolipin and lower phosphatidylserine in 
resistant acute lymphoblastic T cells than in their sensitive 
counterparts. An indication was noted in this report that these 
cells were generally more mechanically sturdy, this could indicate 
that an increase in the levels of sphingomyelin and cardiolipin in 
our resistant variants could be the causative reason for the 
increased sonication time required for cell lysis. Also alterations 
in the fatty acid content of the membrane has been reported. 
Adriamycin resistant rat glioblastoma cells are reported (Vrignaud
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et al.,1986) to incorporate fatty acids from the media more rapidly 
than in sensitive counterparts resulting in greater relative 
amounts of oleic acid than in the sensitive line. In P388 cells no 
difference between adriamycin resistance and sensitive cells in the 
fatty acid distribution was detected (Holleran et al,1986). It was 
observed that the fatty acid composition of adriamycin resistant 
Friend leukemia cells is more saturated, has a greater 18:0 
content and has a larger neutral lipid component than the 
adraimycin sensitive cells. Additionally low density lipoprotein 
transport has been found to be altered in ovarian resistant 
A2780-DX3 cells indicating altered membrane lipid concentration 
(Mazzoni et al.,1991). To confirm this hypothesis for a mechanism 
of resistance to sonication, future work involving analysis of 
lipid composition of the MDR variants is necessary.
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by Western Blotting and Immunofluorescence.
Multidrug resistant cells are reported to show characteristic 
changes in surface glycoproteins. The most prominent of these is 
the enhanced expression of an M.W. 170,000 to 180,0000 
glycoprotein, the amount of which has been shown to be related to 
the degree of resistance (Riordan et al.,1985 ; Debenham et al., 
1982; Hamada et al.,1986, Bradley et al.,1989; Chen et al.,1987; 
Redmond et al.,1991; Croop et al.,1988; Endicott and Ling 1989). A 
new membrane antigen associated with drug resistance in lung cancer 
of size 46kD, (SQMI) was reported by Bernal et al.(1990). The cDNA 
and predicted amino acid sequence showed no significant
similarities with P-170. SQMI has been identified as a 
differentiation-related membrane protein that appears to be 
associated with a new mdr phenotype particularly noted with
resistance to MTX and C-PT. Several other membrane proteins unique 
to MDR cells has been observed in addition to P-170, such as an 
85kD glycoprotein in K562/ADM cells (Hamada et al.,1988) and a 
150KDa protein immunologically distinct from P-170 ( Me Grath et 
al.,1988). The C219 monoclonal antibody was used for the analysis 
of the resistant variants by western blotting and 
immunofluoresence. Western blots results illustrated the highest 
levels of P-170 were present in the prototype resistant cell line 
CHrC5, a second band was evident at 70 kD. This is possibly 
another member of the P-glycoprotein gene family. It could
represent a truncated form of the P-170 protein, P-170 being known
to consist of two homologous halves this second band could
represent an unphosphorylated form of one half of P-170. 
Immunological reactivity was very evident for both DLKP-A and
4.6 Analysis of P-170 in Sensitive and Resistant Cell lines
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SKMES1-A with one very discrete band evident for both of these 
variants. With HEP-2A, HEP-2B and OAW42-A very lighty stained
bands were evident that were not as discrete as in SKMES1-A. This 
could indicate heterogeneity in the rate of phosphorylation of 
P-170 in these cell lines giving a broader M.W. range of the P-170 
hence the larger band, or partial degradation of the membrane 
glycoprotein during the preparation procedure. The immunological 
reactivity of HEP-2B membrane glycoproteins were lower compared to 
HEP-2A, these two cell lines have been found to react very 
similarly in antisense oligomer transfection and 
immunofluorescence. The significance of the lesser reactivity of 
HEP-2B P-170 in the western blotting procedure is unknown. 
Consistent with the remainder of the results SKLU1-A showed no 
immunological reactivity to P-170.
Immunofluorescence staining using C219 as the primary antibody and 
antimouse FITC as the secondary antibody yielded a number of 
different patterns of staining. CHrC5 staining was very evenly 
distributed across the population, indicating the presence of a 
very homogeneous population in their expression of P-170 
glycoprotein. The pattern of staining in DLKP-A was relatively 
homogenous, signifying the dominance of a resistant population, 
there was less intense staining which accounted for less than 1 0 % 
of the population and were only evident in some fields. The 
staining of SKMES1-A, OAW42-A, HEP-2A and HEP-2B were very 
heterogenous with a number of populations evident. Metabolic 
cooperation, which is a common feature of epithelial cells, is a 
possible mechanism which could allow a less resistant population to 
survive at higher drug concentrations. The technique of
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immunohistochemistry has been used in the clinical situation for 
the analysis of a large number of malignancies, particularly 
haematological disease (Carulli et al.,1990), however there have 
been a number of short comings in the basic methodology and the 
manner with which positivity is scored. In earlier studies the role 
of P-170 utilised bulk tissue, no tissue sections were taken and 
analysed to confirm the presence and what percentage of neoplastic 
tissue was present. Another factor in which inconsistancies are 
definitly present is the manner in which positivity is scored as a 
means of determining P-170 expression (Kumazuru et al.,1990). In 
the study of AML, differences in scoring positivity have been very 
evident. Mattern et al.,(1989) looked at nine cases using 5-50% 
positive cell on staining as the criteron for P-170 expression. 
However, Ito et al.,(1989) described 14 patient with AML. Using 
flow cytometric analysis with FITC fluorescence, more than 20% of 
fluoresence positive cells were defined as positive, from 1 0 -2 0 % as 
intermediate, and less than 10% as negative. Needless to say it 
is very difficult to compare the results of these two experiments. 
It is necessary to set a standard level of positivity for the study 
of P-170 in the clinical situation, until this is done it will be 
impossible to compare different investigators results. The primary 
advantages of using immunohistochemistry in the clinical situation 
include the ability to detect P-170 in a single cell, to determine 
subcellular distribution of P-170 and to discriminate between P-170 
expression in normal and neoplastic tissue (Dalton et al.,1991). 
The inconsistencies noted in the immunohistochemical procedures 
have been the high levels of false posistives and negatives noted 
from different investigators for the same tumor type. The level of 
false positives tends to be quite high given the nature of the 
protein under investigation and its distribution in normal tissue.
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Introduction of routine H+E staining in conjunction with staining 
for the presence of P-170 is a definite prerequisite necessary for 
routine examination of clinical samples. This could possibly cut 
down on the number of false positives and negatives received. 
Another possible way in which this could be overcome is to use a 
panel of antibodies which may prove to be more efficient than the 
use of a single one. Alternatively, competitive immunohistochemical 
staining may be preformed with epitope specific peptides to ensure 
specificity of detection (Marquardt et al,1990). The use of bulk 
tissue for DNA, RNA and protein analysis should be firstly examined 
to ascertain the proportion of neoplastic cells present. The 
introduction of the above stated factors into routine clinical 
practice for examination of neoplastic tissue should improve the 
consistancy of results and should overall paint a clearer picture 
as to the clinical role of P-170. (See section 4.10.3. for details 
of possible use of anti MDR antibodies for therapeutic purposes and 
section 4.10.1. for details of RT-PCR).
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using Antisense Technology.
Currently there is much excitment about antisense oligonucleotides, 
both as drugs of the future for the treatment of cancer and viral 
infections (Tidd et al.,1991). The present state of the art is 
that antiaense oligodeoxynucloetides or oligodeoxy nucleotide 
analogues can apparently inhibit gene expression when presented 
exogenously to cell lines, but its efficacy as a therapeutic tool 
has not as yet been ascertained. Two studies have been presented 
relevant to the MDR area. It was reported by Vsanthakumar et 
al.,(1989) that the K562/111 cell line positive for MDR1, on 
exposure to non-ionic oligonuceoside methylphosphonates, 
complementary to the initation codon and 15 bases upstream of the 
mdrl gene, can completly inhibit the synthesis of P-170 and 
partially decrease the toxicity of daunorubicin. Additionally, 
Rivoltini et al.,(1990) used antisense oligonucleotides in the 
modulation of MDR. The aim of their study was to test the 
susceptability of Lovo/Dox cells to lysis by different types of 
immune effectors, modulation of toxicity with the use of antisense 
oligonucleotides, and the reversal of resistance by verapamil. The 
effect of verapamil and the modulation by antisense oligomers were 
found to be very similar. Our experiments involved the 
transfection of an 18mer downstream of the mdrl promoter. Both 
sense and antisense oligomers were transfected. No alteration in 
adriamycin toxicity profiles was noted after culture in the 
presence of sense oligomers for any of the cell lines analysed. 
Only one of the parental cell lines (SKMES-1) showed any affect in 
the presence of antisense oligomers with a slight decrease in IC50
4.7. Analysis of the Role of mdrl Over Expression in MDR
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noted from 0.03^/g/ml to 0.02/jg/ml of adriamycin (figure 3.10.9); 
this could indicate the presence of a subpopulation of P-170 
expressing cells in the SKMES-1 population. The greatest reversal 
of resistance was noted in the resistant control cell line CHrC5 
(figure 3.10.11) with a reduction in IC50 form 4.1pg/ml to 0.02 
fjg/ml of adriamycin, this highly sensitizing affect noted in the 
presence of antisense oligomers indicates that P-170 expression is 
a definite and major mechanism of MDR in CHrC5, as indicated in 
literature. An important observation noted in all the antisense 
assays is the requirement to include oligonucleotide into the assay 
medium during the course of the adriamycin toxicity assay. When 
the cells are only pretreated with oligomer a blocking affect of 
P-170 expression is noted, but not to such an extent ; this 
indicates the instability of the oligomers and the necessity to 
incorporate them into the toxicity assay to obtain a definite 
effect. A reduction in IC50 of 1.4pg/ml to 0.4^g/ml was seen for 
SKMESl-A (Figure 3.10.11), with both HEP-2A (figure 3.10.17) and 
HEP-2B (3.10.19) a four fold decrease in IC50 was noted on addition 
of antisense oligonucleotides. In the case of OAW42-A (Figure 
3.10.13) only a 1.6 fold reversal of resistance was noted. A 
reduction in IC50 of 3.8/jg/ml to 1.6/jg/ml was noted with DLKP-A 
(Figure 3.10.7). SKLU1-A did not show positivity for P-170 in 
either western blotting or immunofluorescence, no affect was noted 
with the addition of antisense oligomers. Results from western 
blotting and immunofluoresence indicated high levels of expression 
of P-170 in SKMESl-A and DLKP-A, with lower levels present in 
HEP-2A, HEP-2B and OAW42-A. A greater blocking affect with 
antisense oligomers was expected particularly for DLKP-A and 
SKMESl-A. This would suggest that P-170 expression might not be 
the only mechanism of resistance in DLKP-A and SKMESl-A ;
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additionally the lack of complete block of P-170 expression in 
cells exposed to antisense oligmers could be due to the short time 
of treatment, or a too low concentration of antisense 
oligonucleotide used. The half life of the P-170 has been found to 
be variable depending on the cell line analysed, 24 hours for 
SW620 (Richert et al.,1988) and 72 hours for KB-V1 (Rivolitini et 
al.,1990). Further work to estimate the half life of the P-170 in 
the MDR variants developed, is necessary to use antisense
technology technology to its full potential in the analysis of
P-170 as a mechanism of resistance. However, P-170 expression,
through subsequent decreased adriamycin toxicity, is a definite 
mechanism of resistance in CHrC5, DLKP-A, HEP-2A, HEP-2B and 
OAW42-A. The data presented gives hope for the use of antisense 
technology as a diagnostic tool and future valuable applications in 
therapeutic control of drug resistance.
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4.8. Cytogenetic Analysis of DLKP-A, HEP-2A and HEP-2B.
Numerical heterogeneity and varying degrees of staining of Double 
minute chromosomes (DMs) were cytogenetic hallmarks of the cell 
lines characterised. DMs were very faintly stained in HEP-2B 
(figure 3.8.7). HEP-2A (figure 3.8.6) shows a large number of DMs 
varying in size and intensity of staining and possibly the presence 
of a large HSR. The percentage of metaphases analysed with DMs 
present was 47% for HEP-2A and 39% for HEP-2B. HEP-2A and HEP-2B 
were both found to be markedly similar in their spectrum of the 
number of DMs present in the metaphases analysed. In DLKP-A 
(Figure 3.8.2.) four pairs of DMs are present, varying in uptake of 
stain and size, and the presence of a ring chromosome. It has been 
suggested by Sandberg et al.,(1983) that DMs are derived from HSRs 
with the location and the size of the HSR differing from one cell 
to the next. Ring chromosomes have been reported to be an 
intermediate stage in the progression of DMs to HSRs (Barker et 
al.,1982) this could indicate the presence of HSRs in DLKP-A 
(although we did not attempt to analyse for the presence of HSRs), 
this could also explain the fact that DLKP-A has less DMs than 
HEP-2A and HEP-2B despite the fact that DLKP-A is the more 
resistant of the two cells line. Generally either double minute
chromosomes or homogenously staining regions are evident on 
analysis of a MDR population of cells (See table 1.3 for details). 
Only three cell lines have been reported were the presence of DMs 
and HSRs are found concomitantally (Quinn et al.,1979, Meyers et 
al.,1989 and Slovak et al.,1987). Double minute chromosomes are 
generally found at lower levels of resistance and at this stage the 
number of double minute chromosomes correlates well with the degree 
of resistance. HSRs number tends to increase with increased levels
2 1 1
of resistance and as can be seem from table 1.3 the location of 
HSRs is not limited to chromosome 7 (the site of the P-170 gene), 
indicating that amplification of other genes are also implicated in 
the MDR phenotype. The reason why numerical heterogengenity of DMs 
exists and the unusual coexistance of DMs and HSR are unknown. The 
numerical heterogenity of DMs in a population implies that DMs 
segregate differently from chromosomes. Underlying mechanisms of 
heterogeneity might include disproportionate replication of DMs, 
unequal distribution to daughter cells at anaphase of mitosis, or 
intra cellular transfer of DMs by processes other than 
mitosis,numerical heterogenity of DMs is due to unequal
distribution of DMs at mitosis resulting from the lack of
centromers. Replication studies indicated that DMs replicate early 
in S phase in certain systems (Levin et al.,1976). In other DMs 
replicated proportionately with chromosomal DNA during S phase of 
the cell cycle (Barker et al.,1980). Schimke et al.,(1984, 1985,
1986) has proposed a different theory that HSRs and DMs arise from 
the same events. First overreplication of DNA occurs by multiple 
initations of DNA replication. The initial reduplication of DNA is 
apparently followed by a step involving DNA recombination. When 
the recombination event occurs chromosomally, an HSR may develop 
at the site of the integrated gene. When this event occurs
extrachromsomally, a DM is formed. It has been suggested that 
homologous recombination of the amplified DNA sequences that are 
transiently formed may result in a number of other cytogenetic 
aberrations in addition to HSRs and DMs, including sister chromatid 
exchanges, discentric chromosomes, and chromosomal inversions. 
This theory adds some explanation for the large number of 
chromosomal abnormalities encountered in the three MDR variants
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spreads in HEP-2A, HEP-2B and DLKP-A could be the result of high 
level drug exposure.
On reviewing the human gene map of chromosome 7, several 
observations are noteworthy. First, no currently recognised 
cellular oncogene sequence is localised to the distal arm of 
chromosome 7 where the P-glycoprotein is localised. However, the 
ii-subunit of the T-cell receptor has been localised to this 
approximate chromosome region (Isobe et al,1985). Secondly it has 
been shown that the distal arm of chromosome 7 is a hot spot for 
rearrangement in normal lymphocytes (Scheres et al.,1985), although 
in general this region is infrequently altered in neoplastic tissue 
(Mitelman et al.,1984). The third alteration of chromosome 7ql4-36 
is in fact a very common karyotypic alteration found in two forms 
of cancer that display profound resistance to chemotherapy 1. 
Secondary myelodysplastic syndromes and 2. Acute non-lymphocytic 
leukemia occuring in patients with documented exposure to various 
leukemogenic agents (eg chemicals, solvents, insecticides) (Rowley 
et al.,1983). It is suggested that chromosomal alteration involving 
7q may alter expression of P-glycoprotein in some cases and this 
may lead to development of resistance to chemotherapy.
Future work in this area should include a study of the HSRs present 
in HEP-2A, HEP-2B and DLKP-A, it is impossible to make any 
conclusions from the above data regarding the degree of resistance 
proportionate to either the number of DMs or the length of HSR 
present. However, the definite presence of DMs indicate 
cytogenetic manifestations of gene amplification in HEP-2A, HEP-2B 
and DLKP-A.
analysed (Table 3.8.1 ). Alternatively the abnormal metaphase
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4.9. Pharmacological Reversal of MDR.
Circumvention of resistance at clinically relevant levels was 
achieved with all the agents tested, verapamil, nifedipine, 
quinine, quinidine, chloroquinine, caffeine and aspirin. However 
some were found to be much more efficient; relative efficiency was 
however quite dependent on the cell line in question. Analysis of 
circumvention agents and their effects will be discussed under 
their group classification and compared to observations from the 
literature. All of the compounds used in this study were used at 
clinically relevant concentrations at which toxicity to normal 
tissue would be minimal.
4.9.1. Calcium Antagonists.
These are categorised into three subclasses,
1.Dihydropyridines, eg nifedipine
2.Verapamil, diltiazem
3.Diphenylalkylamines eg Flunarizine.
Verapamil is the most widely tested calcium channel blocker in the 
area of circumvention. The listing of cell lines on which it has 
been tested and proven to reverse resistance either partially or 
completly, is extensive (see table 4.2 and 4.3 for further 
details). The two compounds tested from this classification were 
verapamil and nifedipine.
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The calcium channel blocker verapamil is traditonally used in the 
treatment of coranory heart disease, arterial hypertension and 
supraventricular arrhthmias, has vasodilatory effects on vascular 
smooth muscle, has negative ionotropic effects on myocardial cells 
and lengthens atrioventricular conduction time (Fleckenstein et 
al.,1977). Verapamil is almost completly absorbed after oral
administration and is affected by extensive first pass hepatic
metabolism, with P-450-mediated N-dealkylation and O-demethylation 
accounting for the majority of identified metabolites (Eichelbaum 
et al.,1979). The bioavailability of verapamil is low (10-35%), it 
has a high systemic clearance and its half life of 3-7 hours
(Echizen et al.,1986). The majority of metabolites lack
cardiovascular activity. Whether they posses chemosensitizing 
activity is unknown . The effect of verapamil on cross resistance 
to chemotherapeutic drugs other than those used for selection has 
yielded some very interesting results, with respect to both the 
chemosensitizing effect and in defining the mechanisms by which 
P-170 transport structurally unrelated compounds.
In our studies verapamil proved to be most effective agent in the 
reversal of resistance to the control cell line CHrC5; with a RMR 
of 14.9, this was the largest RMR noted for any of the 
circumvention agents. Verapamil has been consistantly noted to be
a very effective circumvention agent for the reversal of the P-170 
mechanism of resistance (Ford et al.,1990). There is a correlation
between the level of P-170 expression and extent of effect by
verapamil, with the most marked effect noted for cell lines
expressing highest levels of P-170, CHrCS in the cases of our 
studies. Additionally verapamil proved to be the most effective 
agent for the reversal of resistance in SKMES1-A with a RMR of 3.9.
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This is consistant with the high level of expression of P-170 in 
this cell line. Verapamil was also found to be an effective agent 
in the reversal of resistance to DLKP-A with an RMR of 3.5. In the 
case of HEP-2A and HEP-2B RMRs of 1.5 and 2.4 were found
respectively with no circumvention effect noted on SKLU1-A.
In some cases, verapamil produced as great effect on cross 
resistance to drugs as on primary resistance to the selecting 
agent. Sikic et al.(1989) using the MES-SA Uterine carcinoma cell 
line (100 fold resistance to adriamycin), which has been shown to 
have elevated levels of mdrl gene expression, achieved seven fold 
reversal of MDR with 6/jM verapamil. It was also noted that
adriamycin uptake was increased. Similar reversal of resistance 
with different drugs (Daunomycin, Actinomycin D and Mitroxantrone, 
Harker et al.,1986) plus 6/jM verapamil, was achieved at the same 
magnitude. An interesting factor noted with vinblastine was that 
verapamil increased accumulation of the drug without altering
MES-SA/Dx5 resistance to vinblastine. Similarly using an NIH3T3
cell line transfected with the mdrl gene 12^M verapamil completely 
reversed resistance to colchicine (40 fold) and cross resistance to 
adriamycin (20 fold). In certain studies, verapamil was more 
effective in reversing resistance to the drug used in selection 
rather than cross resistant drugs. For example Becks et al.(1986) 
reported that 10^ /M verapamil produced a 75 and 87 fold decrease in 
the 244 and 1163 fold resistance to vinblastine and vincristine in 
the vinblastine selected CEM/VLB100 cell line but only two to five 
fold reversal to daunorubicin and doxorubicin resistance, to which 
the cells were 100 fold resistant. Similary although 5pH verapamil 
caused a 13 fold reversal of 200 fold doxorubicin resistance and 33 
fold reversal of 100 fold vinblastine resistant MCF-7 ADRr cells,
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it resulted in only a four fold change in the 400 fold cross 
resistance to colchicine (Ford et al.,1990). Why MDR cell lines 
differ in the effect in which verapamil has on cirumventing 
resistance to various drugs is unclear. An interesting possibility 
is that alterations in the MDR at the genomic level (Choi et 
al.,1988) or posttranslation modification in P-170 may cause 
changes in the affinity of cytotoxic drugs for the putative binding 
site(s). Alternatively, multiple mechanisms of resistance to 
various chemotherapeutic agent operating within a single cell line, 
could explain this phenomenon. Although verapamil has been widely 
studied and is a potent and effective circumvention agent, it 
possesses potentially life threatening cardiovasicular effects in
humans at plasma concentrations in the 2 to 6 pM range required for 
circumvention of MDR (Candall et al.,1979). It is cytotoxic at 
higher doses to normal tissue (Lampidis et al.,1986). Therefore 
more potent and less toxic chemosensitizing agents need to be 
studied. Alteration in calcium transport or distribution may not be 
involved in the circumvention process (Naito et al.,1989) and many 
compounds with calcium blocking activity are inactive in reversing 
MDR. Verapamil is bound to a- acid glycoprotein (AAG) in human 
serum but this problem is absent from culture media (FCS). 
Chatterjee et al.(1990) studied the presence of absence of AAG on 
the circumventing ability of verapamil. The presence of AAG was 
found to increase the circumventing affect. These results suggest 
that in addition to a plasma memebrane site, there may be a major
endosomal site of action of verapamil in MDR cells. Kessel et
al.(1985b) examined 14 analogues of verapamil and found that
tiapamil caused a partial reversal (15 fold), in 100-fold 
doxorubicin resistant P388/ADR cell line, whereas the analogue 
DMDP was only seven fold less potent and was 10 fold more effective
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in reversing resistance (Radel et al.,1988). Also, nor verapamil 
has been effectively used as a circumvention agent (Merry et 
al.,1989) Yamaguchi et al.(1986) reported that SDB 
ethylenediamine, a synthetic isoprenoid with a structurally 
similar backbone to verapamil containing a 9 carbon isoprene side 
group produced a two to five fold increase in toxicity to 
adriamycin in addition to partial reversal of resistance to 
vincristine, vinblastine and daunomycin. In the papers cited, the 
effect of verapamil on MDR has used racemic mixtures. Because the 
S-enantiomer of verapamil selectively binds to calcium channels 
recent studies have compared the effects of S- and R-enantiomers of 
verapamil and its analogues desmethyoxyverapamil and emopamil on 
MDR (Keilhaurer et al.(1990); Qian et al.(1990); Pirker et 
al.(1990) and found them to be equally active chemosensitisers in 
MDR CEM/VLB and KB-C1 cells. The closely related analogues 
gallopamil and devapamil were more potent calcium channel blockers 
but less potent chemosensitizers in MDR cells (Pirker et al.,1990). 
Therefore the use of less cardiotoxic enantiomers of verapamil and 
its analogues may provided clinically useful compounds. A number 
of other calcium channel blockers structurally dissimilar to 
verapamil, have been found to be effective circumvention agents. 
Nifedipine proved to be an effective agent in the reversal of 
resistance to a number of cell lines in vitro (Tsuruo et al.,1986; 
Onada et al.,1989).This compound proved effective for the reversal 
of resistance to DLKP-A (RMR of 2.988), OAW42-A (RMR of 2.85) and 
to a lesser extent for HEP-2A, HEP-2B and SKLU1-A. It is noticable 
that nifedipine did not affect the reversal of resistance in CHrC5, 
this indicats that the mode of action of nifedipine is markedly 
different to that of verapamil. However the noticable advantage of 
nifedipine over verapmil is the marked reduction in cardiac
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toxicity. Other dihydropyridines that have been proven to be 
particularly effective are Diltazem (Kolhs et al.,1986), Niludapine 
(Yoshinari et al.,1989), Nicardipine (Tsuruo et al.,1986). Also a 
number of dihydropyridine analogs have been found to be 
particularly potent circumvention agents. NK-138 and NK-194 (Nogia 
et al.,1989), BS300 and BS304 (Yoshinari et al.,1989), Carovine
(Tsuruo et al.,1983), PAK-104P (Shudo et al.,1990), N-Solanesyl-N, 
N'bis(3,4 -dimethyoxybenzyl) Ethylenediamine (Kamiwatari et 
al.,1989) Prenylamine (Tsuruo et al 1983a), Bepridil (Schuurhuis et 
al.,1987), (Shinoda et al.,1990), NK-242, (Kiue et al.,1990) and 
AHC-52 (Shinoda et al.,1989). As can be noted a number of calcium 
channel blockers from different classes have been identified as 
agents capable of circumventing MDR. Unfortunately, because of the 
cardiovascular effects of these agents their clinical use is 
limited. However several of the dihydropyridine chemosensitizers 
that lack calcium channel blocking activity hold promise as 
relatively specific agents. Of those calcium channel blockers in 
clinical use, bepridil and nifedipine appear to be the most 
promising for continued pre clinical developmental research on for 
the in vivo reversal of drug resistance.
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Table 4.2. Summary of Studies Using Verapamil to Reverse MDR.
Verapamil Cell Line Cytotoxic Reference
(pM) -Fold
Resistance
-Fold
Resistance
6.6 P388/VCR VCR(31) 122 Tsuruo et al.,
VLB(7) 7 1981.
2.2 VCR(31) 
VLB(7)
34
7
3.3 P388/VCR VCR(20) 26 Tsuruo et al., 
1982.
10 P388/VCR VCR(20) 40 Tsuruo et al., 
1985.
3.3 P388/ADM DOX(43) 12 Tsuruo et al.,
6.6 13 1982.
10 P388/ADR DOX(27) 9 Tsuruo et al.,
DAU(19) 9 1985.
30 P388/ADR DOX(40) 28 Ramu et al., 
1984.
10 P388/ADR DOX(51) 11 Klohs et al.,
DAU(38) 9 1986.
5 P388/DOX DOX(100) 6 Ford et al., 
1990.
2 P388/ADR DOX(69) 9 Yoshinari et 
al.,1989.
40 EA/DAU DAU(5) 4 Slater et al., 
1982.
5 EA/DAU DAU(5) 5.6 Schested et 
al.,1990.
6.6 K562/VCR VCR(17) 61 Tsuruo et al.,
DOX(3) 4 1982.
6 C6/DOX DOX(20) 10 Huet et al., 
1988.
1 CHO/B30 DAU(100) 8 Cano-Gauci et 
al.,1987.
10 8226/DOX40 DOX(50) 40 Bellamy et 
al.,1988.
1 8226/DOX6 DOX(9) 4.5 Lehert et al.,
0.5 8226/DOX6 DOX(9) 3.8 1991.
0.1 8226/DOX6 DOX(9) 2.4
16 MGH-U1R DOX(20) 2.2 Long et al., 
1990.
10 MCF-7ADRr DOX(100) 1 Fine et al.,
VCR(100) 10 1988.
20 MCF7-ADRr DOX(100) 7 Kramer et al., 
1988.
5 MCF-7ADRr DOX(200) 13 Ford et al.,
VLB(100) 33 1990.
VCR(74) 15
COLH(40) 4
2 2780-ADM DOX(100) 4 Schuurhuis et 
al.,1987
1 2780-ADM DOX(170) 6 Rogan et al., 
1984.
1 1847-ADM DOX(5) 6
10 CEM/VLB100 VLB(420) 22 Zamora et al., 
1988.
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Table 4.2. Summary of Studies Using Verapamil to Reverse MDR. 
(Cont'D)
Verapamil
(PM)
Cell Line Cytotoxic
-Fold
Resistance
-Fold
Resistance
Reference
10 CEM/VLB100 VLB(930) 21 Beck et al.,
1988.
10 CEM/VLB.10 VLB(420) 17 Cass et al.,
5 HL60/ADR DOX(NR) 1.2 1989.
10 HCT-8 DOX(NR) 1.2
Colon 26 DOX(NR) 4
LOVO DOX(NR) 3
10 HT29 I.R. 1 Spoelstra et
Colon 26 7.6 al.,1991.
COLO 320 4.6
SW1116 2.1
0.7 Lewis Lung I.R. 1.6 Tsuruo et al.,
6.6 Lewis Lung I.R. 2.6 1983.
6.6 B16 I.R. 2.5
6.6 C-26 Colon I.R. 12
6.6 C-38 Colon I.R. 6.4
10 HT1080/DR4 ADM(55) 7.4
10 HT69AR ADM(NR) 4.9
6.6 NCI-H69/Cx DOX(85) 19 Twentyman et
VCR(750) 72 al.,1986.
MOR/DOX DOX(12) 5
COR-L23/DO DOX(12) 4
20 KB-CHr Fojo et al.,
(8-5-11-24) COLH(22) 63 1990
DOX(21) 23
VLB(21) 38
VCR(73) 183
5 KB-VI VLB(500) 4
VLB(500) 15 Ford et al.,
VCR 2000 8 1990.
DOX(200) 30
COLH 166 20
6 MES-SA/Dx5 DOX(100) 7 Harker et al.,
1986.
NR - Not Reported I.R.-Intrinsically Resistant
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Table 4.3. Summary of In Vivo Studies with Verapamil.
Concentration 
Verapamil : Drug 
ug/ml
Tumor Schedule ILS
%
Reference
0 VCR 0.03 P388/VCR QD X 10 0 Tsuruo et
0 0.2 0 al.,1981
50 0.1 34
50 0.2 29
100 0.03 29
100 0.1 45
0 DAU 0.4 Ehrlich QD X 5 8 Slater et
25 0.4 Ascites 120 al.,1984
50 0.4 EA/DR 106
0 DOX 0 P388/DOX QD X 8 2 Randal et
0 1 7 al.,1988.
75 1 25
0 BOU 0.6 Sarcoma QD X 4 0 Chitnis et
10 0 180 5 al.,1985.
10 0.6 45
100 VCR 0.1 P388/VCR QD X 10 45 Tsuruo et
125 ADM 1.0 P388/ADM 37 al.,1983.
Abbrevations : BOU-Bouavidin,EA/DR-Ehrlich ascite /daunomycin 
resistant,QD -1 time/day,ILS - Increased Life Span.
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4.9.2. Calmodulin Antagonists.
These agents possess the ability to inhibit calmodulin (CaM) 
mediated processes such as activity of the Ca++/CaM dependent form 
of cyclic nucleotide phosphodiesterase (Levin et al.,1976). 
Nontoxic concentrations of the phenothiazine antipsychotic, 
trifluroperazine, caused a 5 to 10 fold increase in VCR and DOX 
toxicity 20-fold and 40-fold resistant P388/VCR and P388 /ADM cells 
respectively (Tsuruo et al.,1982) and fully reversed 17 fold 
K562/VCR resistance to vincristine. A large range of other CaM 
antagonists has been proven to be effective circumvention agents: 
Thioridazine (Akiyama et al.,1986), Chlorpromazine (Ford et 
al.,1989), Prochloroperazine (Ford et al.,1989), Fluphenazine (Ford 
et al.,1990), cis-Flupentixol (Ford et al.,1989), trans- 
Flupenthixol (Ford et al.,1990), cis- and trans-Chlorprothixene 
(Ford et al.,1990) and cis- and trans-Clopenthixol (Ford et 
al.,1990). By the examination of the structure function 
relationship of a series of 22 phenothiazines for circumvention of 
adriamycin resistance (Ford et al .,1989), hydrophobicity of the 
tricyclic ring and the structural features of the amino side chain 
were found to be independently important for circumventing ability. 
The compound that appears to be the most suitable for in vivo use 
is trans-fluxpenthixol. Clinical trials have shown that 
cis-flupenthixol was far more effective than trans-flupenthixol but 
that the latter drug was far less toxic (Johnson et al.,1978). It 
has been found that cis-flupenthixol is a potent antagonist of 
dopamine receptors (Huff et al.,1984). In mouse trials 
trans-flupenthixol has been found to have 100-1000 fold less 
potency than the active cis-isomer. In addition, in vitro studies 
demonstrate that [3H]trans-flupenthixol completly lacks the
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specific dopamine receptor of [3H] cis-flupentixol (Hyttell et 
al.,1984), hence resulting in lack of extrapyramidal side effects. 
Because extrapyramidal side effects have proven to be a limiting 
factor in phase 1 trials that combined trifluroperazine with 
bleomycin (Hait et al.,1989a) or adriamycin (Miller et al.,1988). 
Further preclinical trials are necessary to establish the efficacy 
of this compound in the clinic.
4.9.3. Non Toxic Antracycline and Vinca Alkaloid Analogues.
Soon after the discovery that MDR cells accumulate less drug 
because of an active transport (Skovsgaard et al.,1978), Skovsgaard 
et al.(1980) tested the hypothesis that a specific drug transport 
pump would be competitively inhibited by an excess of a nontoxic 
substrate. A suitable anthracyline structural analog for thiB 
purpose was N-acetyl-daunorubicin, which lacks the free amino group 
of daunomycin essential for DNA intercalation and thus has a lower 
affinity for DNA resulting in less nuclear accumulation, less 
cytotoxicty and higher cytoplasmic concentrations. This compound 
has only been tested in Ehrich ascites cells (Skovsgaard et 
al.,1980) and it was found that a 1:20 combination of 
n-acetyl-daunorubicin with daunomycin, increased the life span in 
mice with MDR Ehrlich ascites innoculated intraperitoneally 
compared to no effect with either drug alone. Inaba et al.(1984) 
analysed the chemosensitizing effect of three additional 
anthracycline analogs on MDR cells and found enhancement of 
vincristine toxicity in P388 cells in vitro when used in 100 fold 
excess. One of these analogs also partially reversed the cross 
resistance to daunomycin, indicating that either that a similar 
drug transport mechanism effects both the anthracyclines and vinca
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alkaloids or else that dauomycin analogs compete with both 
anthracycline and vinca alkaloids for seperate binding sites on the 
P-170. Similary a number of nontoxic vinca alkaloid analogs have 
been studied, such as vindoline. This was found to effectively 
reverse the primary resistance and the cross resistance of MDR 
P388/ADM and P388/VCR (Inaba et al.,1986). In order to understand 
the mechanism of these effects,it would be desirable to establish 
whether these non toxic analogs competitively inhibit the 
photoaffinity labelling of the photoactive vinblastine analog 125 
[I]-NASV (Akiyama et al.,1988) or the photoactive verapamil analog 
125 (I]NASAV (Safa et al.,1986). This class of circumvention agent 
is of particular interest because the modifiers themselves possess 
cytotoxic activity. The combination with other chemotherapeutics, 
both at subtoxic doses may produce a combination with increased 
therapeutic index of more relevance clinically.
4.9.4. Steroid and Hormonal Compounds.
Prompted by the discovery of high levels of MDR1 mRNA in the
pregnant murine uterine uterus (Arceci et al.,1988), Yang et
al.(1989) recently studied the effect of various steroids on MDR 
cells. They found that progesterone and deoxycorticosterone, but 
not estradiol, caused an increase in labelled vinblastine 
accumulation in MDR J7.V1-1 murine macrophages, similar in degree 
to equivalent doses of verapamil. Furthermore progesterone was the 
most potent in a series of steroids tested for inhibition of 
azidopine labelling of endometrial P-170 as well as inhibition of 
labelled vinblastine or vincristine binding to MDR cell membranes 
(Naito et al.,1989). This suggests the possibility that certain
hormones may be the natural substrates for P-170 and that the less
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physiologically active steroid hormones may be capable of 
circumventing drug resistance. It has been that found the 
antiestrogens tamoxifen, toremifene and other structurally related 
triparol analogs can partially overcome resistance in P388/DOX 
cells and MCF-7 ADRr cells independently of their effects on 
estrogen receptor (Foster et al.,1988; DeGregorio et al.,1989; 
Berman et al.,1991).
4.9.5. Miscellaneous Hydrophobic Cationic Compounds.
A large number of compounds found to be effective for circumvention 
of MDR cannot be grouped in the classification of calcium channel 
blockers or CaM antagonists and are not otherwise related 
pharmacologically. Most of these compounds are amphipathic and 
lipophilic in nature and share a broad structural similarity that 
includes a heterocyclic ring nucleus separated at a distance from a 
cationic,amino group (Hofsli et al.,1990). Chemosensitising agents 
as varied as the antiarrhythmics amidorone (Chaffert et al.,1986) , 
an inhibitor of cyclic AMP dependent protein kinase C, H-87 
(Miyamot et al.,1990), the lysomotropic agents atropine,propranol 
and amantadine (Shiraishi et al.,1986; Zamora et al.,1988),the 
alkaloid derivative cepharanthine (Shiraishi et al.,1987), Cremphor 
EL (Woodcock et al.,1990) a common vehicle for water insoluble 
vitamins and drugs, the antimalarial agent guinacrine (Inaba et 
al.,1988 ; Zamora et al.,1988), the indole alkaloids reserpine and 
yohimbine (Beck et al.,1988; Pearce et al.,1989), NC-190 , A
benzophenazine derivative (Tsuruo et al.,1990) the platlet 
anticoagulant dipyridomole (Howell et al.,1989; Ramu et al.,1989), 
Solutol H515 (Coon et al.,1991), Erthroid differentiation factor 
(Activin A) the efficacy of this compound suggests that
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differentiation inducers may be useful in chemotherapy of Leukemic 
cell lines (Okabe-Kado et al.,1991) and the antibiotics erthromycin 
(Hofsli and Nissen-Meyer ,1989a,b), cefoperaone and ceftriaxone 
(Gosland et al.,1989) have been reported to partially circumvent 
drug resistance and to increase intracellular accumulation of drug. 
Whether many of these compounds are acting in a similar 
pharmacological manner to circumvent MDR or whether numerous drug 
target interaction are capable of producing this effect, (or indeed 
depending on the degree of the hydrophobicicty of the agent and its 
ability to cause membrane pertubations leads to decreases drug 
accumulation) is as yet unclear. Four agents from this 
classification were analysed for their effectivness in the reversal 
of resistance, quinine, quinidine (Dextroisomer of quinidine) and 
the lysosomothropic agents, chloroquinine and caffeine. Quinidine 
and quinine have previously reported to be effective circumvention 
agents both in vivo and in in vitro (Tsuruo et al.,1984; Pommeremke 
et al.,1990; Lehert et al.,1991). In our studies quinine was found 
to be an effective agent for the reversal of resistance to DLKP-A 
(RMR 3.25), SKMES1-A (RMR 3.03) and SKLU1-A (RMR 2.27). Quinidine 
was found to be effective in the reversal of resistance to CHrC5 
(RMR of 4.39), HEP-2A (RMR of 3.3), HEP-2B (RMR of 3.5) and SKLU1-A 
(2.69). As highlighted by Pommerenke et al.(1990) a higher 
concentration of quinidine is required to elicit a circumvention 
effect (25 fold in the cases of our studies and 33 fold in the 
cases of Pommerenke et al.(1990). It is noticable that quinidine 
and quinine display different circumventing affects, both 
compounds are effective on different cells lines. This could be 
due to different mechanism of action because of their differing 
steroisomeric characteristics. Both quinine and quinidine have been 
found to affect PKC activity, this could also give an indication to
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their mode of action as circumvention agents. A very interesting 
procedure was highlighted by Mickisch et al.,(1991) that transgenic 
mice that express the mdrl gene in bone marrow represent a rapid 
system of identification of agents that are able to reverse 
resistance. The drugs that were tested in this model were 
verapamil, quinidine and quinine. Verapamil and quinine, both at 
levels suitable for human trials produced only partial 
sensitization but when these compounds were used in combination 
complete reversal of resistance was noted. This observation could 
imply high clinical efficacy for the use of a combination of these 
agents at clinical non toxic levels. These observations indicate 
the need for clinical trials using both these compounds,at 
concentrations that are not toxic in vivo. Another system (Horio et 
al.,1991) indicates the efficacy of quinidine, using an in vitro 
ATP dependent multidrug transport system using vesicles isolated 
from resistant cells. The further efficacy of quinidine and quinine 
need to be ascertained in the clinical situation.
The lysosomotropic agent chloroquinine was found not to be a very 
effective circumvention agent for any of the cell line in our 
study, with highest efficay noted for HEP-2A and HEP-2B with RMRs 
of 2.043 and 1.7 respectively. This agent was effectively used for 
the circumvention of resistance to KB-CHr-24 cells with a RMR noted 
of 5.6, this level of circumventing ability was noted with any of 
the cell lines in our study. The affect of caffeine was only 
ascertained on one cell line DLKP-A with an RMR of 2.17. Further 
work with this compound is necessary on a number of cell lines, 
exhibiting different mechanisms of resistance.
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4.9.6. Cyclosporins.
Structurally and pharmacologically cyclosporins are very different 
to other classes of circumvention agents. CsA consists of a 
hydrophobic cyclic peptide ring of 11 amino acids. Although there 
were several reports that CsA could potentiate various cytotoxic 
drugs in non resistant cells (Kloke et al.,1985). It was found 
that CsA caused a three to four fold circumvention of MDR in 
Ehrilch ascites (Slater et al.,1986). However, there are some 
conflicting reports, whereby CsA was found to circumvent MDR in 
resistant cells only by Twentyman et al.(1987), Twentyman et 
al.(1988b), Hait et al.,(1989b), but was reported to also produce 
a drug potentiation to certain sensitive as well as resistant cells 
(Chambers et al.,1989; Gaveriaux et al.,1989). The mechanism of 
action of CsA appears to be more complex than the chemosensitizers 
described to date. Other cyclosporins have been investigated for 
their ability to circumvent MDR. Cyclosporin C, cyclosporin G and 
cyclosporin H have been found to be very effective (Twentyman et 
al.,1987, Gaveriaux et al.,1989) in the circumvention of Small Cell 
Lung Carcinoma (SCLC). In summary, although the cyclosporins are 
clearly agents that can circumvent drug resistance, it is uncertain 
whether the mechanism is through a direct effect on the P-170, 
through an indirect effect on the cellular metabolism, through 
direct potentiation of chemotherapeutic drug toxicity, or a 
combination of all these.
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4.9.7. Agents That reverse At-MDR.
Much of the emphasis to date has been reversal of P-170 mediated 
resistance. New approaches to circumvention of At-MDR will come 
from a better understanding of the mechanisms of action of these 
classes of Topo 11 acting drugs and the biochemistry of this form 
of resistance (Kaufmann et al.,1990). Preliminary results indicate 
(Wolverton et al.,1990) that At-MDR CEM/VM1 cells are collaterally 
sensitive to the cytotoxic effects of ultraviolet radiation , 
nitrogen mustard and 3-aminobenamide indicating that abberant 
mechanisms DNA repair may determine resistance in some At-MDR 
cells. The present strategies for circumvention of Topo 11 
mediated MDR is the use of agents that are not substrates for DNA 
topoisomerase 11, one such class of compounds is aminoacridine 
analogs (Baguley et al.,1990). Similarly five anthracyline 
analogues are as cytotoxic in the At-MDR cells as they are in drug 
sensitive parents: N-benzyladriamycin-14 valterate (Sweatman et
al.,1990), morpholino- and methomorpholinodoxorubicin (Grandi et 
al.,1990), 4'-ido-doxrubicin and 4-demethoxydaunorubicin (Robert et 
al .,1990). In contrast to these results , Pearce et al.(1990) 
have found that an N for C substitution in the 2' moiety of VP-16, 
creating "aza-VP" completly reduced the cytotoxic and topo 11 
inhibitory activity of VP-16. This reveals the significance of the 
electronic and stereochemical aspects of epipdophyllotoxin-topo 11 
mediated DNA interactions. These results demonstrate the importance 
of rational drug design, molecular modeling and structural 
activity studies in At-MDR research. Reversal of Topo 11 At-MDR 
has also been reported with 3'DEamoino-3'-Morpholino-3-deox-10 
Hydroycorinmycin, (Horichi et al.,1990). BSO has been described in
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a large number of systems which have GSTtf mechanisms of MDR as an 
effective agent in vivo (Ford et al.,1990). However, because of 
endogenous activity of BSO in destruction of GSTs, its use in the 
clinical situation could be limited, due to the large number of 
essential GST dependent processes.
4.9.8. Non Steroidal Anti-Inflammatory Agents (NSAIAs)-Aspirin.
Both standard aspirin and generic aspirin were found to be 
effective in the reversal of resistance for all the cell lines 
tested. Both these agents were used at clinically relevant 
concentrations; a maximum tolerated dose of aspirin of 4g/day (for 
most adults) has been reported. The effect of standard aspirin on 
CHrC5 was substantial; with an increase in the concentration in 
aspirin the RMR also increases (2.4 to 3.44). The same affect was 
not noted with generic aspirin; with an increase in concentration 
of aspirin from 0.1 to 0.25mg/ml, an increase in the RMR is noted 
but a subsequent decrease in RMR is noted at concentration of 
0.5mg/ml; the reason for these observations is unknown. The 
initial studies with aspirin were preformed with generic aspirin. 
To ensure that the effect being noted was due to aspirin and not to 
one of the agents used in the formulation of generic aspirin, 
standard aspirin was incorporated into the study. It was observed 
for a number of the parental cell lines, that the adriamycin 
toxicity profile is also affected. This indicates the broad range 
of action of aspirin in that it can circumvent resistance both in 
sensitive and resistant cells,which have been shown to have altered 
biochemical and pharmacological features. A similar affect was 
noted with DLKP-A, with a increase in concentration of both
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standard and generic aspirin. An increase in the RMRs of both DLKP 
and DLKP-A is noted in the presence of aspirin (Table 3.11.3). The 
greatest circumvention affect is noted with CHrC5 and DLKP-A with a 
lesser decrease in IC50 noted for SKMES1-A,SKLU1-A,HEP-2A and 
HEP-2B and OAW42-A.
The mechanisms of action of aspirin are very varied. It has been 
shown that the effectiveness of the compound is largely due to its 
capacity to inhibit prostaglandin synthesis (Abramson et al.,1989); 
however this hypothesis does not account for all the effects of 
aspirin at all dosages. Higher doses of aspirin are required to 
suppress inflammation than are required to inhibit prostaglandin 
synthesis; moreover sodium salicyclate is an effective inhibitor of 
cycloxygenase at all concentrations used clinically (Morris et 
al.,1985). Alternative hypotheses have therefore been proposed to 
explain the antiflammatory affects of aspirin. Additionally a 
number of mechanisms of action of aspirin could contribute to its 
chemosensitizing affect. When exposed to ligands such as the 
chemoattractants C5a of FMLP (Abramson et al.,1990) , neutrophils 
are activated as part of a general stimulus-response coupling to 
phospholipid remodelling (Weismann et al.,1988). The twin signals 
(See figure 4.1) are provided by mobilization of intracellular 
calcium and the activation of protein kinase C. Aspirin inhibits 
the aggregation of neutrophils in vitro and _in vivo , and shows 
inhibitory effects additive to those of stable PGs on the 
generation of superoxide anion, a product of inflammatory cells. 
The activity of aspirin in terms of PKC may be important as regards 
its circumventing affect. PKC is known to affect the 
phosphorylation of P-170, this may in turn alter the function of 
P-170 producing a circumventing affect (Aquino et al.,1988) Aspirin
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has also been found to disrupt a variety of processes at the
plasmalemma that regulate the generation of twin signals. These
effects are most likely due to the capacity of aspirin,which is a
planar lipophilic molecule, to insert into the lipid bilayer, this
process results in the disruption of signal transduction through
the membrane. Aspirin was also noted to affect the viscosity of
neutrophil plasma membranes (Abramson et al.,1990). This could be
a possible mechanism of circumvention of resistance, by the
altering of the fluidity of the membrane, this could possibly lead
to increases intracellular concentration of drug. Aspirin also
interferes with the chemical mediators of the kallikrein system,
inhibits granulocyte adherence to damaged vasculature, stabilises
lysosomes, and inhibits the migration of polymorphonuclear
leukocytes and macrophages to the site of infection. Finally,
aspirin was shown to be effective in the increase in intracellular
2++accumulation of Ca (Flescher et al.,1991). However, increases in 
. 2++intracellular Ca is not a specific requirement of a
circumvention agent (Nokia et al.,1990) calcium antagonising 
ability is a feature of a number of useful circumvention agents. 
This feature of the mechanism of action of aspirin could also 
contribute to its circumvention affect.
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X  = NSAIDs
Figure 4.1 :Stimulus -Response Coulping 'Twin Signals' in the
neutrophil. X represents the insertion into the lipid bilayer and 
the potential uncoulping of protein-protein interactions by 
non-steroidal antiinflammatory drugs (NSAIDs)-Aspirin.
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A tremendous amount has been learned about MDR at the molecular, 
biochemical, and cellular levels, but little as yet as been 
translated into clinical therapeutic gains. However much of the 
data arising from literature relevant to circumvention of MDR 
suggests that chemosensitizers will play an important role in 
future chemotherapy regimes. Most of the in vivo studies have used 
verapamil, which has been proven to be very cardiotoxic, thus it 
is not a suitable chemosensitizing agent for routine use in the 
clinic. Clearly, the indentification of more potent and less toxic 
chemosensitizers remains a critical parameter to the routine use of 
chemosensitizers. Our studies indicate that a number compounds 
including aspirin (both standard and generic), nifedipine, quinine 
and quinidine are be suitable candidates for futher in vivo study. 
The in vivo use of quinine, quinidine and nifedipine have all been 
proven in animal systems ; there is a need for future studies to 
evaluate the use of these compounds in human clinical trials. 
Aspirin was never reported previously as possessing any 
circumventing ability, however it proved to have an affect on all 
the cell lines tested. This indicates the need for future in vivo 
studies with animal model systems to see if a similar effect is 
noted in vivo. If these results prove positive, further studies in 
the clinical situation would be necessary to ascertain the true 
value of aspirin as a circumvention agent. So much information is 
available on the in vivo uses of aspirin, if this compound was 
proven effective in clinical trials it could be introduced into 
standard chemotherapeutic regimes very quickly and make a major 
impact on standard chemotherapeutic regimes.
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4.10.1. Development of Quantitative PCR.
4.10. Future Developments.
To improve the ability to detect low levels of P-170 expression in 
clinical samples, a number of investigators (Noonan et al.,1990; 
Murphy et al.,1990; Horikoshi et al.,1991; Sugawara et al.,1991) 
are starting to use PCR. For application to the MDR area, PCR has 
been found to be a highly sensitive, specific and quantitative 
procedure for measuring the levels of mdrl mRNA in clinical 
samples. Noonan et al.,(1990) used PCR to analyse mdrl gene 
expression in normal tissue, MDR cell lines and more than 300 
clinical samples. The most critical parameter in the PCR procedure 
relevant to MDR, is that accurate quantification requires the 
demonstration of an exponential range that varies among samples, 
hence it is of the utmost importance to determine the exponential 
range for each sample. Normalisation of results can be determined 
by the independent amplification of a control gene such as 
Ji2-microglobulin, where by the latter is also evaluated in 
exponential range. The results have indicated to date that low 
level mdrl expression undetectable by conventional assays, 
frequently occurs in tumors before chemotherapy. As in the case of 
immunofluorescence procedures, adequate histology must be 
preformed with each sample to ascertain the quantity of neoplastic 
tissue present, additionally no vascular tissue could be present in 
the sample to be analysed, as it highly positive for P-170. 
Provided adequate controls are a routine part of the PCR procedure 
and the tissue under analysis is scrutinised thoroughly before RNA 
extraction PCR technology could serve as a very important 
diagnostic tool for the detection of mdr gene products in human 
tumor samples.
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4.10.2. Human Gene Therapy as a future Goal in Clinical Studies.
Human gene therapy involves the introduction of genes which are 
frequently unselectable into a stable expressing cell type or 
tissue to correct an inborn error of metabolism or provide a 
therapeutic gene product. This technology could have a direct 
effect on the routine treatment of patients with tumors that fall 
into the MDR classification of drugs. Because bone marrow 
supression is a common consequence of chemotherapy, it might be 
possible, using gene therapy, to make the bone marrow of patients 
who will be subjected to cancer treatment resistant to 
chemotherapeutic agents. This could be achieved by removing the 
bone marrow, introducing the MDR gene into the marrow, and 
returning the bone marrow to the patients. Retroviral vectors 
carrying the mdrl gene could be used for this purpose;in fact, the 
mdrl cDNA has already been introduced into the mouse bone marrow 
cells and shown to protect them from vinblastine and colchicine (Me 
Lachlin et al.,1990). To develop such therapies, transgenic mice 
were created in which the human mdrl gene is expressed in bone 
marrow cells (Mickisch et al.,1990). These mice are resistant to 
the bone marrow suppressive effects of adriamycin and other drugs 
in the MDR group,this study suggests that bone marrow replacement 
therapy may be successful in humans. In addition these mice 
provide a very useful model for the study of efficacy of certain 
compounds to reverse MDR (See section 4.9 for details). It is 
relatively simple to show that a compound has the ability to 
reverse resistance in in vitro cell culture systems, but it is 
essential to know if these agents will work in animals before human 
trials can begin. The method in which these experiments would work 
would involve the monitoring of the white blood cell count of a
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transgenic mouse that is drug resistant because of expression of 
the mdrl gene in its marrow. The addition of reversing agents 
causes the white cell count of such mice to fall in the presence of 
cytotoxic agents and provides proof that reversing agents work in 
animals (Mickisch et al.,1990).
4.10.3. Anti-MDR antibodies.
Another strategy for circumvention of MDR is the possibility of
inhibiting protein function by the use of immunotoxins, this could
be the basis of new therapeutic protocols. The in vivo use of
immunotoxin conjugated anti P-170 antibody would seem to be
impossible due to its wide expression in normal tissue, but this
approach could be used for purging autologous bone marrow until
subsequent transplatation. Some experimental procedures carried
out with the MRK16 antibody (Willigham et al.,1987) suggest that
P-170 is not efficiently internalised or rapidly recylced. However
since only a small amount of immunotoxin needs to enter cells to be
toxic, a MRK16 toxin conjugated antibody could be effective in
killing cells expressing P-170. Dinota et al (1989) used
incubation with MRK16 followed saporine-6 conjugated antimouse
serum in order to kill the LOVO/DOX MDR cell line. The inhibition
of the clonogenic growth of this cell line was 96% and 91% with
— 7 —8saporine concentrations of 10 and 10 M respectively. Using a
cellular suspension made up of normal bone marrow cells (90%)and 
LOVO/DOX mdr cells (10%) saporine conjugated antibodies killed 99% 
of the tumor cells; myeloid precursor cells were not affected. 
Also Aihara et al.,(1991) used a combined approach for purging MDR 
leukemic cell line bone marrow using a monoclonal antibody and 
chemotherapy. MAB Moabl7F9 was effectively in the selective
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purging of MDR cells from bone marrow. Using two different cell 
lines, K562/DOX and CEM/VLB, it was found that three rounds of 
17F9 and complement (C') treatment results in the 96.4% kill of 
K562/DOX and 1005 kill of CEM/VLB. Mixtures of malignant and 
normal bone marrow results in 99.85% removal of K562/DOX and 99.91% 
removal of CEM/VLB.
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4.11. Conclusions.
Seven multidrug resistance variants were established ; HEP-2A, 
HEP-2B, DLKP-A, OAW42-A, SKMES1-A, SKLU1-A and DLRP-A. All the 
variants were found to be multiply drug resistant but to markedly 
varying degrees. Generally the most resistant cell lines exhibited 
the greatest diversity and highest range of cross resistance. The 
MDR variants displayed significantly altered biochemical , 
biophysical and genetic characteristics from their parental 
counterparts. The MDR variants were found to be heterogenous in 
the level of drug resistance with more than one drug resistant 
population present. A resistant population in the parental 
population of DLKP possibly accounted for the ease of adaptation of 
the DLKP-A variant. MDR cells were found to be more sensitive to 
standard freezing procedures and standard subculture procedures. 
HEP2-A and HEP-2B the most sensitive to standard freezing 
procedures. From the cloning experiments before and after freezing 
it was evident that suboptimal freezing conditions had an overall 
affect on the whole population rather than on just the most 
resistant population. It was evident that the cell lines expressing 
the high levels of P-170 were most susceptible to standard 
freezing, this indicates the fragility of the cell membrane 
containing high levels of P-170. Sensitivity to trypsin was a 
feature of a number of the cell lines. In the cases of DLKP-A, 
HEP-2A and HEP-2B sensitivity to T.V. correlated well with the 
degree of resistance. However high levels of P-170 were evident in 
SKMES1-A but prolonged exposure of this cell line to T.V. had no 
adverse effect on the adriamycin toxicity profiles. This could 
indicate that over expression of P-170 must differ in some way in
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SKMES1-A to DLKP-A, HEP-2A and HEP-2B; P-170 in SKMES1-A could 
possibly have a different effect on membrane structure , maybe 
through extensive phosphorylation. However, somewhat contradicatory 
to the above findings, the MDR variants were found to more 
mechanically sturdy to standard sonication. Alterations in the 
lipid composition of the plasma membrane of the MDR variants could 
possibly contribute to the increased mechanically strength of the 
MDR variants. A P-170 related mechanism of resistance was
suggested in CHrC5, DLKP-A, SKMES1-A , OAW42-A, HEP-2A and
HEP-2B from Western blotting, immunofluorescence and antisense 
techniques. However, one conflicting result was evident; HEP2-A 
and HEP2-B displayed very similar properties pharmacologically and 
by antisense techniques and immunofluorescence, but on Western 
Blotting HEP-2B displayed less immunologically reactive P-170, 
although this could be a technical artifact. There are indications 
of additional mechanisms of resistance to P-170 in a number of the 
cell lines. This was suggested by cross resistance to 
5-flurouracil and cis-platin and also incomplete reversal of
resistance of adriamycin by antisense oligomers. Further work on 
alternative mechanisms of MDR to P-170 is required in order to 
explain fully all the findings of this thesis. Cytogenetic 
manifestations of MDR (DMs ) were evident in DLKP-A, HEP-2A and
HEP-2B. Finally, drug resistance cell lines were generated by
transfection with a complete murine cDNA for mdrl. pHAMDRlA. The 
drug resistance patterns observed were significantly different from 
those of the variants obtained by adaptation from the corresponding 
parental lines. It was found possible to circumvent MDR with a 
number of compounds at clinically relevant doses , verapamil, 
nifedipine, quinine, quinidine, caffeine, chloroquinine, 
standard aspirin and generic aspirin. The effect of each of the
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compounds varied depending on the cell line in question, the most 
consistantly efficient compounds were found to be verapamil, 
standard aspirin, generic aspirin and quinidine. In the case of 
DLKP-A every circumvention agent under study was found to have an 
affect on reduction of RMR; this is a somewhat surprising finding. 
This could possibly indicate the presence of multiple mechanisms of 
resistance in DLKP-A. This was concluded from the diversity of the 
mechanisms of action of the circumvention agents under study.
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APPENDIX OF BUFFERS.
Carnoys Fixative
Acetic acid : Methanol 
1 : 3
P-NP Substrate
0.1M Sodium Acetate, pH5.5
0.1% Triton X-100
lOmM P-Nitrophenyl Phosphate.
DNA Gel Loading Buffer
12.5% Ficoll, by weight
0.2% Bromophenol Blue,by weight
6.7% 10 X Electrophoresis buffer,by volume.
2 X Hepes -Buffered Saline (2X HBS)
1.63g NaCl
1.19g Hepes 
0.023g Na2 HP04 .2H20 
Ultrapure ^Oto 100ml.
Adjust the pH to exactly 7.1 with 0.5M 
NAOH. Filter sterilise and store at 4°C
Lysis Buffer
10 mM KCL
1.5mM MgCl2
10 mM Tris/HCL ,pH 7.4
2 mM PMSF (added fresh just before use )
Sucrose Cushion
38% (w/v) Sucrose 
10 mM KCL
1.5mM MgC12
lOmM Tris/HCL,pH 7.4
2mM PMSF
Washing Buffer
5 mM Tris/HCl ,pH 7.5 
2mM PMSF
Storage Buffer
5 mM Tris/HCL ,pH7.5
0.25 M Sucrose 
2mM PMSF
Acrylamide Stock Solution 
29.1 % (W/V) acrylamide
0.9 % (W/V) NN1-methylenebis -acrylamide
6.2. APPENDIX - DRUG STRUCTURES.
6,2.1. Adriamycin (Doxorubicin).
o
II
C — CH,R 
OH
H
NH}H
ft
Adriamycin OH
Daunorubicin H
6 .2 .2 . VP16 and VM26.
O H ^-O
Epipodophyllotoxin analogs R 
VMI 26 (NSC-122819) j j _
VP 16-213 (NSC-14 15-10) CHj
6.2.3. Vincristine. OH
o=c 
I
Cl I j
K
CIIOCHj
2 8 4
6.2.4. 5-Fluoruracil.
o
H
6.2.5. Cis-Platium.
2.7S AI
1.95A /  j .33An  
NH3
Cls
3.3A
Cl\ LIV
P i ­
er | \
NHi
NH,
Cl
CIS
6.2.6. Colchicine.
6.2.7. Verapamil.
c k 3
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Quinine/Quinidine (Steroisomers).
CH0=
Nifedipine.
H
Aspirin.
CCOH
6 . 2 . 1 1 . Chloroquinine.
6 .2 . 12.
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APPENDIX 6.3. SAMPLE CALCULATION OF XC50nM
3 4 5 6 7 8 9
Adriamycin  C o n c . ( u g / m l )
Molcular Weight of Adriamycin = 580
IC50 pg/ml from above graph = 0.002 5/jg/ml
7 X 106
Calculation = ----------
580
12068 nM
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APPENDIX 6.4. ABBREVIATIONS
ADR Adriamycin
A.T. After transfection
A.T.C.C. Amercian Type Culture Collection
BCA Bincinchonic acid
BOU Bouavidin
bp Base pair
B.S.A. Bovine Serum Albumin
B.T. Before Transfection
BSO Buthionine Sulfoximide
C.A. Circumvention Agent
COLH Colchicine
C-PT Cis-Platin
Cone. Concentration
DEPC Diethylpyrocarbonate
DME Dulbeccos Modified Eagles Medium
DM Double minute chromosome
DMSO Dimetyl Sulfoximide
EA/DR Ehrlich ascites/dauxorubicin resistant
EDTA Ethlene diamino tetra-acetic acid
ECACC European Collection of Animal Cell Cultures
FCS Foetal Calf Serum
5-FU 5-Fluorouracil
GST Gluathione-S Transferase
HBS Hepes Buffered Saline
HCL Hydrochloric Acid
HEPES 4-(2-hydroxethyl)-piperazineeethansulphonic acid
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HSR Homogenously Staining regions
IC50 Inhibitory concentration SO percent
ILS Increased life span
kb Kilobase
MAB Monoclonal Antibody
MDR Multidrug Resistance
MEM Minumum Essential Medium
M.W, Molecular weight
n Number of replicates
NBCS New Born Calf Serum
NAOH Sodium hydroxide
NSCLC Non Small Cell lung Cancer
O.D. Optical Density
PBSA Phosphate Buffered Saline A
P-170 Glycoprotein M.W. 170,000
pt S » X * Pounds per square inch
RMR Resistance Modfying Region
r.p.m. Revolution per minute
S.D. Standard deviation
S. D. S. Sodium Doceyl Sulfate
TE Tris-EDTA
T.V. Trypsin Versene
Topo 11 Topoisomerase 11
VCR Vincristine
VM26 Teniposide
VP16 Vepesid (Etoposide)
2 9 0
